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AP-1 activator protein-1 
Apaf-1 apoptotic protease activating factor-1 
ATP adenosine triphosphate 
BACH1 BTB and CNC homology 1, basic leucine zipper transcription factor 1 
Bad BCL2-associated agonist of cell death 
Bax BCL2-associated X protein 
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Eto etoposide 
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FAS fatty acid synthase 
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FCCP carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone 
FDA Food and Drug Administration (USA) 
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MDH malate dehydrogenase 
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Mg magnesium 
MMP matrix metalloproteinases 
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MSN4 multicopy suppressor of SNF1 mutation 4 
mTOR mammalian target of rapamycin 
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NADH nicotinamide adenine dinucleotide (reduced) 
NADPH nicotinamide adenine dinucleotide phosphate (reduced) 
NCAM neural cell adhesion molecule 
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NCI National Cancer Institute (USA) 
NF1 neurofibromin 1 
NF-E2 nuclear factor-erythroid 2 
NFkB nuclear factor-kappa B 
NH4OH ammonium hydroxide 
NIA National Institute on Aging 
NIH National Institutes of Health 
O2 oxygen 
OAA oxaloacetate 
OCR oxygen consumption rates 
OD optical density 
p107 retinoblastoma-associated protein homolog 
p130 retinoblastoma-associated protein homolog 
p16INK4A cyclin-dependent kinase inhibitor 2A 
P53 tumor protein 53 
p66shc 66-kilodalton isoform of the growth factor adapter Shc 
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PCR polymerase chain reaction 
PDH pyruvate dehydrogenase 
PDK1 3-phosphoinositide-dependent kinase 1 
PI3K phosphoinositide 3-kinase 
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PIP3 phosphatidylinositol (3,4,5) trisphosphate 
Pit-1 pituitary-specific transcription factor-1 
PKA protein kinase A 
Prlr prolactin receptor 
Prop-1 homeobox protein prophet of PIT-1 
PTEN phosphatase and tensin homolog 
Puma P53 upregulated modulator of apoptosis 
qRT-PCR quantitative real-time polymerase chain reaction 
RAS small GTPase protein family member 
Ras GAP Ras GTPase-activating protein 
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rHO-1 rat heme oxygenase-1 
Rip1Tag2 transgenic mouse model of β-cell carcinogenesis 
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Abstract 
Short-term starvation (STS or fasting) protects normal cells, mice and 
potentially humans from the harmful side-effects of chemotherapeutic drugs. In this 
dissertation, I demonstrate that fasting-like cell culture conditions reduce cancer cell 
survival and sensitize human and murine cancer cell lines to chemotherapy. In vivo, 
cycles of STS were as effective as chemotherapeutics in delaying the progression of 
specific tumors and increased the effectiveness of these drugs and radiotherapy 
against melanoma, glioma, and breast cancer cells. In mouse models of 
neuroblastoma, STS cycles in combination with chemotherapy, but not either 
treatment alone, resulted in long-term cancer-free survival. In 4T1 breast cancer 
cells, STS led to increased phosphorylation of the stress-sensitizing AKT and S6 
kinases, increased oxidative stress, caspase-3 activation, DNA damage, apoptosis, 
and reduced expression of the stress resistance transcription factor NFkB; all 
changes were not observed in normal tissues. Several of these effects are linked to 
the activity of the stress-responsive enzyme heme oxygenase-1, whose modulation 
was central in regulating chemotherapy-dependent cell death in breast cancer cells. 
These studies suggest that multiple cycles of STS promote differential stress 
sensitization in a wide range of tumors and could potentially replace or augment the 
efficacy of some toxic chemotherapy drugs in the treatment of various cancers.  
In addition, we evaluated the contribution of calorie restricted (CR) diets and 
defined macronutrient (carbohydrate, protein, fat) ratios for their effects on stress 
sensitization markers and protection in mice treated with high-dose chemotherapy. 
Short-term 50% CR, combined with either severe protein-deficient or ketogenic diets, 
improved chemotoxicity resistance similarly to the standard 50% CR, but did not 
result in the high protection caused by STS. Notably, a high protein diet reversed the 
beneficial effects of short-term CR. In a subcutaneous mouse model of glioma, 
feeding a low protein diet (4% calories from protein vs. 18% in the control) for more 
than 20 days did not delay tumor progression once the tumor became palpable. 
Also, cycles of short-term (3 days) 50% CR did not augment the chemotherapy 
efficacy of cisplatin in a murine breast cancer model. These results indicate that the 
protection from chemotoxicity and retardation of tumor progression achieved with 
fasting could not be obtained with short-term calorie and/or macronutrient restriction.  
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Zusammenfassung 
Kurzzeitiges Fasten (STS) schützt normale Zellen, Mäuse und potenziell auch 
Patienten vor den schädlichen Nebenwirkungen einer Chemotherapie. In dieser 
Dissertation demonstriere ich, dass fasten-ähnliche Zellkulturkonditionen das 
Überleben von Nagetier- und menschlichen Krebszellen reduziert und diese 
gleichzeitig gegenüber chemotherapeutischen Interventionen sensitiviert. In vivo sind 
Fastenzyklen für manche Krebszellen ähnlich effektiv wie die verwendete 
Chemotherapie und reduzieren das Tumorwachstum. In Tierversuchsmodellen für 
Melanome, Gliome und Brustkrebs konnte die Effektivität der verwendeten 
Chemotherapeutika und auch Strahlentherapie in Kombination mit Fasten erhöht 
werden. In Mausmodellen für Neuroblastome resultierte die Chemotherapie 
zusammen mit Fasten in einem langzeitigen Überleben der Mäuse, während die 
einzelnen Therapien erfolglos blieben. In dem 4T1 Maus Brustkrebs-Modell 
resultierte STS in einer erhöhten Phosphorylierung der Stress sensitivierenden 
Kinasen AKT und S6, erhöhtem oxidativen Zellstress, Spaltung der Caspase-3, 
DNS-Schäden, Apoptose und der gleichzeitig reduzierten Expression von 
Transkriptions-Faktoren (z.B. NFkB) die eine Rolle im Widerstand gegen Zellstress 
spielen. Interessanterweise konnten diese Veränderungen in normalen Zellen nicht 
aufgefunden werden. Mehrere dieser intrazellulären Effekte stehen mit der Aktivität 
des Enzyms heme oxygenase-1 in Verbindung, dessen Regulierung eine zentrale 
Rolle in der durch das Fasten bedingten Sensitivierung von 4T1 Brustkrebs spielt. 
Unsere Studien deuten darauf hin, das Fasten eine differentielle Stress-
Sensitivierung in einer Vielzahl von Tumoren auslösen kann, die Effektivität von 
Chemotherapeutika erhöhen kann und somit möglicherweise eine Alternative zu 
Chemotherapie darstellt. 
Um Alternativen zum Fasten zu finden, evaluiere ich in dieser Dissertation 
zusätzlich noch die Effekte von kalorienreduzierten (CR), und Nährstoff (Eiweiß, Fett 
und Kohlenhydrate) definierten, Nahrungsmitteln hinsichtlich ihrer Effektivität im 
Schutz gegen akut hohe Chemotherapie und Tumorprogression. Eine kurzzeitige 
50% Reduzierung der konsumierten Kalorien, auch in Zusammenhang mit 
Proteindefiziten oder ketogenen Diäten, erhöhte die Resistenz gegenüber der 
Chemotherapie, blieb jedoch weniger effektiv als Fasten per se. Eine Diät mit hohem 
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Proteingehalt reversierte die positiven Effekte der CR. In subkutan implantierten 
Gliomen blieb die Ernährung mit auf niedrigem Eiweiß basierten Kalorien (4%) in der 
Maus nach mehr als 20 Tagen ohne Effekt auf das bereits etablierte 
Tumorwachstum. Zyklen in denen die Kalorien auf 50% reduziert wurden hatten, im 
Gegenteil zu Fasten, keine additive Wirkung auf die Behandlung von 
Brustkrebszellen mit Cisplatin in der Maus. Die präsentierten Ergebnisse belegen 
dass Fasten, jedoch nicht kurzeitige CR oder die Modifizierung der konsumierten 
Nährstoffe, vor der Toxizität von Chemotherapeutika schützt und gleichzeitig 
Krebszellen zu einer Vielzahl von Chemotherapien sensitiviert. 
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1 Introduction 
1.1 Aging and Senescence 
Aging in humans refers to a multidimensional process that includes, but is not 
limited to, the physiological, psychological, and social changes that accumulate 
chronologically in the lifetime of an individual. While some dimensions of aging grow 
and expand with time in the elderly, e.g. wisdom, others, such as physical strength, 
may drastically decline. Aging plays not only an important part of all humans on a 
personal level, but its consequences have a large impact on all human societies, as 
manifested in many cultural and societal conventions to date. Yet, a more biological 
definition of aging is the physiological deterioration that accompanies increasing age, 
raising the risk of death form a variety of causes (Finch and Schneider 1985). Alex 
Comfort defines aging as a progressive increase throughout life, or after a given 
condition, in the likelihood that an individual will die during the next succeeding unit 
of time from randomly distributed causes (Comfort 1956). Aging therefore includes a 
defining element: the increase in mortality (and decrease in fertility) that occurs in 
older organisms and is based on a gradual decline in the capacity to respond to 
environmental challenges (Rose 1991), also known as fitness. 
 
Senescence (from Latin: senescere: to grow old) is commonly described as 
the accumulation of changes that cause alterations in the molecular and cellular 
structure, thereby affecting the metabolic capacity over time and consequently 
resulting in deterioration and death. Senescence occurs on the level of individual 
cells (cellular senescence) and subsequently causes alterations, including the onset 
of age-related diseases, within the whole of the organism (organismal senescence). 
There are a numerous hypotheses as to why senescence occurs. For example, 
some propose senescence occurs due to changes of gene expression (a cause for 
failure), others claim it is the cumulative damage caused by biological processes (a 
consequence of failure). If senescence as a biological process can be slowed down, 
halted or even reversed is a subject of ongoing scientific research.  
Cellular senescence is the phenomenon by which normal cells lose the ability 
to divide and multiply; after about 50 cell divisions in vitro, known as the Hayflick limit 
in honor of Dr. Leonard Hayflick (Hayflick 1965). Some cells become senescent after 
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fewer replication cycles as a result of DNA double strand breaks, exposure to toxins 
or the shortening of telomeres located at the end of eukaryotic chromosomes (a 
phenomenon generally attributed to "replicative senescence"). In 2009, Elizabeth 
Blackburn, Carol Greider and Jack Szostak were awarded the Nobel Prize in 
Physiology or Medicine (the closest Nobel Prize to date related to the field of aging) 
for their significant contributions of how telomeres are maintained by the specialized 
reverse transcriptase telomerase. Rapid telomere shortening may indicate cellular 
hyper-activation, hyper-proliferation and/or hyper-secretory phenotypes that are 
often associated with cellular senescence, stem cell exhaustion and diseases of 
aging. In agreement with these possibilities, telomere shortening has been shown to 
regulate the expression of the interferon-stimulated gene 15 (ISG15). Lou and 
colleagues demonstrated, for the first time, that an endogenous human gene can be 
regulated by telomere length prior to the onset of telomere dysfunction and DNA 
damage signals. Therefore, ISG15 up-regulation in response to telomere shortening 
may contribute to a chronic inflammation commonly associated with human aging 
(Lou, Wei et al. 2009). In 2009, several publications by Epel, Blackburn and co-
workers provided a new link between telomere length and age-related diseases. As 
published in the first issue of Aging, the rate of telomere shortening in peripheral 
leukocytes predicts mortality from cardiovascular disease in elderly men (Epel, 
Merkin et al. 2009). In response to DNA damage or shortened telomeres, cells either 
“age” or self-destruct through apoptosis, a highly regulated process that involves 
characteristic changes such as cell shrinkage, nuclear fragmentation, chromatin 
condensation, and chromosomal DNA fragmentation. This “cellular suicide”, the 
death of one or more cells may benefit the organism as a whole because it depletes 
compromised or deficient cells from the body; thereby preventing the accumulation 
of potentially cancerous cells.  
1.2 Theories of Aging 
Theories of Aging try to explain the various aspects of senescence. Some of 
the major cellular and functional changes of aging and the potentially underlying 
theories are shown in Table 1-1. Due to the process of senescence being complex, 
and deriving from a variety of different mechanisms, the closest we can currently get 
to understand the exact etiology of aging is by accepting that all aging-theories 
contribute to a holistic understanding of the aging process. 
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Table 1-1. Major cellular and functional changes of aging by prominent 
theories and major associated clinical disease outcomes.  
Modified from (Cefalu 2011). 
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Existing theories of aging can be divided into the programmed or stochastic theories 
of aging and are subsequently classified into evolutionary, physiological, structural 
and functional changes. Physiologic processes included into theories of aging 
emphasize the role of oxidative stress, immunology, neuro-endocrinology, the 
metabolism, insulin signaling pathways, and caloric restriction. At the cellular level, 
structural and functional processes that emphasize the role of intrinsic timing 
mechanisms and signals (for example through hormone signaling or programmed 
genetic signals), free radical formation, nuclear or mitochondrial DNA mutations or 
damage, the accumulation of damaged and abnormal proteins, accidental chance 
events, cross-linkage, glycation, waste accumulation, general molecular wear and 
tear, and specific cellular components such as genes, chromosomes or 
mitochondria, are all included into the aging theories (Cefalu 2011). Theories that 
include parts of these aspects are presented here after.  
Understanding the biological evolution of aging and lifespan is based on 
observations of the life cycles of biological species. Evolutionary aging theories try to 
explain the differences in aging rates and longevity across different biological 
species (e.g. mice and humans) through the interplay of mutation- and selection-
processes. For example, observations of the “suicidal” life cycles of species like the 
pacific salmon have promoted the idea that sexual reproduction may come with a 
cost for species longevity. Thus, in addition to mutation and selection, the 
reproductive cost, or, more generally, the trade-offs between different traits of 
organisms may also contribute to the evolution of species aging and longevity 
(Gavrilov and Gavrilova 2002). The “disposable soma theory” was proposed by 
Kirkwood in 1977 and describes that all living organisms have finite energy 
resources (Kirkwood 1977). The available energy must be balanced between 
maintenance and reproduction. Reproduction occurs when nutrients are sufficiently 
available to secure offspring survival. Under conditions of reduced nutrient 
availability, the reproductive rate is reduced in order to ensure cellular function. It is 
the compromise of allocating energy between reproduction and repair that causes 
the body gradually to deteriorate with age. 
The logical foundations for most of the modern evolutionary theories of aging 
were completed relatively late in the 1950s and almost a century after Darwin 
suggested his theory of biological evolution (Darwin 2003). The biological evolution 
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of aging was initially studied in a purely theoretical and non-experimental way by 
Weismann (Programmed death theory, 1882; later adapted), Medawar (Mutation 
accumulation theory, 1952), Williams (Antagonistic Pleiotropy theory, 1957) and 
others. Their evolutionary theories of aging were subsequently (although only 
partially) tested by evolutionary experiments on D. melanogaster (Stearns, 
Ackermann et al. 2000) and on natural populations of Poecilia reticulata guppies 
(Reznick, Buckwalter et al. 2001). In these two studies, selection for later 
reproduction (artificial selection of late-born progeny) produced, as expected, longer-
lived fruit flies while placing guppies in a more dangerous environment with high 
extrinsic mortality redirected evolution to a shorter lifespan in the following 
generations. These experiments found that aging and lifespan do evolve in 
subsequent generations of biological species in a theoretically predicted direction 
depending on the particular living conditions. Therefore, the early criticism of the 
evolutionary theory of aging as merely theoretical speculation, with limited and 
indirect supporting evidence obtained from retrospective and descriptive studies, has 
been overturned. A detailed overview about evolutionary aging theories is provided 
by Gavrilov et al. (Gavrilov and Gavrilova 2002). 
The evolutionary theories of aging are closely related to the genetics of aging 
because biological evolution can only be possible through inheritable manifestations 
of aging. Programmed aging theories propose that senescence is the final 
destination in a developmental pathway that culminates in death. These theories 
suggest that aging is under control of “biological clocks” which operate throughout 
the lifespan of an organism. The regulatory effects of these clocks seem to be 
depending on changes in the gene expression pattern of systems involved in 
cellular-maintenance, -repair, and -defense. One such theory is the “Reproductive-
Cell Cycle Theory” which reasons that cell growth, development, and death are 
under the regulation of reproductive hormones derived from the hypothalamic-
pituitary-gonadal (HPG) axis. According to this theory, reproductive hormones, such 
as estrogens, progestagens, androgens and gonadotropins, and their receptors, 
have an essential function in promoting growth and development of the organism. 
Normal function in early life is important in order to achieve a maximal reproductive 
rate. With the onset of hormonal changes (in men around age 30 and in women 
when they reach menopause, around age 50), the HPG axis becomes unbalanced, 
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cellular growth and development become deregulated, cellular-dysfunction and cell-
death are increasingly more prominent and thus promote senescence (Atwood and 
Bowen 2011). Supporting evidence for the reproductive-cell cycle theory includes 
studies that demonstrate that women with menopause occurring later in their life 
show reduced heart disease, fewer incidences of stroke, are less prone to dementia, 
and experience less osteoporosis. Conversely, early surgical menopause has been 
demonstrated to increase the incidence of these diseases (Ossewaarde, Bots et al. 
2005). In addition, studies in support of the theory have shown that suppressing 
growth hormone, regulated by the neuro-secretory nuclei of the hypothalamus, and 
insulin-like growth factor 1 (IGF-I) signaling (a part of the growth hormone axis), 
such as caused by caloric restriction or exercise, increases lifespan (Atwood and 
Bowen 2011). Another programmed theory of aging is related to a similar “fixed” life 
span model. The developmental–genetic theory of aging proposes that the 
genetically programmed induction of senescence occurs during adult lifespan, which 
results in either the activation or suppression of specific “aging” genes. Support for 
this theory comes from studies that indicate that longevity in humans seems to be 
hereditable related to the presence of specific genes. One such “aging gene” is the 
human leucocyte antigen (HLA), which showed significantly high levels in a study of 
old (over the age of 85) healthy subjects (Ricci, Colombo et al. 1998). However, 
research that showed that physical fitness improves longevity in humans speaks 
against the developmental–genetic theory. 
Stochastic theories position environmental impacts, which induce cumulative 
damage at various levels, as the cause of aging. Examples include oxygen radicals 
(widely known as free radicals and countered by the even more prominent 
antioxidants) that can damage DNA (e.g. by cross-linking), cells and tissues. The 
“Chromosomal Alterations Theory” proposes that normal aging is related to 
alterations in the chromosomal structure: deletions, mutations, translocations, and 
polyploidy acquired chromosomal instabilities contribute to gene silencing or gene 
specific expression over time (Cefalu 2011). Another popular theory of aging is the 
autoimmune theory, which is based on the hypothesis that the human body 
produces auto-antibodies against its own tissues and/or that deficits, primarily in T-
cell function, predispose the elderly to the development of infections, chronic 
disease, cancer, and autoimmune diseases, e.g. rheumatoid arthritis (Kent 1977).  
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One of the most commonly accepted aging theories is the “Free Radical 
Theory of Aging”, first proposed by Harman in the 1950s (Harman 1956). The theory 
states that highly reactive oxygen-derived substances (free radicals) result in the 
accumulation of protein-, lipid-, and DNA-damage as a result of normal cellular 
metabolism. In later years, the theory was extended to include the role of 
mitochondrial free radical production (Harman 1972). Free radicals are mainly 
produced inside cellular organelles, in particular the mitochondria, which convert 
energy for the cell into adenosine triphosphate (ATP). Oxidative phosphorylation, the 
process in which ATP is produced, involves the shuttled transport of protons 
(hydrogen ions) through the electron transport chain across the inner mitochondrial 
membrane. For ATP production, electrons are passed through a series of proteins; 
each acceptor protein along the chain has a greater reduction potential than the 
previous one. The last destination for an electron along the electron transport chain 
is an oxygen molecule which is then reduced to produce H2O. The reduction of 
oxygen and the transported electrons, however, is not 100% efficient. Approximately 
0.1–2%, oxygen is prematurely and incompletely reduced to produce the superoxide 
radical (·O2-), mostly documented for Complex I and Complex III (Gomez and 
Hagen 2012). Reactive oxygen species are therefore a byproduct of normal cellular 
metabolism. Superoxide is not particularly reactive by itself, but plays a role in 
hydrogen peroxide formation (H2O2), which can leak from the mitochondria into the 
cell. It is postulated that reactive oxygen may be a signal for aging and its levels in 
tissues may determine the aging process and lifespan. 
However, multiple experiments critically question the free radical theory. First, 
the over-expression of major antioxidant enzymes (e.g. superoxide dismutase or 
catalase), does not extend the lifespan of mice (Perez, Van Remmen et al. 2009) 
and mitochondrial superoxide dismutase (Sod-2) haplo-insufficiency does not 
accelerate murine aging, even in mice with dysfunctional telomeres (Guachalla, Ju 
et al. 2009). Even more surprisingly is that the deletion of Sod-2 extends the lifespan 
in the nematode Caenorhabditis elegans (Van Raamsdonk and Hekimi 2009). It was 
also reported that RNAi of five genes encoding components of mitochondrial 
respiratory complexes I, III, IV, and V leads to increased life span in flies. Long-lived 
flies with reduced expression of these electron transport chain genes do not 
consistently show a reduced assembly of respiratory complexes or reduced ATP 
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levels. In addition, extended longevity is not consistently correlated with increased 
resistance to the free-radical generator paraquat (Copeland, Cho et al. 2009). These 
results are in agreement with previous papers showing that antioxidant over-
expression causes minor effects in life span extension in yeast, flies, and mice 
compared to those caused by mutations in signal transduction genes. It is likely that 
the increased protection against superoxide must be accompanied by a number of 
other changes to be effective in life span extension. For instance, LON, a protease 
located in the mitochondrial matrix, increases stress tolerance, prevents the 
accumulation of oxidized proteins (Ngo, Pomatto et al. 2011) and increases 
mitochondrial oxygen consumption, while decreasing oxidative damage of proteins 
in the fungal aging model Podospora anserine (Luce and Osiewacz 2009). In the 
same model organism, deletion of a gene encoding an O-methyltransferase, which 
decreases levels of reactive oxygen species, leads to a decreased lifespan 
(Kunstmann and Osiewacz 2009). 
1.3 Aging-related Diseases 
In the United States, the geriatric population, individuals 65 years of age or 
older, has been continuously increasing in size. Between 1989 and 2010, this 
population rose from 25 to 40 million and is expected to grow to almost 90 million by 
2050 (Zoorob, Kihlberg et al. 2011). Aging is by far the leading cause of death: an 
estimated 100,000 people die of age-related causes per day, about two thirds of the 
roughly 150,000 people who die each day across the globe. In industrialized nations, 
the proportion is much higher, reaching 90% (Lopez, Mathers et al. 2006). The 
majority of these deaths can be attributed to age-associated diseases which include 
a wide array of illnesses, including cardiovascular disease, cancer, arthritis, 
cataracts, osteoporosis, type 2 diabetes, hypertension and Alzheimer's disease. 
Essentially, all of these aging-associated diseases are complications that arise from 
cellular deterioration. Despite the pronounced interconnection of aging and disease 
is it important to distinguish age-associated diseases from the aging process itself: 
all animals will age, yet not all adult animals, as either an individual or as a species, 
experience age-associated diseases. Mice for example generally do not, unless 
genetically altered, experience atherosclerosis (Breslow 1996).  
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 In a study conducted by Baker and colleagues in 2011 on mice, senescent 
p16INK4A -positive cells were deliberately eradicated, leading to greater resistance 
against aging-associated diseases in the BubR1 progeroid mouse background. 
Therefore, cellular senescence is causally implicated in generating age-related 
phenotypes, and the removal of senescent cells can prevent, or delay, tissue 
dysfunction and extend health span (Baker, Wijshake et al. 2011). 
1.4 The Epidemiology of Cancer 
Although all the aforementioned aging-related diseases present a particular 
challenge for ongoing and future research, the data I present in this dissertation will 
focus mainly on the treatment of malignant neoplasms known as cancer. 
In 2008, 12.7 million cases of cancer are estimated to have occurred and 7.6 
million people died of cancer worldwide (Fig. 1-1). The exact number however can 
only be estimated because incidence rates and treatment modalities for some parts 
of the world are not fully established. With the expected increase in the population of 
the elderly, as well as the adaption to cancer-causing behaviors (e.g. cigarette 
smoking), the death rate is projected to increase to 13.2 million in 2030 (Brawley 
2011). Malignant neoplasms are the major cause of death in economically developed 
countries and the second leading cause of death in developing countries. Breast 
cancer in the female population and lung cancer in the male population are the most 
frequently diagnosed malignancies in both developed- and developing-countries 
(Jemal, Siegel et al. 2008). Of particular interest is that a large percentage of most 
cancer deaths seem to be avoidable. In 2005, Danaei and colleagues proposed that 
about 35% of all cancer deaths worldwide could have been avoided through 
adjustments to lifestyle- and environmental-factors (Danaei, Vander Hoorn et al. 
2005). Based on these (rough) estimations, out of the 7.6 million cancer deaths in 
2008, about 2.6 million (or ~7000 deaths/day) could have been avoided through the 
prevention of exposure to major risk factors such as tobacco use, diet, infections and 
alcohol use. Tobacco use is of significant importance to these statistics, as it not only 
drastically increases the risk of lung cancer, but at least 15 additional locations, and 
is the most preventable cause of cancer-related death. Cancer-deaths attributed to 
tobacco usage account for 20% (1.6 million) of the total deaths worldwide. A 
particular contribution to cancer rates in developed countries can be correlated to 
lifestyle choices such as reduced exercise (and the correlating increase in obesity) 
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and unhealthy diets. Several cancers, including the most common malignancies in 
developed countries such as breast, colorectal, stomach, liver, kidney and uterine 
cancers have been shown to have a clear link to these risk-factors (Watson and 
Collins 2011; Cabibbo, Maida et al. 2012; Cramer 2012; Li, Zhang et al. 2012; Navai 
and Wood 2012; Wang, Lehuede et al. 2012).  
 
Due to the impact of dietary choices on cancer, parts of my dissertation are 
focused on the role of dietary macronutrient compositions and the effects on stress-
resistance and tumor progression, as well as potential implications of short-term 
fasting regimes for the improvement of existing cancer treatments, including chemo- 
and radio-therapy. 
 
 
 
 
Figure 1-1. Estimation of new cancer cases and deaths worldwide for the 
leading cancer sites in 2008.  
Source: GLOBOCAN 2008. Modified from (Jemal, Siegel et al. 2008). 
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1.5 Development of Malignant Cells 
In 2000, Douglas Hanahan and Robert Weinberg postulated the “hallmarks of 
cancer” and formulated the hope that cancer-research of the next century will 
“become understandable in terms of a small number of underlying principles” and 
“that the teachings of cell biology that virtually all mammalian cells carry a similar 
molecular machinery regulating their proliferation, differentiation and death” will be 
the foundation of cancer research for the new century (Hanahan and Weinberg 
2000). Over the last 50 years, research has made progress in at least partly 
recognizing the underlying mechanisms that govern the transformation from normal 
into malignant cells.  
The genetic alterations of cancer cells, known as the hallmarks of cancer, 
include the 1) self-sufficiency in growth signaling and the 2) insensitivity to growth-
inhibiting signals, 3) evasion of apoptosis, 4) a limitless replicative potential, 5) 
sustained angiogenesis, and finally 6) the capacity to metastasize. Work of the past 
decade has made substantial contribution to further our understanding and required 
the addition of new hallmarks: 7) genome instability, 8) inflammation, 9) avoiding of 
immune destruction and 10) reprogramming of energy metabolism (Fig. 1-2) 
(Hanahan and Weinberg 2000). Based on the variety of cancer types in the human 
population, with more than 100 distinct types and various subtypes, it is clear that 
tumor cells have experienced alterations ranging from small point mutations 
(Rodenhiser, Chakraborty et al. 1996) up to significant changes in their 
chromosomes (Albertson, Collins et al. 2003). In tissue culture models, the 
transformation of rodent cells to achieve tumorigenic competence requires the 
acquisition of at least two genetic alterations; human cells are even more difficult to 
transform in vitro (Hahn, Counter et al. 1999). In vivo, transgenic mouse models of 
tumorigenesis led to the conclusion that multiple steps have to occur before rodent 
cells can become malignant (Berns, van der Lugt et al. 1994; Wu and Pandolfi 
2001). In the human population, a minimum of four stochastic, rate-limiting events 
with multiple intermediate steps are required to transform normal cells into an 
invasive cancer cell, thus explaining why the development of cancer is a relatively 
rare event (when considering the estimated up to 100 trillion cells that form the 
human body) and why it occurs in an aging-related manner during the average 
human lifetime (Foulds 1954; Renan 1993). Considering that tumorigenesis is a 
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multi-step process that requires specific genetic alterations to successfully avoid the 
regulatory mechanisms that govern normal cell proliferation and homeostasis, it is 
not surprising that research increasingly focuses on cancer-specific treatment 
options and personalized medicine. 
In the following section, I will describe some of the underlying mechanisms 
that are essential to cancerous cells. However, a comprehensive review on 
transformation and malignancy is beyond the scope of this dissertation. 
 
 
Figure 1-2. The hallmarks of cancer. 
The six original hallmarks postulated in 2000 include self-sufficiency in growth 
signaling and the insensitivity to growth-inhibiting signals, the evasion of apoptosis, a 
limitless replicative potential, sustained angiogenesis, and metastatic capacity. The 
addition of the new hallmarks genome instability, inflammation, avoiding of immune 
destruction, and reprogramming of energy metabolism are added based on recent 
discoveries in the development of cancerous cells (cartoon in the center of the 
image). From (Hanahan and Weinberg 2011). 
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Self-sufficiency in growth signaling was among the first clearly identified 
capacities of malignant cells due to the defined roles of oncogenes. Normal cells rely 
on carefully released mitogenic signals (mediated by intercellular communication 
such as autocrine, paracrine or endocrine signaling pathways) to actively exit a 
quiescent state and proliferate, to maintain a balanced cell number, and to ensure 
normal tissue architecture/function. Growth signals are transmitted through a wide 
variety of transmembrane receptors which can bind diffusible growth factors (e.g. 
IGF-I or EGF), act as cell-cell adhesion molecules (e.g. cadherins) and can bind 
extra-cellular matrix components (e.g. integrins). The majorities of transmembrane 
receptors that mediate growth signals belong to the tyrosine kinase family and 
transmit signals through downstream signaling cascades to regulate gene 
expression, protein-modifications, and functions; thereby modulating energy 
metabolism and survival. Deregulated growth signaling in tumor cells can be due to 
the increased number of cell surface receptors, which causes cells to be hyper-
sensitive to their ligands. Further, hyper-responsiveness of signaling receptors to 
their ligands can result from structural alterations in the extra-, transmembrane-, 
and/or intra-cellular structure of the receptor itself; these alterations may even cause 
ligand independent receptor activation (Lyons, Rao et al. 2008). Malignant cells may 
also be independent of exogenous signals through oncogenes, located downstream 
of the transmembrane receptors, that mimic, or even enhance, normal growth 
signaling; thus disrupting cellular homeostasis. 
 Mutations downstream of the IGF-I receptor, such as the hyper-activation of 
phosphoinositide 3-kinase (PI3K), or the mutations in the protein B-Raf (resulting in 
activation of the mitogen-activated protein kinase (MAPK) pathway) have been 
detected in multiple tumor types (Jiang and Liu 2009; Davies and Samuels 2010; 
Sander, Calado et al. 2012). Further, malignant cells are capable of synthesizing 
growth factors to create a positive feed-back loop with autocrine function (Schlange, 
Matsuda et al. 2007; Wilson, Lee et al. 2011). Alternatively, cancer cells can signal 
the surrounding tissue, and normal cells in the tumor-associated stroma, to stimulate 
growth factor production (Bhowmick, Neilson et al. 2004; Cheng, Chytil et al. 2008). 
Sustained proliferative signaling can also result from the disruption of negative 
feedback-loops. One of the most commonly found proto-oncogenes in human cancer 
is the Ras proto-oncogene, which activates proteins that ultimately regulate genes 
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involved in cell growth, differentiation and survival (Downward 2003; Pylayeva-
Gupta, Grabocka et al. 2011). Another example of the disruption of negative 
feedback signaling are loss-of-function mutations in the phosphatase and tensin 
homolog PTEN. In normal cells, PTEN negatively regulates PI3K signaling by 
degrading its product phosphatidylinositol (3,4,5) trisphosphate (PIP3). Therefore 
loss-of-function mutations in PTEN promote tumorigenesis by sustained PI3K 
signaling (Song, Salmena et al. 2012). Of further interest, in particular due to the role 
of integrating the input from upstream pathways, including insulin, growth factors 
(e.g. IGF-I), and amino acids, is the serine/threonine protein kinase mammalian 
target of rapamycin (mTOR) (Laplante and Sabatini 2012). The modulation of mTOR 
activation can, via negative feedback-loops, affect PI3K signaling. The 
pharmacological inhibition of mTOR, by rapamycin for example, results in an 
increased activity of PI3K and therefore rapamycin treatment might actually blunt the 
anti-proliferative effects of mTOR inhibition (O'Reilly, Rojo et al. 2006).  
The excessive expression of proto-oncogenes, including RAS and PI3K, and 
the resulting proliferative signaling can trigger cellular senescence (Fig. 1-3) and 
hence seems to reflect an intrinsic cellular defense against cells that experience an 
uncontrolled proliferative state. Senescent cells, identified by markers such as the 
expression of senescence-induced β–galactosidase, enlarged cytoplasm and the 
absence of markers indicative of proliferation, are prominent in tissues of mouse-
models of proto-oncogene deregulation (Collado and Serrano 2010), such as ras 
(Serrano, Lin et al. 1997), but can also be found in human tumor samples 
(Michaloglou, Vredeveld et al. 2005). The maximal proliferative stimulation in 
malignant cells must therefore be accompanied by mutations that help to avoid the 
anti-proliferative response of “induced senescence”.   
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Figure 1-3. Pathways of oncogene-induced senescence. 
Signaling pathways that lead to senescence induction in vivo when aberrantly 
activated. Oncogenes and tumor suppressers shown in red correspond to those that, 
when mutated, have been shown to lead to senescence in vivo. (GRB2, growth 
factor receptor-bound protein 2; GSK3β, glycogen synthase kinase 3β; HIF1α, 
hypoxia-inducible factor 1α; NF1, neurofibromin 1; P, phosphorylation; PDK1, 3-
phosphoinositide-dependent kinase 1; PIP2, phosphatidylinositol 4,5-bisphosphate; 
PIP3, phosphatidylinositol 3,4,5-trisphosphate; Ras GAP, Ras GTPase-activating 
protein; Ras GEF, Ras guanine nucleotide exchange factor; TSC, tuberous sclerosis; 
VHL, von Hippel–Lindau. From (Collado and Serrano 2010) 
 
Evading growth suppression is the second important hallmark. Cancer cells 
must evolve to evade multiple anti-proliferative signals that regulate cellular 
quiescence to maintain tissue homeostasis. These anti-growth signals act as tumor-
suppressors and include both soluble and immobilized inhibitors (e.g. on the cell 
surface of neighboring cells or the extracellular matrix), which can interfere with 
cellular proliferation in two ways: 1) signal cells to enter the quiescent G0 cell cycle-
state or 2) to differentiate into a post-mitotic cell state. The two most well-known 
tumor-suppressors are the retinoblastoma-associated (RB) and P53 proteins. The 
RB protein, and its two homologs p107 and p130, govern the transit of the 
proliferating cell through the G1-phase of the cell cycle by integrating signals from 
extra- and intra-cellular sources (Burkhart and Sage 2008). The hypo-
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phosphorylation of RB blocks proliferation by inhibiting the E2F transcription factors, 
which control the expression of genes necessary to progress from G1 to S phase. 
Transforming growth factor beta (TGFβ) prevents the phosphorylation of, and thus 
inactivates, RB and blocks the progression into the S phase of the cell cycle. Cancer 
cells with disrupted TGFβ and RB pathways thus have active E2F function, resulting 
in cell proliferation and render cells insensitive to anti-proliferative signaling. RB 
signaling disruption can result from various alterations, such as the down-regulation 
of TGFβ-receptors (Meng, Xia et al. 2011) or displaying dysfunctional TGFβ-
receptors (Markowitz, Wang et al. 1995). 
P53 functions as a sensor that integrates input from stress and abnormalities 
such as damage to the genome, reduced levels of nucleotides, reduced glucose 
levels, disrupted growth-signaling and suboptimal levels of oxygenation and halts cell 
cycle progression until normal cellular conditions have been re-established. If the 
conditions do not normalize, P53 can induce apoptosis. P53 null (-/-) mice develop 
tumors at a young age: 75% of p53 -/- mice develop tumors of various types by 6 
months of age and all succumb to tumors by 10 months of age (Donehower, Harvey 
et al. 1992). The p53 heterozygous (p53+/-) mice are also susceptible to tumors, but 
these neoplasms arise later than those observed in the p53 -/- mice; tumors are 
rarely observed until nine months of age. By 18 months, roughly 50% have 
developed cancers, and by 24 months, over 95% of the animals have had tumors or 
died (Venkatachalam, Shi et al. 1998). 
 
Evading apoptosis is essential for cancer initiation because growth and 
expansion are not only based on the rate of cellular proliferation, but also on the 
capacity to maintain the already established pool of cells. Apoptosis serves as a 
check point to uncontrolled proliferation because apoptosis can be triggered in 
response to abnormalities such as oncogene-related imbalances (Vaux, Cory et al. 
1988) and DNA damage associated with hyper-proliferation (Zindy, Eischen et al. 
1998). Many apoptotic signals converge on the mitochondria and in response to pro-
apoptotic signals (e.g. cytokines, nitric oxide, temperature, hormones and toxins) 
cytochrome C is released from the mitochondria through the formation of the 
mitochondrial apoptosis-induced channel (MAC) in the outer mitochondrial 
membrane. The MAC formation is regulated by various proteins, such as those 
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encoded by the mammalian Bcl-2 family with either anti-apoptotic (Bcl-2, Bcl-XL, Bcl-
W, Mcl-1, A1) or pro-apoptotic (Bax, Bak, Bid, Bim, Puma) properties. The released 
cytochrome C binds with the apoptotic protease activating factor-1 (Apaf-1) and ATP, 
which then bind to pro-caspase-9, creating a protein complex known as the 
apoptosome. The apoptosome cleaves the pro-caspase to its active form (caspase-
9), which in turn activates an intra-cellular cascade of proteases (effector caspases 
3, 6 and 7) to execute cell death.  
The deregulation of apoptosis is, in part, mediated by the loss of the tumor-
suppressor p53 in malignant cells, eliminating this “damage sensor”. Further, tumor 
cells may avoid the induction of apoptosis by increasing the expression levels of anti-
apoptotic regulators such as Bcl-2 and Bcl-XL (Kroemer 1997), or the down-
regulation of pro-apoptotic factors such as Bax, Bim or Puma (LeBlanc, Lawrence et 
al. 2002). The underlying principles to evade apoptosis are based on the structure of 
the pro- and anti-apoptotic pathways, but also rely on autophagy (which can mediate 
tumor cell survival, and death, based on genetic and cell-physiological conditions 
that dictate either fate) or necrosis (which has a pro-inflammatory and tumor-
promoting potential). See Favaloro et al. for a review on the role of apoptosis in 
diseases (Favaloro, Allocati et al. 2012).  
 
Enabling replicative immortality is another hallmark of cancer cells and is 
important to avoid cell death. The potential for limitless proliferation is a phenomenon 
generally not attributed to normal cells; stem- and germline-cells are an exception 
from this rule. This limitation, known as the Hayflick limit (Hayflick 1965), depends on 
two hurdles: cellular senescence (and the decrease in the replicative potential) as 
well as a subsequent crisis, resulting in cell death. Telomeres, composed of 
thousands of 6 base-pair (bp) sequence repeats at the end of the chromosomes are 
constantly shortened by 50-100 bp during each replication. The eventual loss of 
telomeres leaves the end of the chromosome unprotected and exposed to end-to-
end fusions, resulting in unstable dicentric chromosomes, karyotypic disarray and 
death. The shortening of telomeres is caused by the incapacity of the DNA 
polymerase to completely replicate the 3’ ends of the chromosomal DNA. 
Telomerase, a reverse transcriptase, protects the chromosome by adding 
hexanucleotide repeats onto the end of the telomeric DNA. Although the above 
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described acquired capabilities (self-sufficiency in growth signaling, insensitivity to 
growth-inhibiting signals and evasion of apoptosis) are necessary for the malignant 
cell to evade organismal regulation, the maintenance of the telomeres is essential to 
maintain a constant pool of cells. Otherwise, pre-malignant cells eventually succumb 
to senescence and death based on their own up-regulated proliferative capacities. 
The role of telomere maintenance in mediating replicative immortality has been 
demonstrated in vitro: the expression of telomerase conveyed unlimited replicative 
potential to a set of normal, pre-senescent cells (Bodnar, Ouellette et al. 1998; Vaziri 
and Benchimol 1998), and late passage cells (Counter, Hahn et al. 1998; Halvorsen, 
Leibowitz et al. 1999). In tumor-suppressor P53 deficient mouse models, engineered 
to lack telomerase, pre-malignant cells could be pushed towards a senescent state 
that contributed towards attenuated tumor development (Artandi, Chang et al. 2000). 
In contrast to normal cells, virtually all tumor cells have increased telomere 
maintenance, largely (85-90%) depending on the up-regulation of telomerase 
expression (Shay and Bacchetti 1997) or through the activation of a recombination-
based telomere maintenance known as alternative lengthening of telomeres (Bryan, 
Englezou et al. 1995; Biessmann and Mason 2003). Mice carrying a homozygous 
deletion of the negative cell cycle regulator p16INK4A with elevated telomerase activity 
are particularly prone to develop tumors. However, applying carcinogen treatment to 
p16INK4A–null mice which lack telomerase activity results in reduced tumor incidence 
and telomere shortening with karyotypic disarray (Greenberg, Chin et al. 1999). 
It can be argued that senescence, similar to apoptosis, reflects a protective 
mechanism that forces deregulated cells into a non-proliferative cell state when DNA 
damage becomes increasingly abundant. Tumor cells evade these protective means, 
thus making sustained telomerase function essential to maintain high cell 
proliferation rates.  
 
Induced and sustained angiogenesis is essential to maintain the progressive 
growth of solid tumors. Like most normal tissues, cancer cells rely on the sustained 
availability of O2 and nutrients. Further, residing close to the vasculature is 
necessary to remove carbon dioxide and metabolites. It is this dependency that 
obligates metabolically-active cells in the tissue to maintain in close proximity, no 
more than 100 µm, to capillary blood vessels. This connection emphasizes why 
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tumor progression is essentially depending on continued angiogenesis (the sprouting 
of vessels from the existing vasculature). In the adult tissue, angiogenesis is a rare 
and highly regulated event with the main physiologic function to ensure wound 
healing, but further plays a role in the female menstrual cycle and under hypoxic 
conditions. Tumor cells cannot passively rely on the surrounding vessels but have to 
induce the sprouting of new vessels from the quiescent vasculature, a step known as 
the “angiogenic switch”. Mechanisms to induce this switch are based on alterations 
in balancing the production of angiogenic inducers or inhibitors through changes in 
the gene expression profile (e.g. increased levels of the vascular endothelial growth 
factor (VEGF) and the fibroblast growth factor (FGF), reduced levels of 
thrombospondin-1 and β-interferon). VEGF and FGF both bind to tyrosine receptor 
kinases presented on endothelial cells and induce sprouting. The prototype of 
angiogenic inhibitory proteins, thrombospondin-1 (TSP-1), binds to multiple receptors 
(including CD36, integrins and integrin-associated proteins) and suppresses pro-
sprouting stimuli.  
Mice lacking genes encoding for angiogenic inhibitors, e.g. TSP-1 null mice 
(Rodriguez-Manzaneque, Lane et al. 2001) or TSP-1/P53 deficient mice (Lawler, 
Miao et al. 2001), show enhanced tumor progression. Vice versa, the genetic 
increase of angiogenic inhibitors in mouse models impairs tumor progression; 
examples of this inhibition include the delayed and decreased papilloma formation in 
the skin of TSP-1 over-expressing mice in a chemical-induced skin carcinogenesis 
model (Hawighorst, Oura et al. 2002). Further, anti-VEGF antibodies (Kim, Li et al. 
1993) and the dominant interfering VEGF-receptor 2 (Millauer, Shawver et al. 1994) 
reduced the growth of subcutaneous tumor models, mediated by an impaired 
angiogenesis. 
The mechanisms that cause shifts in the equilibrium of angiogenic regulators 
towards an increase in neo-vascularization/angiogenesis in malignant cells are still 
only poorly understood. However, proto-oncogene and tumor-suppressor gene levels 
are tightly knit to regulate levels of angiogenic regulators. The p53 tumor-suppressor 
negatively regulates TSP-1 and loss of function mutations in p53 can result in 
decreased levels of the angiogenic inhibitor TSP-1 (Dameron, Volpert et al. 1994). 
The ras oncogene, on the other hand, causes the up-regulation of the pro-
angiogenic VEGF (Rak, Mitsuhashi et al. 1995). 
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Activating tissue invasion and metastasis enable cancer cells to leave the 
primary tumor and invade nutrient- and oxygen-rich tissues, where they begin to 
form new tumor sites through a multistep process known as the “invasion-metastasis 
cascade”. This cascade is based on local invasion, the intra-vasation into proximal 
blood- and lymph-vessels, transition through the lymphatic- and hematologic-system, 
infiltration of the parenchyma of distant tissues, nodule formation (micro-metastasis) 
and the subsequent growth of macroscopic tumors (Fig. 1-4). Metastases are the 
cause of up to 90% of cancer-related deaths in humans (Sporn 1996). It is of 
particular interest that tumor cells can undergo dormancy, leading to recurrence after 
therapy and long periods of remission also known as “minimal residual disease” 
(MRD) (Aguirre-Ghiso 2007). For example, 20 to 45% of patients with breast or 
prostate cancer will relapse years or decades later (Karrison, Ferguson et al. 1999; 
Weckermann, Muller et al. 2001). The formation of metastases, like the formation of 
the primary tumor, depends on the previously described hallmarks of cancer (see 
above). The capacity to metastasize involves alterations in the interaction of tumor 
cells with the surrounding normal cells/tissue through cell adhesion molecules 
(CAM), including members of the immunoglobulin family, integrins and cadherins.  
E-cadherin is ubiquitous expressed in epithelial cells and bridges adjacent 
cells, resulting in anti-growth signaling and contact inhibition (Aplin, Howe et al. 
1999). In the majority of epithelial cancers, including squamous cell carcinoma, E-
cadherin function is drastically reduced and even lost due to mutational inactivation 
of the E-cadherin or β-catenin (a functional subunit of the cadherin protein complex) 
genes (Jiang and Mansel 2000), by transcriptional repression (Hajra, Ji et al. 1999) 
or by proteolysis of the extracellular domain (Bergers and Coussens 2000). 
Subsequently, exploring the role of E-cadherin in tumor cell lines in vitro 
demonstrated that re-establishing a functional cadherin complex resulted in the 
reversion from malignant, invasive cancer cells into a more benign epithelial tumor 
cell phenotype (Frixen, Behrens et al. 1991). Studies exploring the role of E-cadherin 
in tumor development in vivo demonstrated that the expression of this cell adhesion 
molecule in a transgenic mouse model (Rip1Tag2) of carcinogenesis blocked 
invasion and metastases (Perl, Wilgenbus et al. 1998).  
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Figure 1-4. The invasion-metastasis cascade of malignant cells. 
Tumor cells carrying genetic or epigenetic changes, enabling motile and invasive 
properties, can invade the underlying stroma and interact with fibroblasts or immune 
cells and the stromal matrix. Tumor cells (in cooperation with stromal cells) can 
degrade the extracellular matrix (ECM) and the vascular walls and intra-vasate 
through either arterial or lymphatic routes. Tumor cells that arrest in the vasculature 
of the bone marrow can proliferate or remain dormant. Although the bone can be a 
target organ, it might also serve as a transit site from which cells can again 
disseminate, through yet unknown mechanisms, to their final destination. Tumor 
cells can arrest in lymph nodes or in the target organ vasculature, where they can 
extra-vasate into the organ parenchyma. At this stage, intra- or extra-vascularly 
lodged tumor cells have four possible fates: 1) they die (the vast majority of cells 
undergo apoptosis), they can enter a state of quiescence or dormancy, either as 2) a 
single solitary cell or 3) as a micro-metastatic lesion that underwent a proliferative 
expansion and cannot recruit a vascular bed, or 4) they can resume proliferation into 
micro-metastases. Modified from (Aguirre-Ghiso 2007). 
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In addition to cadherins, immunoglobulins play a critical role in invasion and 
metastasis. The most prominent member of this super-family is the neural cell 
adhesion molecule (NCAM). NCAM deregulation in tumor cells can be based on 
poorly adhesive, even repulsive, isoforms (Rutishauser, Acheson et al. 1988), or on 
reduced expression (Fogar, Basso et al. 1997). In a transgenic mouse model of β-
cell carcinogenesis (Rip1Tag2), the tumor-phenotype correlates with a changed 
expression from the 120 kDa isoform in normal tissue to the 140/180 kDa isoforms in 
the tumor. NCAM-deficient Rip1Tag2 mice develop metastases, which has generally 
not been observed in normal Rip1Tag2 mice. In contrast, over-expression of NCAM 
120 in NCAM-deficient Rip1Tag2 mice rescued this phenotype (Perl, Dahl et al. 
1999). 
Although there are shared and common attributes of tumor cells (the abilities 
to be self-sufficient in growth signaling, insensitive to growth-inhibiting signals, evade 
apoptotic signaling, replicate without limits, induce angiogenesis and to metastasize), 
the underlying mutations in cellular pathways can be highly variable. Even further, 
mutations in certain proto-oncogenes and tumor-suppressor genes can occur 
relatively early in development of one tumor or late in others. The subsequent 
acquisition of any other of the cellular alterations, such as resistance to apoptosis, 
determines how fast tumor development progresses (Fig. 1-5). All these necessary 
changes that I briefly described above, demonstrate that the development of a single 
malignant cell relies on the acquisition of a vast variety of genomic alterations to 
allow sustained growth. Considering how small the chances are to successfully gain 
all these “cancer hallmarks”, despite the generally very well maintained genome, 
demonstrates the rarity of the development of a malignant cell. It is therefore that the 
occurrence of these chance-events is strongly depending on time. 
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Figure 1-5. Parallel pathways of tumorigenesis 
Virtually all cancers must acquire the same six hallmark capabilities (top panel), yet 
their means of doing so will vary significantly, both mechanistically (see text) and 
chronologically (bottom panel). The order in which these capabilities are acquired 
seems likely to be quite variable across the spectrum of cancer types and subtypes. 
Moreover, in some tumors, a particular genetic lesion may confer several capabilities 
simultaneously, decreasing the number of distinct mutational steps required to 
complete tumorigenesis. For example, loss of function of the p53 tumor suppressor 
can facilitate both angiogenesis and resistance to apoptosis (e.g. in the five-step 
pathway shown), as well as enabling the characteristics of genomic instability. In 
other tumors, a capability may only be acquired through the collaboration of two or 
more distinct genetic changes, thereby increasing the total number necessary for 
completion of tumor progression. Thus, in the eight-step pathway shown, invasion/ 
metastasis and resistance to apoptosis are each acquired in two steps. Modified 
from (Hanahan and Weinberg 2000).  
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Research over the past decade has expanded our understanding of tumor 
development and revealed that tumors cannot be simplified as a random assembly 
of these six cancer hallmarks. Comprehensive studies increasingly reported that it 
requires more than these hallmarks to successfully form and maintain a cancer cell. 
In addition, the tumor micro-environment significantly allows malignant cells to 
survive and thrive. In the normal tissue, deregulated cells are usually detected by the 
immune system which antagonizes uncontrolled growth. It is thus of particular 
importance that malignant cells acquire attributes to evade the immune surveillance, 
e.g. through the secretion of TGF-β which suppresses cytotoxic T lymphocytes and 
natural killer cells (Yang, Pang et al. 2010). Immune surveillance is not always fully 
successful, resulting in “edited” tumor cells that have escaped the immune 
surveillance and remain intact (Ostrand-Rosenberg 2008). Nonetheless, immune 
processes play a conflicting role: in the majority of all neoplastic lesions tumor-
antagonizing and tumor-promoting leukocytes can be found; emphasizing that tumor 
development relies on the well orchestrated connection of all the contributing factors 
(Fig. 1-6). Immune cells such as certain macrophage subtypes, neutrophils, mast 
cells, and T- and B-lymphocytes, have all been attributed with tumor-promoting 
function (Johansson, Denardo et al. 2008); often resembling a chronic inflammatory 
state (Grivennikov, Greten et al. 2010). The pro-malignant qualities of some immune 
cells seem to be depending on signaling molecules such as the tumor growth factor 
EGF, the pro-angiogenic VEGF, chemokines and cytokines that amplify the 
inflammatory state and pro-invasive matrix degrading metalloproteinases (Egeblad 
and Werb 2002; Qian and Pollard 2010). Vice versa, studies have demonstrated that 
persistent inflammation is associated with pathologies including fibrosis, aberrant 
angiogenesis and cancer (Mantovani, Allavena et al. 2008). 
In addition, the reprogramming of the cellular metabolism plays an essential 
role for the sustained growth and proliferation of cancer cells. I will discuss the 
metabolic requirements for cellular proliferation in Chapter 1.7. 
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Figure 1-6. Pathways connecting inflammation and cancer.  
Cancer and inflammation are connected by two pathways: 1) the intrinsic pathway is 
activated by genetic events, including the activation of various types of oncogenes, 
chromosomal rearrangement or amplification, and the inactivation of tumor-
suppressor genes. Cells transformed in this manner produce inflammatory mediators 
and generate an inflammatory environment without any underlying inflammatory 
condition. 2) In the extrinsic pathway, inflammatory or infectious conditions augment 
the risk of developing cancer (e.g. in the colon, prostate and pancreas). The two 
pathways converge, resulting in the activation of transcription factors that coordinate 
the production of inflammatory mediators, including cytokines and chemokines, and 
recruit and activate various leukocytes. Cytokines activate the same key transcription 
factors in inflammatory-, stroma- and tumor-cells, resulting in the production of more 
inflammatory mediators and a cancer-related inflammatory microenvironment. 
Modified from (Mantovani, Allavena et al. 2008).  
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1.6 Overview of Cancer Treatment  
Cancer has become a leading global health issue and cause of mortality, only 
second to heart disease. In the United States, it is predicted that one out of every 
four deaths will be due to cancer. However, compared to the fast improvements in 
the treatment of heart disease, cancer treatment has been relatively steady over the 
past 30 years (Jemal, Siegel et al. 2008). Before the 1950s, tumor therapy remained 
largely in the hands of the surgeon. Understanding that an effective treatment for 
cancer-patients requires every organ in the body to be reached, led to the 
development of drugs that could be systemically administered. With the invention of 
the linear accelerator, radiation therapy became a valuable tool for the control of 
local and regional cancer after 1960, but could not eradicate metastatic cancer. As of 
today, chemotherapy and radiotherapy are still the main treatment choices for many 
cancers. Although they are effective in the treatment of certain cancers, the clinical 
potential is greatly limited by their toxic side effects.  
Chemotherapy is a major part of current cancer treatment. The first 
chemotherapy drug was adapted based on the discovery that exposure to the 
chemical warfare agent mustard nitrogen gas, bis-(2-chloroethyl) sulfide, led to the 
depletion of bone-marrow cells. Frank Adair and Halsey Bagg, researchers in the 
Douglas Laboratory of the Memorial Hospital in New York, put the idea that this 
agent could reduce tumor progression to the test. They applied tar to mice to induce 
skin cancer and treated neoplastic lesions with diluted solutions of mustard gas. The 
lesions were reduced and disappeared after some scabbing and the mice appeared 
cured. Encouraged by the results, Adair and Bagg applied their solution to 13 human 
patients, mainly suffering from some form of skin cancer (Adair and Bagg 1931): 
“The patient had a lesion 2.5 by 3 by 1 cm thick. Frequent applications were made to 
the lesion of small doses of the mustard gas. The tumor has been destroyed 
gradually and at present, four months after beginning treatment, there is no evidence 
of the disease and there is good healing over the site of the original tumor”. In 1942, 
Goodman and Gilman were commissioned by the United States Department of 
Defense to examine the potential therapeutic value of a series of toxins developed 
for chemical warfare. Goodman and Gilman treated a patient with non-Hodgkin's 
lymphoma with nitrogen mustard (Gilman and Philips 1946). The mediastinal and 
lymphatic masses of the patient regressed shortly after the treatment. However, the 
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observed remission lasted only a few weeks and was followed by disease 
progression. Nonetheless, the principle was established that the systemic 
administration of drugs could induce tumor regression. 
 
It has been almost 60 years since the establishment of the National Cancer 
Chemotherapy Service Center (NCCSC) at the National Cancer Institute (NCI), 
which has significantly contributed to the discovery of various chemotherapeutic 
drugs (Fig. 1-7). The underlying strategy of chemotherapeutic drugs relies on the 
targeted killing of rapidly proliferating cells, by means of genotoxicity and the 
production of reactive oxygen species (Look and Musch 1994; Conklin 2004; Kaina, 
Christmann et al. 2007). The US Food and Drug Administration (FDA) has approved 
132 cancer chemotherapy drugs, of which 56 have been reported to cause oxidative 
stress, including anthracyclines (e.g. cyclophosphamide, cisplatin, doxorubicin, 
busulfan, fluorouracil, cytarabine, and bleomycin), which lead to collateral damage to 
normal cells (Chen, Jungsuwadee et al. 2007). Although these drugs were first 
believed to be quite selective, we now know that normal cells also experience severe 
toxicity, leading to dose-limiting side effects. 
 
 
Figure 1-7. The history of chemotherapy.  
Modified from (Chabner and Roberts 2005).  
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The other major arm of modern cancer treatment is radiation-based therapy. 
Irradiating biological materials leads to a rapid burst of ROS, which is generated 
primarily from the ionization of water molecules and direct ionization of target 
molecules (Riley 1994). It is estimated that ~ 60% of the damage is caused by ROS 
(Barcellos-Hoff, Park et al. 2005). In addition, X-rays and γ-rays cause direct 
macromolecular damage by energy deposition. Despite its therapeutic benefits, ROS 
significantly damage normal cells and are responsible for various side-effects 
(Wilson, Taffe et al. 1993; Bialkowski, Kowara et al. 1996; Olinski, Zastawny et al. 
1996; Zastawny, Czerwinska et al. 1996). To make matters worse, it has been 
reported that even localized small field radiotherapy of head and neck cancers can 
cause oxidative damage at the organismal level, and may even lead to the 
development of secondary mutations (Roszkowski, Gackowski et al. 2008). 
Currently, fractionation strategies are considered as an effective approach to 
improve tumor control rates without increasing chronic toxicity, yet often causing 
enhanced acute toxicity (Schulz, Harari et al. 2001). Multiple studies indicated that 
the administration of antioxidants in combination with radiotherapy reduces the toxic 
side-effects. For instance, the free-radical scavenger amifostine has been shown to 
reduce the side-effects in patients with differentiated thyroid cancer (Bohuslavizki, 
Klutmann et al. 1998); although it will be necessary to critically assessed if this 
treatment option might result in collateral tumor protection (Andreassen, Grau et al. 
2003). In another study, the pharmacological targeting of the toll-like receptor 5 
(TLR5) which activates nuclear factor-kappa B (NFκB) signaling and in turn 
increases superoxide dismutase 2 (SOD2) expression, selectively protected mice 
and rhesus monkeys against radiation induced damage (Burdelya, Krivokrysenko et 
al. 2008). 
 As different as these strategies are, both therapies ultimately converge on 
cytotoxicity directed against proliferative cells, aiming to preferentially kill malignant 
cells. However, the selectivity is far from ideal, and collateral damage to normal cells 
is inevitable and commonly leads to severe side-effects such as emotional distress, 
myelo-suppression, fatigue, vomiting, diarrhea, and in some cases even death 
(Love, Leventhal et al. 1989; Partridge, Burstein et al. 2001). Although chemotherapy 
improves the survival rates of cancer patients, oxidative stress–mediated impairment 
of normal tissues is a significant side effect and decreases the quality of life of 
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patients. Today the same fundamentals still apply to modern chemo- and radio-
therapy, and its clinical potential is greatly shadowed by its side effects. Despite the 
focused efforts on drug development designed to target certain cancer markers, 
cytotoxic drugs will have accompanying side effects unless novel interventions or 
strategies are adopted. Chemo-protectants such as amifostine, glutathione, mesna, 
and dexrazoxane are investigated and shown to provide drug-dependent protection 
to specific tissues, but the use of these compounds has not been shown to increase 
disease-free or overall survival (Links and Lewis 1999). 
Chemotherapy and/or radiotherapy in combination with surgical removal of 
the tumor mass, by popular belief the single best option for cancer treatment, 
remains standard care. It is noteworthy that chemotherapy is not the efficacious 
remedy it promised to be in the 1970s (Devita, Serpick et al. 1970; Einhorn and 
Donohue 1977) and that early results could not be translated into an efficient 
treatment for the more common cancers (Kearsley 1986; Tannock 1998). For the 
majority of cancer patients, cytotoxic chemotherapy is being used as palliative care, 
with prolongation of survival often remaining the less important outcome (Slater 
2001). Despite the development of “new” (and expensive) single and/or combination 
drugs to increase the response rates, there has been little impact from new regimens 
and barely any changes in the prescribed regimens over the past 20 years. 
Examples for this are non-Hodgkin’s lymphoma and ovarian cancer in which the 
standard choices of care are cyclophosphamide (introduced in 1959, Fig. 1-7), 
doxorubicin and platinum. The median survival benefit that has been achieved by the 
adjuvant treatment of breast, colon, head and neck cancers is less than 5% (Dube, 
Heyen et al. 1997; Pignon, Bourhis et al. 2000). For lung cancer, the most frequently 
diagnosed malignancy in the male population (Jemal, Siegel et al. 2008), the median 
survival has only increased by two months (Carney and Hansen 2000; Breathnach, 
Freidlin et al. 2001). In 2004, a literature search for randomized-controlled trials by 
Morgan et al. came to the conclusion that the overall contribution of curative and 
adjuvant cytotoxic chemotherapy to 5-year survival in adults (>20 years of age) with 
cancer was estimated to be 2.1% in the USA (Morgan, Ward et al. 2004). Overall, 13 
out of the 22 evaluated malignancies showed an improvement in the 5-year survival, 
with an improvement bigger than 10% in only 4 out of the 22 cancer sites tested 
(Table 1-2). 
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Table 1-2. Impact of cytotoxic chemotherapy on 5-year survival in American 
adults. 
*Numbers from the Cancer Statistics Branch NCI. SEER Cancer Incidence Public-
use Database 1973-1998. Bethesda: NCI; 2000. † Absolute numbers. ‡ Percent for 
individual malignancy. Modified from (Morgan, Ward et al. 2004). 
 
 
As outlined above, the present approach to cancer treatment mimics a “trial 
and error” or “one size fits all” practice that is inefficient and frequently results in 
inappropriate therapy and treatment-related toxicity (Duffy and Crown 2008). In 
contrast, personalized treatment shows the potential to increase efficacy and 
decrease chemo-toxicity. As of now, personalized treatment for cancer is only 
beginning, with a small number of validated drug-test products available (Allison 
2008). For breast cancer, tests such as ER, uPA/PAI-1, HER-2, Oncotype DX, and 
MammaPrint are available to personalize the treatment decisions. Although some 
progress has been made, the evolution of personalized treatment is likely to be slow 
and costly.  
In my dissertation, I will describe a novel approach to cancer treatment that 
integrates the fields of biogerontology and oncology and is based on well accepted 
dietary and genetic interventions that extend lifespan and/or enhance stress 
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resistance. Studies from our lab, including results from yeast, mammalian cells, 
mice, and preliminary results from humans greatly emphasizes the potential 
usefulness in the clinical scenario. In this thesis, I will present evidence that fasting 
specifically sensitizes tumor cells to chemo- and radiotherapy and thus separates 
normal and malignant cells. 
1.7 Metabolic Requirements of Cellular Proliferation 
Cells have evolved metabolic control systems to sense the nutrient-level in 
their periphery, coupling cellular proliferation to sufficient nutrient supply. In order to 
allow proliferation, cells must increase the rate of their metabolism to generate 
energy (mostly in form of ATP) and provide lipids, nucleotides and amino acids as 
building blocks for daughter cells. In most organisms, sufficient nutrients are 
generally available and thus require a system that regulates nutrient uptake. The 
uncontrolled uptake is blocked because mammalian cells do not take up nutrients 
from their proximity unless a stimulatory impulse is triggered by growth-factors. As 
outlined above, malignant cells do not rely on this growth-factor mediated regulation 
and can thus utilize this constant nutrient supply to divide. In addition, mutations in 
regulatory pathways may result in constitutively active uptake, in particular of 
glucose. In fact, glucose plays a critical role for malignant cells and is displayed in 
metabolic alterations that increase the rate of glycolysis, e.g. through the up-
regulation of the glucose transporter Glut1 (Macheda, Rogers et al. 2005). Otto 
Warburg noted that cancer cells have a high rate of glycolysis followed by lactic acid 
fermentation in the cytosol, even in the presence of oxygen (Warburg 1956). This 
observation, known as the “Warburg Effect”, seems initially odd because our general 
understanding is that the complete catabolism of glucose through mitochondrial 
oxidative phosphorylation maximizes energy yield. It is therefore of interest to 
determine which requirements of cell division are being fulfilled by metabolizing 
glucose through aerobic glycolysis.  
In the presence of oxygen, supplied by the surrounding vasculature of the 
differentiated tissue, most non-proliferating cells metabolize glucose through 
glycolytic pyruvate in the mitochondrial TCA- (also known as Krebs-) cycle into 
reduced nicotinamide adenine dinucleotide (NADH) and carbon dioxide (Fig. 1-8). 
The produced NADH fuels the mitochondrial oxidative phosphorylation to yield 
energy in the form of ATP. Under normoxic conditions, the production of lactate is 
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minimal, whereas under hypoxia differentiated cells produce large amounts of 
lactate. The complete oxidative phosphorylation of one glucose molecule generates 
up to 36 ATPs, the lactate metabolism only 2 ATPs. The fact that cancer cells rely on 
aerobic glycolysis, despite the disadvantage in terms of ATP generation, implies that 
this form of metabolism provides sufficient energy for cellular proliferation. Yet, as 
recent studies indicated, ATP is not the limiting factor for proliferating cells because 
the ratios of ATP/ADP and NADH/NAD+ remain constantly high (Vander Heiden, 
Cantley et al. 2009). Additional support for this hypothesis is based on the 
observations that even minor disturbances in the ATP concentration could impair 
growth and trigger apoptosis (Eguchi, Shimizu et al. 1997; Izyumov, Avetisyan et al. 
2004).  
Cell division imposes a large requirement for metabolites beyond ATP 
production, namely nucleotides, amino acids and lipids that are all essential to 
replicate the cellular content of the dividing cell. For instance, the anabolic synthesis 
of nucleotides and amino acids requires more carbon and reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) than actual ATP. An even better example 
is the synthesis of the cellular membrane lipid palmitate which requires 7 molecules 
of ATP but an additional 16 carbons (supplied from 8 molecules acetyl-coenzyme A 
(CoA)) and 28 electrons from 14 NADPH molecules. One glucose molecule can 
generate 36 ATPs, or two molecules NADH and 30 ATPs from the pentose 
phosphate shunt, or 6 carbons (Lunt and Vander Heiden 2011). To synthesize 
palmitate, a 16-carbon fatty acid chain, 7 glucose molecules are needed to generate 
the necessary NADPH while the required ATP could be supplied by a single glucose 
molecule alone (Vander Heiden, Cantley et al. 2009). This exemplifies that in order 
for a cell to divide, converting all of the glucose to CO2 to maximize ATP production 
would become a limiting factor for the synthesis of macromolecular precursors, e.g. 
acetyl-CoA for fatty acids, glycolytic intermediates for (non-essential) amino acids 
and ribose for nucleotides, which are needed as cellular building blocks. The majority 
of glucose can therefore not be shunted towards ATP production. Uptake of the 
amino acid glutamine appears to play an important role for lipid synthesis because it 
supplies carbon (from mitochondrial oxalacetate) to maintain citrate production in the 
TCA cycle (Fig. 1-8) (DeBerardinis, Mancuso et al. 2007), supporting the production 
of acetyl-CoA and NADPH together with glucose. 
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Figure 1-8. Carbon flux differs in quiescent versus proliferating cells.  
Quiescent cells have a basal rate of glycolysis, converting glucose (glc) to pyruvate 
(pyr), which is then oxidized in the TCA cycle. Cells can also oxidize other substrates 
like amino acids and fatty acids, obtained from either the environment or the 
degradation of cellular macromolecules. The majority of ATP (yellow stars) is 
generated by oxidative phosphorylation in the mitochondria. During proliferation, the 
large increase in glycolytic flux rapidly generates ATP in the cytoplasm. Most of the 
resulting pyruvate is converted to lactate (lac) by lactate dehydrogenase A (LDH-A), 
which regenerates NAD+ from NADH; allowing glycolysis to persist, and the lactate is 
secreted from the cell. Some of the pyruvate is converted to acetyl-CoA (Ac-CoA) by 
pyruvate dehydrogenase (PDH) and enters the TCA cycle, where it is converted into 
intermediates like citrate (cit) that can be used for macromolecular biosynthesis. 
Citrate is required for the synthesis of fatty acids and cholesterol used to generate 
lipid membranes for daughter cells. After export to the cytoplasm, citrate is cleaved 
by the enzyme ATP citrate lyase (ACL). The resulting acetyl-CoA is used by fatty 
acid synthase (FAS) to synthesize lipids, while the oxaloacetate (OAA) is converted 
to malate (mal) by malate dehydrogenase (MDH). Malate can either be returned to 
the mitochondria during citrate-malate antiport or be converted to pyruvate by malic 
enzyme (ME), generating NADPH to be used in fatty acid synthesis. Modified from 
(DeBerardinis, Lum et al. 2008) 
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One could argue that the excess generation of lactate appears to be a very 
ineffective use of metabolic resources because each lactate that gets excreted from 
the cell wastes three carbons that might be utilized for ATP production and/or the 
biosynthesis of macromolecular precursors. One possibility is that the dumping of 
excess carbon as lactate is effective because it allows for a faster incorporation of 
carbon into biomass, in turn facilitating rapid cell proliferation (DeBerardinis, Lum et 
al. 2008; Lunt and Vander Heiden 2011).  
The regulation of the glucose metabolism and utilization is under control of the 
phosphoinositide 3-kinase (PI3K) pathway, which also plays a vital role in sensing 
amino acids levels and directing them into protein synthesis via the mammalian 
target of rapamycin (mTOR) (Laplante and Sabatini 2012). Activation of the 
PI3K/AKT/mTOR regulatory pathway in growth factor dependent- and tumor-cells 
can regulate the expression of glucose transporters (Taha, Liu et al. 1999), increase 
the uptake of amino acids (Roos, Jansson et al. 2007), enhance hexokinase and 
phosphofructose activity (Jones and Thompson 2009) and renders cells dependent 
on high glucose flux (Buzzai, Bauer et al. 2005). Akt induction increases glycolysis 
and lactate production and induces the Warburg effect in non-transformed and 
cancer cells by effecting gene expression and enzyme activity (Fig. 1-9) (Plas, 
Talapatra et al. 2001; Rathmell, Fox et al. 2003). Together, PI3K and Akt stimulate 
the expression of lipogenic genes, e.g. ATP-citrate lyase and lipid synthesis (Bauer, 
Hatzivassiliou et al. 2005; Chang, Wang et al. 2005); the inhibition of ATP-citrate 
synthase, on the other, hand can suppress tumor growth (Hatzivassiliou, Zhao et al. 
2005). 
Hypoxic conditions stimulate higher glucose uptake rates and lactate 
production. This response is coordinated by the hypoxia inducible factor 1 (HIF-1) 
transcription factor complex (Lum, Bui et al. 2007; Denko 2008). Gene targets of 
HIF-1 include glucose transporters (Mobasheri, Richardson et al. 2005), glycolytic 
enzymes (O'Rourke, Pugh et al. 1996; Marin-Hernandez, Gallardo-Perez et al. 2009) 
and lactate dehydrogenase A (LDH-A). Constitutive cellular stabilization of HIF-1 can 
occur in malignant cells as a result of mutations in the tumor suppressor von Hippel-
Lindau (VHL), which usually targets HIF-1 for ubiquitination and degradation (Pugh 
and Ratcliffe 2003). A more detailed description of the metabolic transformations in 
cancer cells can be reviewed in Tennant et al. (Tennant, Duran et al. 2009). 
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Figure 1-9. Rewiring of metabolic pathways in cancer cells.  
Metabolic pathways active in proliferating cells are directly controlled by signaling 
pathways involving known oncogenes and tumor suppressor genes. The metabolic 
wiring allows NADPH production and acetyl-CoA flux to the cytosol for lipid 
synthesis. Key-steps in these metabolic pathways can be influenced by signaling 
pathways known to be important for cellular proliferation. Activation of growth factor 
receptors leads to both tyrosine kinase signaling and PI3K activation. Via AKT, PI3K 
stimulates glucose uptake and flux through the early part of glycolysis. Tyrosine 
kinase signaling negatively regulates flux through the late steps of glycolysis, making 
glycolytic intermediates available for macromolecular synthesis as well as supporting 
NADPH production. Myc drives glutamine metabolism, which also supports NADPH 
production. LKB1/AMPK signaling and p53 decrease metabolic flux through 
glycolysis in response to cell stress. Decreased glycolytic flux in response to 
LKB/AMPK or p53 may be an adaptive response to shut off proliferative metabolism 
during periods of low energy availability or oxidative stress. Tumor suppressors are 
shown in red, and oncogenes are in green. Key metabolic pathways are labeled in 
purple with white boxes, and the enzymes controlling critical steps in these pathways 
are shown in blue. Some of these enzymes are candidates as novel therapeutic 
targets in cancer. Malic enzyme refers to NADP+-specific malate dehydrogenase. 
Modified from (Vander Heiden, Cantley et al. 2009). 
 
 
57 
 
1.8 Conserved Regulation of Longevity and Stress Resistance: Dietary and 
Genetic Interventions 
Dietary, genetic, and pharmacological interventions have all contributed 
greatly to our understanding of lifespan regulation. The most powerful and 
reproducible dietary intervention that increases life- and health span across species 
is known as calorie restriction (CR), or dietary restriction (DR; the reduced intake of 
specific macronutrients). In the majority of animal models, an increase in longevity is 
often correlated with an increase in the resistance to various stressors, such as heat 
and toxic agents (e.g. hydrogen peroxide, H2O2) (Berg, Breen et al. 1994; Schulz, 
Zarse et al. 2007). Genetic studies demonstrated that increased lifespan and stress 
resistance converge on the growth hormone (GH)/IGF-I axis and its homologs 
(Longo and Fontana 2010). In fact, it is suggested that the GH/IGF-I axis is a major 
mediator of the beneficial effects of CR (Bonkowski, Dominici et al. 2009). 
Pharmacological manipulations, such as rapamycin have also shown to increase 
lifespan (Harrison, Strong et al. 2009; Robida-Stubbs, Glover-Cutter et al. 2012). 
Rapamycin inhibits the mammalian target of rapamycin (mTOR), which is located 
downstream of IGF-I and is a major regulator of cellular proliferation, metabolism, 
and stress (Reiling and Sabatini 2006; Laplante and Sabatini 2012). 
CR is the most effective and reproducible intervention to decelerate the rate of 
aging and increase healthy lifespan, as studied in various model organisms ranging 
from the simple yeast to worms, flies, mice, rats (Fig. 1-10) (Guarente and Kenyon 
2000; Kenyon 2001; Fontana, Partridge et al. 2010). CR reduces oxidative stress 
(Youngman, Park et al. 1992; Sohal and Weindruch 1996) and cell proliferation while 
enhancing autophagy (Cuervo, Bergamini et al. 2005; Wohlgemuth, Julian et al. 
2007) and certain DNA repair processes (Weraarchakul, Strong et al. 1989). CR 
effectively reduces the levels of plasma insulin, cholesterol, triglycerides, growth 
factors such as IGF-I (Mahoney, Denny et al. 2006), and inflammatory cytokines 
(Matsuzaki, Kuwamura et al. 2001). CR also elevates plasma high-density 
lipoprotein levels (Larson-Meyer, Newcomer et al. 2008), resulting in a reduced risk 
for developing a metabolic syndrome, e.g. atherosclerosis, diabetes and obesity 
(Paoletti, Bolego et al. 2006). Additional benefits of CR include reduced blood 
glucose levels and elevated ketonebodies, which lead to lower oxygen free radical 
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Figure 1-10. Effects of DR, mutations and drugs on life- and health span. 
Experiments on dietary restriction (DR) and genetic or chemical alteration of nutrient-
sensing pathways have been performed on a range of model organisms. The results 
differ widely, and little is known about the long-term effects in humans. Modified from 
(Fontana, Partridge et al. 2010) 
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production (Verdery and Walford 1998; Veech 2004). In 1934, Mary Crowell and 
Clive McCay reported that feeding rats with a calorie restricted diet from the time of 
weaning resulted in nearly doubled life spans (McCay CM 1935). Following this 
seminal discovery, Roy Walford and Richard Weindruch from UCLA reported that 
“adult-initiated‟ dietary restriction (“undernutrition without malnutrition”), which began 
at 12 months of age, not only retarded growth and increased life-span, but also 
reduced spontaneous cancer incidence in two different strains of laboratory mice by 
more than 50% (Weindruch and Walford 1982). Weindruch et al. further reported that 
calorie restriction initiated at the time of weaning increased lifespan, reduced tumor 
incidence, and delayed immunologic aging in laboratory mice (Weindruch, Walford et 
al. 1986), confirming the CR studies of rats. Further support arose from the recently 
published 20-year longitudinal adult-onset CR study in rhesus monkeys showing that 
CR (30%) delayed disease onset and mortality, with a 50% decrease in cancer 
incidence (Colman, Anderson et al. 2009). However, a CR regimen implemented in 
young and older age rhesus monkeys at the National Institute on Aging (NIA) has not 
improved survival outcomes (Mattison, Roth et al. 2012). These findings are in 
contrast with an ongoing study at the Wisconsin National Primate Research Center 
(WNPRC), which reported improved survival associated with 30% CR initiated in 
adult rhesus monkeys (Colman, Anderson et al. 2009) and a preliminary report with 
a small number of CR monkeys (Bodkin, Alexander et al. 2003). 
Although the underlying mechanisms of CR are not yet fully established, 
energy allocation appears to play a fundamental role. Given that only a certain 
amount of energy is available at any time, the cellular energetic network must 
economically balance this finite amount of energy between reproduction/growth and 
repair/maintenance (Kirkwood 2005). However, under conditions of limited nutrient 
availability, such as starvation or chronic calorie restriction, the favored cellular 
survival strategy seems to discourage reproduction/growth and rather to invest the 
remaining energy to preserve repair/maintenance (Kirkwood, Kapahi et al. 2000). In 
turn, this approach allows for future reproduction when nutrients become available 
and would favor the survival of the offspring. Throughout this dissertation, I will refer 
to this switch of energy allocation as entering a “maintenance mode‟. Reallocating 
energy when nutrients are scarce or absent could explain why calorie restricted mice 
have reduced size and fertility, but increased lifespan and stress resistance (Shanley 
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and Kirkwood 2000). Notably, mice exposed to chronic calorie restricted diets show 
parallel characteristics with long-lived growth hormone deficient mice (Table 1-3), 
which are resistant to stress and also have smaller body size (known as “dwarfism”), 
suppressed fertility, reduced plasma GH/IGF-I, insulin, and glucose (Longo and 
Finch 2003). Because of this broad ability to promote stress resistance, CR could in 
theory be applied in the clinic to protect patients from toxic side effects of 
chemotherapy. However, CR is not feasible for patients already prone to weight loss, 
from the cancer itself or from the chemotherapy, because, based on animal studies, 
several months may be necessary for patients undergoing CR to reach a protected 
state. Thus, in addition to requiring major life-style changes, CR would inevitably also 
cause chronic weight loss. Also, CR only retards the progression of specific cancers, 
possibly because of its relatively small effect on glucose and growth factors (Kalaany 
and Sabatini 2009; Lee and Longo 2011). In humans, CR does not reduce growth-
promoting IGF-I unless it is combined with protein restriction (Fontana, Weiss et al. 
2008).  
 
 
Table 1-3. Comparison between CR and GH/IGF-I deficient mice. 
Many physiological characteristics of GH/IGF-I deficiency are shared by calorie 
restriction (CR). Modified from (Longo and Finch 2003). 
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Macronutrient defined diets, with altered proportions of fat, carbohydrates and 
protein, do not generally alter the lifespan of rodents; but applying caloric restriction 
to these modified diets does provide the beneficial effects of CR on health span 
(Ross and Bras 1973; Iwasaki, Gleiser et al. 1988; Masoro 1990). Of note, a severe 
restriction of dietary protein can extend the lifespan of rodents by up to 20%, 
independently of the caloric intake (Pamplona and Barja 2006). Reduced levels of 
serum IGF-I in rats and mice fed with protein-restricted diets might explain the 
beneficial effects on longevity (Sonntag, Lynch et al. 1999). 
 
Restricting a single essential amino acid in a normal diet can also increase 
lifespan and stress resistance (Segall 1977; De Marte and Enesco 1986; Pamplona 
and Barja 2006) and indicates that amino acids are central to CR-dependent lifespan 
regulation. In flies, adding back essential amino acids to the CR diet decreased 
lifespan to that of the normally fed group (Grandison, Piper et al. 2009). Laboratory 
rodents fed a methionine or tryptophan restricted diet showed extended lifespan 
(Miller, Buehner et al. 2005) with decreased age-dependent diseases and increased 
resistance to oxidative stress, in part due to increased antioxidant capacity (Richie, 
Leutzinger et al. 1994). In 1969, Lorincz et al. demonstrated that tumor growth was 
moderately reduced in mice fed with a tyrosine and phenylalanine restricted diet 
(Lorincz, Kuttner et al. 1969). Methionine restricted diets can reduce tumor growth in 
laboratory animals (Breillout, Hadida et al. 1987; Tan, Xu et al. 1996), which seems 
to rely partially on alterations in the glucose metabolism (Fu, Lin et al. 2010). In 
patients with advanced cancers, restricting methionine has shown promising results 
(Epner 2001; Epner, Morrow et al. 2002). The effects of amino acid restriction may 
be due to the high requirement of methionine in cancer cells in response to elevated 
protein synthesis and trans-methylation in part owing to epigenetic alterations 
(Hoffman 1997), whereas normal cells are relatively resistant to methionine 
restriction (Cellarier, Durando et al. 2003). In addition to its potential protective 
benefits to the patients, amino acid restriction has been shown to sensitize cancer 
cells to chemotherapy drugs (Goseki, Yamazaki et al. 1992; Hoshiya, Kubota et al. 
1996; Yoshioka, Wada et al. 1998; Kokkinakis, Hoffman et al. 2001). A more detailed 
overview of CR can be found in (Spindler 2010). 
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Genetics have also contributed greatly to our understanding of the pathways 
involved in the regulation of senescence. Studies in S. cerevisiae, C. elegans, D. 
melanogaster and mice have demonstrated that the insulin and GH/IGF-I axis are 
major regulators of lifespan and stress resistance and can be modified in response 
to nutrient and/or growth factor signaling (Fig. 1-11) (Longo 1999; Guarente and 
Kenyon 2000; Longo and Finch 2003; Kenyon 2005; Piper, Selman et al. 2008). Our 
laboratory has demonstrated in yeast that deleting human homologs of Ras (RAS2) 
and/or Akt (SCH9/S6K) increased lifespan by more than 200%, while providing 
increased stress resistance against oxidants, genotoxins, and heat-shock (Fabrizio, 
Pozza et al. 2001; Wei, Fabrizio et al. 2008). Similarly, in C. elegans, mutations in 
the human homologs of insulin/IGF-I receptor (daf-2) and PI3K (age-1) extended 
lifespan to 200% and showed increased resistance to thermal and oxidative stress 
(Kleemann and Murphy 2009; Panowski and Dillin 2009). In the fruit-fly D. 
melanogaster, mutations in the insulin receptor substrate chico lead to a 150% 
lifespan extension (Clancy, Gems et al. 2001; Giannakou and Partridge 2007). In 
laboratory mice, mutations in the insulin- GH/IGF-I axis have an increased lifespan of 
up to 150% (Brown-Borg, Borg et al. 1996; Murakami 2006) and conversely, mice 
that over-express GH have a shortened lifespan (Bartke, Chandrashekar et al. 
2002). In addition, in vitro stress resistance studies on cell cultures from long-lived 
mice with deficiencies in the GH/IGF-I axis have shown to be resistant against 
oxidative stress (H2O2, paraquat), UV, genotoxins (methylmethanesulfonate), heat, 
and cadmium (Salmon, Murakami et al. 2005; Murakami 2006), suggesting that 
enhanced stress resistance is partially responsible for longevity, and the possibility to 
enhance protection by interventions such as CR or down-regulation of the GH/IGF-I 
axis. In mice the longevity effects of CR appear to involve reduced activity of the 
GHR/IGF-I pathways because CR does not further extend the life span of GH 
signaling-deficient mice (Bonkowski, Dominici et al. 2009). These results were 
further confirmed by studies that applied intermittent fasting (IF, known as every 
other day feeding) to GH-receptor deficient (GHR-KO) mice (Arum, Bonkowski et al. 
2009). Fasting on alternating days increased the survivorship and improved insulin 
sensitivity of male wild-type mice, but failed to affect either parameter in GHR-KO 
mice. I will discuss the role of the GH/IGF-I axis on growth and metabolism for 
mammals in greater detail in the following chapter. 
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Figure 1-11. Model for conserved nutrient signaling pathways that regulate 
longevity in various organisms and mammals.  
Dietary restriction reduces the activity of various signal transduction pathways either 
directly (yeast) or indirectly through the reduced levels of growth factors such as 
IGF-I (worms, flies, mammals). The role of TOR and S6K in promoting aging 
appears to be conserved in yeast, worms, flies, and mice. The AC/PKA pathways 
and the TOR/S6K pathway promote aging in yeast and mammals, whereas an 
insulin/IGF-I like receptor or the upstream growth hormone (mammals) accelerates 
aging in worms, flies, and mice. Similar transcription factors (GIS1, MSN2/4, DAF-
16, FOXO) inactivated by the AC/PKA, IGF-I/AKT, or TOR/S6K pathways affect 
cellular protection and/or aging in all the major model organisms. Notably, in the 
multi-cellular worms, flies, and mice, these genes may promote aging within the cells 
in which they are expressed but also in other cells through the regulation of 
circulating factors. The mechanisms proposed for the longevity extension caused by 
inhibition of these nutrient signaling pathways include a decrease in the free radical 
superoxide (mediated in part by SODs) and of its damage to macromolecules, 
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protection of proteins by chaperones (Hsp70), decreased translation, the activation 
of autophagy, and the switch to hypoxia-associated gene expression patterns (in 
yeast and mice). In yeast, the effects of DR on lifespan extension are also 
associated with reduced activities of the Tor-Sch9 and Ras-AC-PKA pathways and 
require the serine-threonine kinase Rim15 and transcription factors Gis1, Msn2, and 
Msn4. In worms, transcription factors regulated by the TOR-S6K and AGE-1-AKT 
pathways are implicated in the anti-aging effects of DR. In flies, the reduced activity 
of both Ins/IGF-I and TOR can protect against shortening of life span by increased 
food intake. However, in both worms and flies the deletion of DAF-2/FOXO shortens 
life span, but the animal continues to respond to DR. Modified from (Fontana, 
Partridge et al. 2010). 
 
1.9 The GH/IGF-I Axis in Growth and Metabolism  
The GH/IGF-I axis is of particular interest to aging researchers because, as 
mentioned above, many genes that regulate lifespan converge on its downstream 
effectors (Longo and Finch 2003; Yang, Anzo et al. 2005). Physiologically, the 
GH/IGF-I axis is a major regulator of primarily two important processes: growth and 
metabolism. GH plays a central role in regulation of organismal growth as indicated 
in animal studies showing that deficiency in GH production, or the deletion of the GH 
receptor gene, cause retardation and growth defects (physically characterized by a 
severely reduced body size) (Fig. 1-12). 
 
 
Figure 1-12. Effects of decreased glucose or Insulin/IGF-I signaling on body 
size. 
Wild-type (left) and long-lived dwarf (right) yeast, flies, and mice. Yeast sch9 null 
mutants form smaller colonies. chico homozygous mutant female flies are dwarfs 
and exhibit an increase in life-span of up to 50%. The GHR/BP mice are dwarfs 
deficient in IGF-I and exhibit a 50% increase in life-span. Modified from (Longo and 
Finch 2003) 
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Growth hormone (GH), also known as somatotropin, is a polypeptide that is 
synthesized, stored, and secreted by somatotropic cells within the anterior pituitary 
gland (Fig. 1-13). Secretion of GH from the pituitary gland is regulated by neuro-
secretory nuclei located within the hypothalamus, which release growth hormone-
releasing hormone (GHRH) and growth hormone-inhibiting hormone (GHIH). GH 
release in the pituitary is primarily determined by the balance of GHRH vs. GHIH, 
which in turn is regulated by physiological stimulators such as exercise, nutrition, 
sleep and inhibitors (e.g. free fatty acids and hyperglycemia). GH exerts its anabolic 
function by stimulating IGF-I production primarily in the liver. IGF-1 is released into 
the periphery and upon binding to its specific tyrosine kinase receptor, the insulin-like 
growth factor 1 receptor (IGF-R), intracellular signaling is initiated. IGF-I is one of the 
most potent natural activators of the pro-growth AKT signaling pathway (resulting in 
cell growth and proliferation) and a potent inhibitor of apoptosis. Approximately 98% 
of IGF-I is always bound to one of 6 binding proteins (IGF-BPs), which prolong the 
half-life of IGF and can alter their interaction with cell surface receptors. IGFBP-3 is 
the most abundant IGF-I binding protein and accounts for 80% of all serum bound 
IGF-I. GH and IGF-I thus function by translating nutrient availability (among other 
factors) in cellular growth. It is therefore that GH deficiency causes reduced body 
size. 
There are many mouse models showing the role of GH in growth, including 
the Snell and Ames dwarf mice, which have point mutations in the pituitary-specific 
transcription factor-1 Pit-1 or its upstream gene Prop-1 (Li, Crenshaw et al. 1990; 
Andersen, Pearse et al. 1995). Dwarf mice do not produce GH and weigh only a third 
of their WT littermates during their adulthood, but live about 50% longer than their 
littermates (Brown-Borg, Borg et al. 1996). In addition, GH receptor/binding protein 
(GHR/BP) knockout mice, which were initially developed to model the human Laron 
dwarfism syndrome, have undetectable levels of hepatic GH receptor expression 
and serum GHBP, leading to a significant decrease in body size and approximately 
50% increase in longevity. Due to the lack of the negative feedback inhibition of IGF-
I on GH production, these mice have elevated GH levels (but a 90% reduction in 
IGF-I levels) (Zhou, Xu et al. 1997; Coschigano, Clemmons et al. 2000). Unlike the 
GHR/BP KO mice, mice that expressed a GH antagonist eventually reached normal 
body weight and their lifespan remained comparable to their WT littermates 
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(Coschigano, Holland et al. 2003). A possible explanation for this effect might be 
based on differences in GH signaling level, i.e. complete deletion of the receptor 
compared to receptor antagonism; suggesting that the degree of GH signaling 
inhibition is central for the regulation of growth and lifespan. Anabolic pathways 
downstream of GH, IGF-I in particular, have been shown to be involved in the effects 
of lifespan regulation. For example, female heterozygotes of the IGF-I receptor (IGF-
1R) display a 33% increase in lifespan, whereas male heterozygotes show a modest 
16% increase in lifespan which is not statistically significant. The homozygous 
deletion of the IGF-Ir gene is lethal in mice (Holzenberger, Dupont et al. 2003). 
Remarkably, the heterozygotes were also better protected against oxidative 
 
 
 
Figure 1-13. The hypothalamic–pituitary–IGF axis with sites of established and 
hypothetical genetic defects. 
Abbreviations: ALS, acid-labile subunit; GH, growth hormone; GHBP, GH binding 
protein; GHRH, GH-releasing hormone; IGF, insulin-like growth factor; IGF-BP, IGF-
binding protein; JAK, Janus kinase; MAPK, mitogen-activated protein kinase; STAT, 
signal transducer and activator of transcription. Modified from (Lopez-Bermejo, 
Buckway et al. 2000). 
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stress, as determined by increased survival following paraquat (an oxidant) 
treatment. Embryonic fibroblasts obtained from this IGF-IR +/- mice showed reduced 
activation of its major effectors including Akt and p66shc, a cytoplasmic signal 
transducer delivering mitogenic signals from activated receptors to Ras (Ma, Liu et 
al. 2010), when cultured in vitro (Holzenberger, Dupont et al. 2003). Interestingly, 
p66shc has been correlated with effects on lifespan prior to the discovery of its role in 
the IGF-IR +/- mice: p66shc -/- mice have an increased resistance to oxidative stress 
and enhanced lifespan (Migliaccio, Giorgio et al. 1999).  
 
Circulating IGF-I, acting synergistically with other hormones, regulates energy 
metabolism, cell proliferation and differentiation, body size and lifespan in response 
to calorie and protein availability (Prisco, Romano et al. 1999; Flototto, Djahansouzi 
et al. 2001; Giovannucci, Pollak et al. 2003; Yu, Shu et al. 2003). As outlined in the 
previous chapter, GH/IGF-I converges on intracellular nutrient sensing pathways that 
mediate growth and proliferation. In addition, IGF-I exerts a potent tumorigenic effect 
on a variety of cancer cells by increasing their proliferative rate and inhibiting 
apoptosis (Prisco, Romano et al. 1999; Ramsey, Ingram et al. 2002). Studies in mice 
with deficiencies in the downstream effectors of IGF-R signaling, including mTOR 
inhibition by rapamycin (Harrison, Strong et al. 2009) and S6K1 (Selman, Tullet et al. 
2009), demonstrate the central role of intracellular mitogenic pathways in regulating 
lifespan and stress resistance while simultaneously reducing tumor growth (Ikeno, 
Bronson et al. 2003; Pinkston, Garigan et al. 2006; Garcia, Busuttil et al. 2008; 
Ikeno, Hubbard et al. 2009).  
Our laboratory, in collaboration with investigators in Ecuador, has recently 
published a study in which we monitored cellular responses to stress, and markers of 
cancer and diabetes in an Ecuadorian cohort with GHR deficiency (GHRD), which 
results in IGF-I deficiency. We found that human GHRD subjects are protected 
against age-related pathologies (Guevara-Aguirre, Balasubramanian et al. 2011) 
(Fig. 1-14). Yet, unlike model organisms with similar mutations, human GHRD 
subjects do not live longer lives. The lack of life-span extension in GHRD subjects 
may be explained in large part by the high proportion of deaths (70%) caused by 
convulsive disorders, alcohol toxicity, accidents, liver cirrhosis, and other non–age-
related causes. 
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Figure 1-14. Causes of death in the Ecuadorian GHRD cohort. 
Causes of death in unaffected relatives (left) and GHRD (right) subjects are shown. 
Modified from (Guevara-Aguirre, Balasubramanian et al. 2011). 
 
1.10 The Feasibility of Fasting: History, Clinical Application, and Stress 
Resistance  
Mammals undergo three metabolic stages when deprived of food (Wang, 
Hung et al. 2006). The first stage is a post-absorptive phase, lasting for 10 or more 
hours following food ingestion. This stage involves the utilization of glycogen as the 
main stored energy source. 2) Once the liver glycogen storage has been depleted, 
amino acids serve as the substrate for gluconeogenesis. 3) The remaining glucose is 
mostly consumed by the brain while glycerol and fatty acids are released from 
adipose tissue and become the major energy source. As a result, the fat-derived 
ketonebodies become the main carbon sources within a few days of fasting. During 
the last phase of prolonged food deprivation, the fat storage is eventually exhausted 
and rapid muscle degradation occurs for gluconeogenesis. Initially, the weight loss is 
rapid but later on tapers off as shown in a human study where an average of 0.9 
kg/day was lost daily during the first week, subsiding to 0.3 kg/day by the third week 
of fasting, causing an approximately 20% body weight loss after 30~35 days of 
fasting (Kerndt, Naughton et al. 1982). Despite this considerable weight loss, it is 
estimated that a 70 kg person can sustain the basal caloric requirements from fat 
reserves during two to three months of fasting (Cahill and Owen 1968; Cahill 2006). 
Within the body, these changes trigger a cellular response including the down-
regulation of pathways involved in proliferation, cell growth and the reduced 
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production of reactive oxygen species, while simultaneously increasing genomic 
stability and cellular stress resistance (Sohal and Weindruch 1996; Hursting, Slaga 
et al. 1999; Holzenberger, Dupont et al. 2003; Longo and Fontana 2010; Lee and 
Longo 2011). GH level in response to fasting are also a critical metabolic switch. GH 
acts as the primary anabolic hormone during stress and fasting by predominantly 
stimulating the release and the oxidation of free fatty acids from lipids (lipolysis). This 
allows the organism to decrease glucose and protein oxidation and consequently 
preserve lean body mass (Moller and Jorgensen 2009). In fasting humans, GH levels 
initially increase, whereas IGF-I levels diminish (Ho, Veldhuis et al. 1988), a 
phenomenon known as “GH resistance”, causing the body to switch fuel sources, to 
discourage growth, and to enter into a maintenance mode. 
Historically, fasting has been performed for a number of reasons including 
medical, cosmetic, religious, and political purposes (e.g. Gandhi engaging in several 
hunger strikes to protest the British rule of India) (Kerndt, Naughton et al. 1982; 
Johnstone 2007). Over the last centuries, much has been learned through either 
involuntary fasting from the victims of famine and war (Scrimshaw 1987; Kalm and 
Semba 2005), or voluntary fasting such as the biblical 40 days of food abstinence 
(Kerndt, Naughton et al. 1982). But beyond its traditional practice, fasting has also 
been demonstrated to have vast clinical benefits. Notably, clinical studies have 
shown that water-only fasting for 10-14 days significantly improved hypertension by 
reducing systolic blood pressure points more than 2-fold compared to that of a 
combined vegan, low-fat, low salt diet and exercise (Goldhamer, Lisle et al. 2001; 
Goldhamer 2002). This study is of particular importance as the leading cause of 
death in the US is heart disease (Jemal, Siegel et al. 2008). Moreover, the safety of 
consuming a very low calorie diet of 350 kcal/day (an almost fasting-like approach), 
in patients with chronic disease, has been studied in a large cohort with over 2000 
participants (Michalsen, Hoffmann et al. 2005). Fasting was considered safe and 
appears promising to be incorporated into an integrative medicine ward. The vast 
majority of the participating patients indicated that the very low calorie diet seemed 
to be beneficial to counter their chronic disease. Within the last 5 years, fasting has 
also been proposed in clinics to protect the patient from ischemic reperfusion 
damage, in which oxidative stress is largely responsible for the damage (Mitchell, 
Verweij et al. 2009; van Ginhoven, Mitchell et al. 2009). 
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A prolonged period of fasting is feasible and generally well tolerated, however 
mild side-effects including headaches, light-headedness, nausea, weakness, edema, 
anemia, amenorrhea (Bloom 1959; Drenick and Smith 1964), and, in some rare 
cases, fatal complications such as renal failure, heart failure, and lactic acidosis, may 
occur (Garnett, Barnard et al. 1969; Runcie and Thomson 1970).  
1.11 Short-term Starvation to Improve the Stress Resistance against 
Chemotherapy 
Calorie restriction (CR) is a well-established intervention to increase lifespan and 
reduce the rate of cancer (Tannenbaum and Silverstone 1949; McCay, Crowell et al. 
1989; Tannenbaum 1996). In addition, CR increases the stress resistance in normal 
cells and organisms (Yu and Chung 2001). The effect of CR on cancer has been 
largely focused on preventing and reducing tumor growth, whereas its effect on 
stress resistance has been poorly explored. Since the efficacy of CR as a single 
treatment modality is limited in curing cancer, and considering that several weeks to 
months are required to be effective, it would be challenging to incorporate CR into 
the lifestyle of healthy individuals, let alone cancer patients.  
We aimed to determine if short cycles of starvation could achieve stress 
resistance because both CR and fasting mediate signaling through the GH/IGF-I axis 
and their downstream signaling pathways. Initial results from our lab in yeast 
demonstrated that glucose reduction (from 2% to 0.5%) increases protection against 
oxidative stress, whereas complete starvation (by switching the population of cells to 
water), promotes not only protection to oxidative insults and heat shock but also 
resulted in a major life span increase (Wei, Fabrizio et al. 2008). Deleting the 
transcription factors Msn2/Msn4 and Gis1, located downstream of intracellular 
nutrient sensing pathways, reversed the protection caused by glucose restriction or 
starvation conditions, suggesting an important role for genes involved in metabolism, 
cellular protection and repair. To expand this approach from unicellular yeast to a 
multi-cellular organism, this starvation mediated protection was applied to mouse 
models treated with high-dose chemotherapy (Raffaghello, Lee et al. 2008), because 
most chemotherapy agents cause considerable damage to normal cells. Out of 28 
mice, from three genetic backgrounds, which were assigned to short-term starvation 
(STS) for 48–60 hours before treatment with the chemotherapeutic drug etoposide 
(Eto), only one mouse died. In contrast, of the 37 control mice treated with etoposide 
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alone, 20 died of toxicity (Fig. 1-15). Of course, utilizing fasting to protect against 
high-dose chemotherapy would be useless in a clinical scenario if cancer cells are 
also entering a protected mode. Considering the hallmarks of cancer, and in 
particular the self-sufficiency in growth signaling, we proposed that malignant cells 
would not, or to a lesser extent, be protected against high doses of oxidative damage 
or chemotherapy under STS conditions. Short-term starved S. cerevisiae were up to 
1,000 times better protected against oxidative stress or chemotherapy drugs than 
yeast expressing the oncogene homolog Ras2val19 (Raffaghello, Lee et al. 2008). 
Low glucose or low-serum media also protected primary glial cells but not six 
different rat and human glioma and neuroblastoma cancer cell lines against 
hydrogen peroxide or the chemotherapy drug/pro-oxidant cyclophosphamide 
(Raffaghello, Lee et al. 2008). We aimed to determine whether the effects we 
observed in yeast and mammalian cells with regard to the protection against 
chemotherapy would also occur in vivo. Mice were injected with cancer cells and 
subsequently treated with etoposide. Short-term starvation provided complete 
protection to mice, but not to the injected NXS2 neuroblastoma cells, against high 
dose etoposide (Raffaghello, Lee et al. 2008). These studies describe a starvation-
based strategy that enhances the protection of normal, not malignant cells; an effect 
we termed “differential stress resistance” (DSR).  
To evaluate how DSR mediates its effects in differential protection, we 
analyzed markers of nutrient availability and the connected GH/IGF-I axis. STS and 
CR both lower circulating IGF-I, which is regulated by GH and nutrition (Clemmons 
and Underwood 1991; Underwood, Thissen et al. 1994). Under normal conditions, 
GH directly regulates the production of IGF-I, but during starvation, several changes 
in the GH/IGF-I axis occur as a result of physiological adaptation to the new 
environment. In humans, IGF-I levels decrease dramatically in response to a short-
term starvation (36-72 hours) despite increased GH secretion (Norrelund 2005; 
Moller and Jorgensen 2009). The reduction in IGF-I, in turn, down-regulates many of 
the intracellular growth signals such as AKT, Ras, and up-regulates stress resistance 
pathways such as FoxO, GRP78 and DNA repair genes (Lee, Raffaghello et al. 
2012; Pfaffenbach, Pong et al. 2012).  
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Figure 1-15. Short-term starvation protects against high-dose chemotherapy in 
vivo. 
(A) A/J mice were treated with 80 mg/kg etoposide with (STS/Eto) or without (Eto) a 
prior 48 hour starvation (STS). (B) Percent weight loss (a measure of toxicity) after 
etoposide treatment in STS-treated or untreated A/J mice. (C) CD-1 mice were 
treated (i.v.) with 110 mg/kg etoposide with (STS/Eto) or without (Eto) a 60 hour prior 
starvation. (D) Percent weight loss after etoposide treatment in STS-treated (n=5) or 
untreated CD-1 mice. Asterisks indicate the day at which all mice died of toxicity. (E) 
Athymic (Nude-nu) mice were treated (i.v.) with 100 mg/kg etoposide with (STS/Eto) 
or without (Eto) a 48 hour prior starvation. (F) Percent weight loss after etoposide 
treatment in the treated (STS/Eto) or untreated (Eto) athymic (Nude-nu) mice. 
Modified from (Raffaghello, Lee et al. 2008). 
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In mice and rats, short-term starvation (24-72 hours) decreases IGF-I 
production (Tannenbaum, Rorstad et al. 1979; Frystyk, Delhanty et al. 1999). In 
agreement, studies from our lab have obtained similar results when the levels of 
circulating GH and IGF-I, and its binding proteins IGFBP-1 and IGFBP-3, were 
measured in mice undergoing 72 hours of STS (Lee, Safdie et al. 2010). The mice 
lost approximately 20% of their pre-fasted body weight, blood glucose levels were 
reduced by 40%, GH levels were slightly increased, and serum IGF-I levels 
decreased by 70%. The bioavailability of IGF-I is regulated by IGF binding proteins. 
In fasted mice, the level of IGFBP-1, which normally reduces IGF-I signaling, 
increased by 11.4-fold and decreased IGFBP-3 levels by 40% (Fig. 1-16). 
  
To determine whether reducing IGF-I signaling protects from high-dose 
chemotoxicity, we tested a transgenic mouse model with a conditional liver Igf1 gene 
deletion (LID), resulting in a 70% to 80% postnatal reduction of circulating IGF-I 
(Yakar, Liu et al. 1999; Anzo, Cobb et al. 2008). These results are similar to that of a 
72 hour fasted mouse. Therefore, LID mice provide a model for investigating the 
mechanistic relationship between IGF-I and fasting in chemotherapy resistance. To 
determine the range of protection by reduced IGF-I, we tested four chemotherapeutic 
drugs: cyclophosphamide (CP), etoposide (Eto), 5-fluorouracil (5-FU) and 
doxorubicin (DXR) (Fig. 1-17). The LID mice experienced a significant protection 
from most drugs, although the protection against Eto in the LID model could not be 
established. These results thus indicate that the compatibility between specific drugs 
and IGF-I reduction/blockade therapy has to be carefully tested in preclinical studies 
before being considered as a candidate. 
 
To test if restoring the IGF-I levels during STS reverses the protection against 
chemotherapy induced toxicity, CD-1 mice underwent a 48 hour STS with IGF-I (200 
μg/kg) administration every 12 hours to match levels of ad libitum fed mice. 
Following the STS/IGF-I treatments, mice were intra-venously (i.v.) injected with 16 
mg/kg DXR. Restoring IGF-I during STS abolished the protective effect of STS on 
DXR toxicity, resulting in a 100% vs. 38% survival in the STS and STS/IGF-I groups, 
respectively (Fig. 1-18). 
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Figure 1-16. The effect of 72 hour fasting on glucose, IGF-I, IGFBP-1 and 
IGFBP-3 levels. 
Thirty week old CD-1 mice were fasted for 72 hours (A) and sacrificed. Blood was 
collected via cardiac puncture under anesthesia, and blood glucose (C) was 
measured immediately. Plasma GH (B), IGF-I (D) and IGFBP-1/ IGFBP-3 (E and F) 
levels were measured by a mouse-specific ELISA (Cohen lab, UCLA). All p-values 
were calculated by Student's t-test except that for IGFBP-1, which was done by the 
Mann-Whitney U test. Modified from (Lee, Safdie et al. 2010). 
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Figure 1-17. Stress resistance testing in a liver Igf1 gene deletion (LID) mouse 
model with high-dosed chemotherapeutic drugs. 
LID and control mice received (A) a single injection of 100 mg/kg etoposide (Eto), 
(B) a single injection of 500 mg/kg cyclophosphamide (CP), (C) a single injection of 
400 mg/kg 5-fluorouracil (5-FU), or (D) two injections of doxorubicin (DXR). The first 
injection of 20 mg/kg was given on day 0, and the second injection of 28 mg/kg was 
given on day 22. Toxicity evaluated by percent survival is shown. Modified from (Lee, 
Safdie et al. 2010). 
 
 
Figure 1-18. IGF-I restoration during STS reverses STS-dependent protection. 
16 to 20 week old female CD-1 mice were fasted for 48 hours (STS). During STS, 
IGF-I (200 μg/kg) was intra-peritoneally injected every 12 hours to restore IGF-I 
levels. Immediately following STS/IGF-I treatment, all mice were intra-venously 
injected with 16 mg/kg DXR. Modified from (Lee, Safdie et al. 2010). 
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Previous human studies have shown that alternate day dietary restriction and 
short-term fasting (5 days) are well tolerated and safe (Isley, Underwood et al. 1983; 
Maccario, Aimaretti et al. 2001; Johnson, Summer et al. 2007). In a study published 
in 2002, children ranging from 6 months to 15 years of age were able to complete 14 
to 40 hours of fasting in a clinical study that was carried out by the Children’s 
hospital of Philadelphia (Katz, DeLeon et al. 2002). Following the publication of our 
pre-clinical work on the effects of DSR, several patients, diagnosed with a wide 
variety of cancers, elected to undertake fasting prior to chemotherapy and shared 
their experiences with us. In 2009, our laboratory published a case series report of 
10 patients diagnosed with various types of cancer (Table 1-4), who have voluntarily 
fasted prior to and following chemotherapy (Safdie, Dorff et al. 2009). Out of the 10 
cancer patients receiving chemotherapy, 7 females and 3 males with a median age 
of 61 years (range 44-78 yrs), four suffered from breast cancer, two from prostate 
cancer, and one each from ovarian, uterine, non small cell carcinoma of the lung, 
and esophageal adenocarcinoma. All patients voluntarily fasted for a total of 48 to 
140 hours prior to and/or 5 to 56 hours following chemotherapy administered by their 
treating oncologists. The obtained results, based on self-assessed health outcomes 
from a questionnaire and laboratory reports, suggest that fasting is safe and raises 
the possibility that it can reduce some of the commonly with chemotherapy-
associated side effects, e.g. nausea and vomiting (Fig. 1-19), although a placebo 
effect cannot be fully excluded.  
In July 2009, the University of Southern California (USC)/Norris 
Comprehensive Cancer Center initiated a clinical trial (ClinicalTrials.gov Identifier: 
NCT00936364) to test the efficacy and safety of 24 to 72 hours of fasting in 
combination with platinum-based chemotherapy treatments in patients diagnosed 
with bladder cancer. A more recent extension includes patients affected by breast, 
ovarian and lung cancer (this trial is still ongoing). As of August 2010, the Mayo 
Clinic Cancer Center (ClinicalTrials.gov Identifier: NCT01175837) started to enroll, 
and is still recruiting, patients older than 18 years who are affected by lymphomas 
and leukemia for fasting in combination with chemotherapy. A clinical trial sponsored 
by the Leiden University Medical Center (ClinicalTrials.gov Identifier: NCT01304251) 
will study the effects of short-term fasting on tolerance to adjuvant chemotherapy in 
breast cancer.  
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Table 1-4. Demographic and clinical information of patients that voluntarily 
fasted prior to chemotherapeutic treatment.  
Modified from (Safdie, Dorff et al. 2009). 
 
 
 
Figure 1-19. Self-reported side-effects after chemotherapy in patients with or 
without fasting. 
Data represent average of Common Terminology Criteria for Adverse Events 
(CTCAE) grade from matching fasting and non-fasting cycles (Ad lib). Six patients 
received chemotherapy alone, or chemotherapy/ fasting treatments. Side effects 
from the closest two cycles were compared to one another. Data presented as 
standard error of the mean (SEM). P-value was calculated with unpaired, two tailed 
t-test; *, P<0.05. Modified from (Safdie, Dorff et al. 2009). 
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From the introduction above, it becomes clear that normal and cancer cells differ in 
many ways. In general, normal cells obey the regulatory signals for growth, 
differentiation, and apoptosis. In contrast, cellular transformation, as a result of 
mutations, collectively empowers a cell with self sufficiency in growth signaling and 
insensitivity to growth inhibitory signaling (Fig. 1-2), which uncouples cancerous cells 
from the organism (Hanahan and Weinberg 2008; Luo, Solimini et al. 2009). Even 
more specific, this self sufficiency in growth signaling is supported by gain-of-function 
mutations in oncogenes (e.g. Ras, Akt, mTor, etc) that enable the constitutive 
activation of proliferation pathways; regardless if the conditions support cellular 
growth. On the contrary, insensitivity to growth inhibitory signals is mediated by loss-
of-function mutations in tumor-suppressor genes (e.g. Rb, p53, PTEN, etc), enabling 
cancer cells to disregard anti-proliferation signals (Hanahan and Weinberg 2000). 
This distinct response to growth regulation between normal and cancer cells is the 
foundation for the differential stress resistance strategy that we employed to protect 
mice, and potentially patients, from chemotherapy induced toxicity. The therapeutic 
potential of fasting may be even greater if it also increases the death of cancer cells. 
I will describe in the following sections of this thesis that the self sufficiency in 
growth signals, insensitivity to growth inhibitory signals, as well as strong 
dependence on glucose, causes cancer cells to be sensitized to chemotherapy, 
radiotherapy and other toxins. Malignant cells under normal cellular conditions 
represent a highly efficient and adapted cell within their proximate niche. However, 
the same mutations that prone tumor cells to unrestricted growth under optimal 
conditions, render them also sensitive to alterations in the cellular environment. One 
such example is the change of the metabolism under fasting conditions. Normal, 
non-malignant, cells have evolved over thousands of years to cope with the ever 
changing environment that they are exposed to. Our fasting based sensitization 
exploits this deficit in cancer cells. 
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2 Material and Methods 
2.1 Yeast Stress Resistance 
Yeast strains used in this study are derivatives of the DBY746 (MATα leu2–
3,112, his3Δ1 trp1-289α ura3-52 GAL+) strain. The over-expressing RAS2val19 strain 
was generated by transforming wild-type DBY746 cells with pMW101 (a pRS416 
vector carrying the Cla I–ras2val19–Hind III fragment form pMF100; a gift from J. 
Broach, Princeton). Yeast cells were grown in SDC supplemented with a 4-fold 
excess of tryptophan, leucine, uracil, and histidine to avoid possible artifacts due to 
auxotrophic deficiencies of the strains. Medium and growth conditions were as 
described (Wei, Fabrizio et al. 2008). Briefly, overnight SDC culture was diluted 
(1:200) in fresh SDC medium to a final volume of 10 ml (with a flask to culture 
volume of 5:1) and was maintained at 30°C while shaking (200 rpm) to ensure 
proper aeration. This time point was considered day 0. Every 2 days, aliquots from 
the culture were properly diluted and plated on to YPD plates. The YPD plates were 
incubated at 30°C for 2 to 3 days, and viability was accessed by Colony Forming 
Units (CFUs). 
Heat shock resistance was measured by spotting serial dilutions (10-fold 
dilution started at OD600 of 10) of cells removed from SDC cultures onto YPD plates 
and incubating at either 55°C (heat-shocked) or 30°C (control) for 45 min to 150 min. 
After the heat shock, plates were transferred to 30°C and incubated for 2 to 3 days. 
For oxidative stress resistance assays, cells were diluted to an OD600 of 1 in K-
phosphate buffer (pH 6.0) and treated with 100 mM to 200 mM of hydrogen peroxide 
for 60 min, or cells were treated with 250 mM of menadione for 30 min in K-
phosphate buffer (pH 7.4). Serially diluted (10-fold) control or treated cells were 
spotted onto YPD plates and incubated at 30°C for 2 to 3 days, and viability was 
accessed by CFUs. 
2.2 Cell Culture of Mammalian Cells 
4T1luc murine breast cancer cells were purchased from SibTech. B16fluc 
murine melanoma cells were provided by N. Craft [University of California, Los 
Angeles (UCLA)]. GL26luc murine glioma cells, as well as human glioblastoma cell 
lines U251, LN229, A172, C6 and U87-MG were provided by T. Chen [University of 
80 
 
Southern California (USC)]. PC3 and 22Rv1 human prostate cancer cells were 
provided by P. Cohen (UCLA). MCF-7 and C42B human breast cancer cells and 
HeLa human cervical cancer cells were provided by A. Lee (USC). LOVO human 
colon cancer cells were provided by D. Shibata (USC). NXS2 and Neuro-2a murine 
neuroblastoma, ACN and SH-SY5Y human neuroblastoma, OVCAR3 human ovarian 
carcinoma, MZ2-MEL human melanoma, A431 human epidermoid carcinoma, and 
MDA-MB-231 human breast cancer cells were routinely cultured in the Laboratory of 
Oncology of Gaslini Institute. Mouse primary mixed glial cells were obtained from the 
cerebral cortices of 1-3 day old C57BL/6 mouse pups. All cells were routinely 
maintained in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) and 10% 
fetal bovine serum (FBS) at 37°C and 5% CO2. 
2.3 In vitro Starvation Model  
Cellular fasting was done by glucose and/or serum restriction to achieve blood 
glucose levels typical of fasted and normally fed mice. The lower glucose level was 
approximated to 0.5 g/liter and the upper level to 2.0 g/liter based on previous results 
(Raffaghello, Lee et al. 2008; Lee, Safdie et al. 2010). For human cell lines, normal 
glucose was considered to be 1.0 g/liter. Serum (FBS) was supplemented at 1% for 
starvation conditions to mimic the reduction in growth factors. Cells were washed 
twice with phosphate buffered saline (PBS) before changing to fasting medium. 
2.4 In vitro Proliferation Assays  
To determine cellular proliferation, we seeded 50,000 cells in 6-well plates 
and immediately upon attachment switched medium to starvation (0.5 g/liter, 1% 
FBS) or control (2.0 g/liter, 10% FBS) conditions. Forty-eight hours later, cell number 
was assessed by trypan blue exclusion. 
2.5 Treatments of Mammalian Cells in vitro 
Cells were seeded into 96-well microtiter plates at 20,000 cells/well and 
incubated for 2 days in DMEM (4.5 g/L glucose and 10% FBS) and washed with PBS 
prior to treatments. Cells were then incubated in glucose free DMEM (Invitrogen) 
supplemented with either 10% or 1% FBS and glucose (0.5 g/L, for starvation-
mimicking condition or 2.0 g/L, for ad lib condition) for 24 hours followed by 24 hour 
treatments with varying concentrations of Temozolomide (TMZ, Schering), 
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Doxorubicin (DXR, Bedford Laboratories) and Cyclophosphamide (CP, Sigma-
Aldrich and Baxter). Optimum drug doses were determined for each individual cell 
line. 
For the treatment with the neutralizing monoclonal antibody α-IR3 (Millipore), 
cells were incubated in DMEM (2.0 g/L glucose with 1% serum) for 24 hours prior to 
and during drug treatment with 4 mM cyclophosphamide. 
The IGF-I treatment was carried out by incubating cells in DMEM with 1% FBS 
and rhIGF-I (200 μM, ProSpec-Tany TechnoGene, Rehovot, Israel) for 24 hours prior to 
and during drug treatment with 16 μM Doxorubicin.  
AHA incorporation was measured and normalized against Hoechst 33342 
values with the Click-iT AHA Alexa Fluor 488 Protein Synthesis HCS Assay 
(Invitrogen) following the manufacturer’s instructions. 
2.6 In vitro Cytotoxicity Assays  
Cytotoxicity was measured by the ability to reduce methyl-thiazolyldiphenyl-
tetrazolium bromide (MTT) or the release of lactate dehydrogenase (LDH).  
MTT was prepared at 5 mg/ml in PBS, diluted to a final concentration of 0.5 
mg/ml for assays and incubated for 3 to 4 hours at 37°C. Formazan crystals were 
dissolved overnight (16 hours) at 37°C with 100 µl of lysis buffer [15% (w/v) SDS, 
50% (v/v) dimethylformamide, pH 4.7]. Survival was presented as percentage of 
MTT reduction level of treated cells to control cells. Absorbance was read at 570 nm 
with the microplate reader SpectraMax 250 (Molecular Devices) and SoftMax Pro 3.0 
software (Molecular Devices).  
Cell survival with the CytoTox 96® Non-Radioactive Cytotoxicity Assay 
(Promega) quantitatively measures the release of lactate dehydrogenase (LDH) 
upon cell lysis. Released LDH in culture supernatants is measured using a coupled 
enzymatic assay, resulting in the reduction of a tetrazolium salt (INT) into a red 
formazan product. The absorbance was read at 490 nm with the microplate reader 
SpectraMax 250 (Molecular Devices) and SoftMax Pro 3.0 software (Molecular 
Devices). Survival presented as percentage of untreated control. 
2.7 In vitro Superoxide Assays  
Superoxide levels were estimated by oxidation of the fluorescent dye DHE 
(Invitrogen). Cells were cultured on slides, treated, and washed twice with PBS 
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before incubation with DHE (10 mM; in 0.1% dimethyl sulfoxide) for 30 min. Total cell 
fluorescence was quantified with ImageJ [National Institutes of Health (NIH)]. 
Corrected fluorescence was calculated with the following equation: integrated 
density × (area of selected cell × mean fluorescence of background readings).  
Mitochondrial superoxide levels were selectively measured with the 
MitoSOXTM Red flourogenic dye (Molecular Probes). MitoSOX™ Red reagent is live-
cell permeant and is rapidly and selectively targeted to the mitochondria. Once in the 
mitochondria, MitoSOX™ Red reagent is oxidized by superoxide and exhibits red 
fluorescence. MitoSOX™ Red reagent is readily oxidized by superoxide but not by 
other ROS, or reactive nitrogen species (RNS), generating systems and oxidation of 
the probe is prevented by superoxide dismutase. The oxidation product becomes 
highly fluorescent upon binding to nucleic acids. The experimental design was 
modified based on the manufacturer’s protocol with the following variations: we 
prepared a 2.5 µM working reagent solution in PBS/Ca/Mg (Cellgro) buffer and 
incubated for 10 min at 37°C after applying 1 ml for cells grown in 6-well plates (for 
imaging) or 100 µL per well of a 96-well plate (for quantification). Microscopic 
imaging was performed with the Nikon Eclipse TE300 system, following the 
manufacturer’s protocol with the excitation and emission at 510 nm and 580 nm, 
respectively. The 96-well plate quantifications were performed using a fluorescence 
microplate reader (Labsystems Fluoroskan Ascent FL) with Ex/Em at 510 nm and 
580 nm, respectively. Fold-increase presented normalized to untreated control (2 g/L 
glucose, 10% FBS). 
2.8 Comet Assay Protocol  
Cells were diluted to 105/ml in culture medium (DMEM with 10% FBS) and 
treated with 50 mM DXR for 1 hour at 37°C. Cells were then washed once with ice-
cold PBS and subjected to CometAssay (Trevigen) according to the manufacturer’s 
recommended procedure. Comet images were acquired with a Nikon Eclipse TE300 
fluorescence microscope and analyzed with the Comet Score software (TriTek 
Corp., version 1.5). Cells (100 to 300) were scored for each genotype per treatment 
group. 
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2.9 Immunoblotting Assay  
Cells were rinsed once in ice-cold PBS and harvested in radio-immuno-
precipitation assay (RIPA) lysis buffer containing protease inhibitors (Roche) and a 
cocktail of phosphatase inhibitors (Sigma). Tumor tissues were homogenized in 
RIPA lysis buffer supplemented with the same protease and phosphatase inhibitors. 
Proteins from total lysates were resolved by 8 to 12% SDS–polyacrylamide gel 
electrophoresis and analyzed by immunoblotting with antibodies for glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), Akt and phospho-Ser473 Akt, p70 S6K and 
phospho-Thr389 p70 S6K, and eIF2a and phospho-Ser51 eIF2a (1:1000 to 1:2000, 
Cell Signaling Technology).  
2.10 Measurements of Mitochondrial Bioenergetic Function using the XF-24 
Extracellular Flux Analyzer 
The XF-24 Extracellular Flux Analyzer (Seahorse Biosciences) was used to 
examine the effects of ad lib (2 g/L glucose, 10% FBS) and fasting-mimicking (0.5 
g/L glucose, 1% FBS) cell culture conditions on glycolysis and mitochondrial 
function. Briefly, the mitochondrial function assay is based on inhibitors of the 
electron transport chain and uncoupling agents to identify alterations in the 
respiratory function (Yadava and Nicholls 2007). Cells were seeded into special 24-
well microtiter plates (Seahorse Biosciences) at 20,000 cells/well and incubated for 2 
days in DMEM (4.5 g/L glucose and 10% FBS) and washed with PBS prior to 
treatments. Cells were then incubated in glucose free DMEM (Invitrogen) 
supplemented with either 10% or 1% FBS and glucose (0.5 g/L, for starvation-
mimicking condition or 2.0 g/L, for ad lib condition) for 48 hours. Four basal oxygen 
consumption rates (OCR) are measured every 8 minutes to obtain baseline OCRs, 
followed by the measurement of OCR after the sequential injection of 1 µM 
oligomycin, 1 µM carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) 
and 0.75 µM rotenone. Glycolysis was assayed through the addition of 75 µM 2,4-
dinitrophenol (DNP), fatty acid oxidation was evaluated by adding 200 µM palmitate 
to the wells. The optimal drug concentration for 4T1 cells was measured prior to the 
experiments. Owing to the effects of starvation on reduced proliferation and cell 
death in cancer cells, total cellular protein was measured following each experiment 
and used to normalize the mitochondrial function rates. To allow comparison 
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between experiments, data are expressed as the rate of oxygen consumption in 
pmol/min or the extra-cellular acidification rate (ECAR) in mpH/min. In some 
experiments, the data are expressed as a percentage of the basal O2 consumption 
rate.  
2.11 Microarray analysis  
Microarray analysis was performed at the NIA/NIH by Alejandro Martin-
Montalvo. In brief, RNA from mouse tissues (heart, liver and lung) was isolated 
according to the procedures described by the manufacturer with the RNeasy kit 
(Qiagen). Then, RNA was hybridized to BD-202-0202 chips from Illumina Beadchips. 
Raw data were subjected to Z normalization as described (Cheadle, Vawter et al. 
2003). Briefly, for each pathway under each pair of conditions, a Z score was 
computed as [Z (pathway)= (sm mu)*pow(m,0.5)/delta], where mu= mean Z score of 
all gene symbols on the microarray, delta = SD of Z scores of all gene symbols on 
the microarray, sm= mean Z score of gene symbols comprising one pathway present 
on the microarray, and m= number of gene symbols in a pathway present on the 
microarray. For each Z (pathway), a P value was also computed in JMP 6.0 to test 
for the significance of the Z score obtained. These tools are part of DIANE 1.0 (NIH). 
Parameterized significant analysis is finished according to the SAM protocol (Tusher, 
Tibshirani et al. 2001) with analysis of variance (ANOVA) filtering (ANOVA P < 0.05). 
Significant genes are selected for each pair-wise comparison. Gene set enrichment 
was tested with the PAGE method as previously described (Kim and Volsky 2005). 
Figures were selected on the basis of the names and descriptions provided by Gene 
Ontology Database and Pathway Data Set (Subramanian, Tamayo et al. 2005). 
Further gene regulatory relation and canonic pathway analysis is done by the 
Ingenuity Pathway Analysis System (Ingenuity Systems). All raw data are available 
in the Gene Expression Omnibus database. 
2.12 Modulation of HO-1 Expression 
To modulate HO-1 activity, 4T1 cells were treated with 10 µM hemin (Sigma) 
or 20 µM zinc protoporphyrin (ZnPP; Sigma) for 24 hours prior to and 24 hours 
during chemotherapy treatment.  
The rHO-1 construct, a kind gift from Dr. Claude A. Piantadosi of Duke 
University, was prepared consisting of pcDNA 3.1/V5-His-rHO-1 containing the entire 
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protein-coding region of the rat HO-1 gene. 4T1 cells were transfected using the 
XtremeGENE HP DNA transfection reagent according to the manufacturer’s protocol 
(Roche Applied Science). Selection for successful transfection was carried out with 
G418 (Genecitin, Sigma). Cells grown from a single clone with the highest HO-1 
expression (based on qRT-PCR) were used for experiments. 4T1-HO1 cells were 
maintained in DMEM (4.5 g/L, 10% FBS with 100 µg/ml G418). 4T1 cells 
transformed with the empty vector were established as controls following the same 
protocol.  
2.13 Real time-PCR 
RNA from tissues was isolated according to the procedures described by the 
manufacturer using the RNeasy kit (Qiagen). cDNA was synthesized using the High 
Capacity cDNA Reverse Transcription Kit (AB Applied Biosystems) and RT-PCR 
was performed using the SYBR Green PCR master mix (AB Applied Biosystems).  
 
The primer sequences for HO-1 are:  
forward 5’ TGCTCGAATGAACACTCTGG 3’ 
reverse 5’ TCCTCTGTCAGCATCACCTG 3’ 
The primer sequences for NFkB (p50) are:  
forward 5’ GGAGGCATGTTCGGTAGTGG 3’ 
reverse 5’ CCCTGCGTTGGATTTCGTG 3’.  
 
Each analyzed treatment was performed with three biological replicates and 
at least three reactions were used to calculate the expression. The expression ratio 
was calculated according to the 2-ΔΔCP method (Pfaffl 2001). 
2.14 Mouse Cancer Models  
All animal experiments were performed according to procedures approved by 
USC’s Institutional Animal Care and Use Committee (IACUC), the licensing and 
ethical committee of the National Cancer Research Institute, Genoa, Italy, and the 
Italian Ministry of Health. All mice were maintained in a pathogen-free environment 
throughout the experiments. 
To establish a subcutaneous cancer mouse model, we injected 12 week old 
female BALB/c, 12 week old female and male C57BL/6 mice, and 7 week old nude 
86 
 
mice with 4T1 breast cancer cells, B16 melanoma, and GL26 glioma cells, 
respectively. 5 to 7 week old nude mice were injected with ACN human 
neuroblastoma cells, MDA-MB-231 human breast cancer cells, or OVCAR3 human 
ovarian carcinoma cells. 
For metastatic mouse models of cancer, 12 week old female BALB/c and 12 
week old female and male C57BL/6 mice were injected intravenously via the lateral 
tail veins with 2 × 105 4T1 or B16 cells, respectively, and 6 week old female A/J mice 
were injected via lateral tail veins with 2 × 105 NXS2 and 1 × 106 Neuro-2a cells. 
Before injection, cells in log phase of growth were harvested and suspended in PBS 
at 2 × 106 cells/ml, and 100 µl (2 × 105 cells per mouse) was injected subcutaneously 
in the lower back or intra-venously via the lateral tail veins. ACN and Neuro-2a cells 
were suspended in PBS at a density of 5 × 107 and 1 × 107 cells/ml, and 100 µl (5 × 
106 ACN cells per mouse and 1 × 106 Neuro-2a cells per mouse) was injected 
subcutaneously in the lower back or intra-venously via the lateral tail veins, 
respectively. 
For the intracranial glioma model, mice were fixed in a stereotactic frame, a 
paramedian incision was made and a 1.5 mm bur hole was drilled in the right frontal 
lobe of the skull (1 mm anterior and 3 mm lateral relative to the bregma). Using a 
Hamilton syringe, 1 × 104 GL26luc cells in 5 µL PBS were implanted 5 mm deep into 
the brain of each mouse. GL26luc cells are genetically engineered to express the 
firefly luciferase gene. Two animals received a mock surgery without the implantation 
of tumor cells. The skin incision was then closed with silk thread 3/0. To evaluate 
tumor progression, luciferin (50 mg/kg body weight) was administered via intra-
peritoneal injections and animals were subjected to Bioluminescence Imaging (BLI) 
with the Xenon IVIS200 system at the USC Small Animal Imaging Center. 
 
Tumor inoculation, drug treatment, radiotherapy and tumor measurements 
were all performed under inhalant anesthesia, utilizing 2% Isoflurane. All mice were 
shaved before subcutaneous tumor injection and were gently warmed before intra-
venous injections to dilate the veins. Body weights were determined periodically, and 
tumor size was measured with a digital vernier caliper. The subcutaneous tumor 
volume was calculated with the following equation: tumor volume (mm3) = Product 
(length × width × height)/2, where the length, width, and height are in millimeters. 
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Animals with a tumor volume bigger than 2500mm3 and animals showing 
signs of severe stress and/or deteriorating health status were designated as 
moribund and euthanized. 
2.15 In vivo Fasting  
For short-term starvation (STS), mice were single caged and maintained in 
standard shoebox-cages without access to food for 48 to 60 hours. To reduce 
cannibalism and to avoid coprophragy or feeding on residual chow, cages were 
changed immediately before STS was initiated. Animals had access to water at all 
times. Body weight of each individual animal was measured routinely during the STS 
regime to ensure controlled loss of body weight to no less than 20%; according to 
the guidelines of our IACUC protocols. 
2.16 Cancer Treatments  
DXR (Bedford Laboratories), CP (Sigma and Baxter), cisplatin (Teva 
Parenteral Medicines Inc.) and Temozolomide (Schering) were used. For in vivo 
studies, DXR and TMZ were injected intra-venously via lateral tail veins, cisplatin 
and CP was injected intra-peritoneally.  
Whole body irradiation was performed with Cesium 137 as the radiation 
source, at a dose of 5 Gy for the first treatment and 2.5 Gy for the second treatment, 
with or without 48 hour starvation. Mice were monitored daily. Animals showing signs 
of severe stress, deteriorating health status or excess tumor load (s.c, 2500 mm3) 
were designated as moribund and euthanized. The data presented in the graphs 
showing moribund animals is based on these exclusion criteria. 
2.17 In vivo Modulation of Heme Oxygenase-1 
Hemin (Sigma) was dissolved in 0.7 N ammonium hydroxide (NH4OH) at 50 
mg/ml to obtain a stock solution. This stock solution was dissolved 1:10 in saline and 
prepared fresh prior to injections. Hemin was delivered by intra-peritoneal injection 
every 12 hours for a total of 6 injections, at a dose of 15 mg/kg each injection. 
Control animals were injected with hemin-free dissolvent. 
Zinc protoporphyrin (ZnPP, Sigma) was prepared as a 100 mg/ml stock 
solution dissolved in dimethyl sulfoxide (DMSO). Prior to injections, the stock 
solution was dissolved 1:10 in DMSO. ZnPP was delivered by intra-peritoneal 
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injection every 12 hours for a total of 6 injections, at a dose of 20 mg/kg each 
injection. Control animals were injected with ZnPP-free DMSO. 
2.18 Blood Collection for Glucose and IGF-I Measurements  
Mice were anesthetized with 2% inhalant isoflurane and blood was collected 
by left ventricular cardiac puncture. Blood was collected in tubes coated with K2-
EDTA (BD) to process serum. Blood glucose was measured with the Precision Xtra 
blood glucose monitoring system (Abbott Laboratories) by clipping the tail. IGF-I was 
measured using a mouse specific ELISA kit following the manufacturer’s protocol 
(R&D Systems). 
2.19 Macronutrient Defined Diets  
AIN93G standard chow (Harlan) was used as the reference diet and supplied 
to all mice if not indicated otherwise. Diets modified in the macronutrient composition 
(fat, protein and carbohydrates) were all based on the AIN93G diet (Table 2-1). Diets 
20% P-1 (soybean oil as fat source) and 20% P-2 (coconut oil as fat source) had 
calories from protein sources reduced to 20% compared to the AIN93G formulation; 
the 0% P diet contained no protein; all these diets were isocaloric to the AIN93G 
standard chow (Table 2-2). The low carbohydrate LCHP diet had calories from 
carbohydrates reduced to 20% compared to the AIN93G formulation (13% vs. 
63.9%) but contained more protein (45.2%) and fat (41.8%). The high fat diet 60% 
HF was designed to supply 60% of the consumed calories from fat sources, the 
calories coming from protein and carbohydrates were reduced proportionally. The 
90% HF diet is a ketogenic diet which contains 90% of fat with minimal 
carbohydrates (less than 1%) and half of the protein content (9%). Detailed diet 
composition and calorie content are summarized in Table 2-2. Mice were fed with 
the AIN93G control diet before the beginning of the experiments and based on their 
initial bodyweight grouped into the experimental groups (N=5/ group). Mice were 
acclimated to the test diets one week prior to the experiments. All diets were 
supplied ad lib unless indicated otherwise.  
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Table 2-1. Detailed composition of macronutrient defined diets.  
Modified from Brandhorst et al.; under review. 
 
 
 
Table 2-2. Overview about the macronutrients and calories contained in the 
experimental diets. 
Modified from Brandhorst et al.; under review. 
 
 
 
 
90 
 
2.20 Caloric Restriction 
For caloric restriction using the AIN93G diet, the standard chow was 
grounded into a powder and mixed in hydrogel (Clear H2O) in the necessary 
amounts to achieve 60%, 50%, 40%, 20%, 10% calorie density of AIN93G (Table 2-
3). The caloric restricted macronutrient modified diets were prepared the same way 
(Table 2-4). To avoid malnutrition all diets were supplemented with vitamins, 
minerals, fiber and essential fatty acids matching those in AIN93G. Baseline food 
intake (3.7 g or 14 kcal/day) was determined with AIN93G feeding prior to the 
experiments (data not shown). For all CR experiments, mice were single caged in 
standard shoebox-cages which were refreshed daily to avoid coprophragy or feeding 
on residual chow. Animals had access to water at all times to ensure sufficient 
hydration. Bodyweight of each individual animal was measured routinely during the 
CR regimens. 
 
Table 2-3. Composition of calorie restricted diets.  
Modified from Brandhorst et al.; under review. 
 
 
Table 2-4. Composition of calorie restricted macronutrient defined diets. 
 Modified from Brandhorst et al.; under review. 
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2.21 Resistance to High-Dose Chemotherapy  
12 to 15 week old female CD-1 mice weighing 25 to 32 g were starved for up 
to 60 hours (STS) or fed with the macronutrient modified 50% CR diets for 3 days, 
followed by an intra-venous injection of 24 mg/kg Doxorubicin (DXR, Bedford 
Laboratories). In all experiments mice were offered AIN93G standard chow after 
chemo-drug injection and monitored daily. Animals showing signs of severe stress 
and/or deteriorating health status were designated as moribund and euthanized. 
2.22 Statistical Analysis  
Statistical analysis was performed using GraphPad Prism v.5. Survival curve 
comparison was performed with the Log-Rank test. All statistical analyses were two-
sided and P values <0.05 were considered significant.   
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3 Results 
A prolonged 20 to 40% reduction in calorie intake or dietary restriction (DR) 
protects a wide variety of organisms against oxidative stress and aging (Weindruch, 
Walford et al. 1986; Longo and Finch 2003; Longo and Fontana 2010). By contrast, 
a limited exposure to a severely restricted diet (short-term starvation or fasting) can 
protect yeast, mammalian cells, mice, and possibly even patients from the toxic 
effects of oxidative and chemotherapeutic agents without the chronic weight loss 
generally associated with prolonged CR (Longo, Ellerby et al. 1997; Raffaghello, Lee 
et al. 2008; Safdie, Dorff et al. 2009; Lee, Safdie et al. 2010; Lee, Raffaghello et al. 
2012). We proposed that the fasting mediated protection of normal cells is based on 
the reallocation of energy towards cellular maintenance pathways from reproduction 
and growth processes, when nutrients are scarce or absent (Kirkwood 2005). This 
switch to a protected mode occurs only in normal cells, not cancer cells, because 
oncogenes prevent the activation of stress resistance pathways in malignant cells. 
This feature of cancer cells thus provides a way to enhance cancer treatment by 
selectively increasing protection of normal cells [differential stress resistance (DSR), 
Fig. 3-1] rather than by the more typical strategy of increasing the toxicity of drugs to 
cancer cells (Raffaghello, Lee et al. 2008; Safdie, Dorff et al. 2009; Lee, Safdie et al. 
2010). DSR in mice and mammalian cells is mediated in part by the reduction of 
extra-cellular glucose and IGF-I concentration/signaling. Potentially harnessing DSR 
for clinical cancer therapy is attractive because fasting for 2 to 3 days before and 24 
hours after chemotherapy is well tolerated by cancer patients receiving a variety of 
toxic treatments and might even reduce the common side effects caused by 
chemotherapy (Safdie, Dorff et al. 2009). Further, in mouse models, fasting protects 
against ischemia-reperfusion injury (Mitchell, Verweij et al. 2009), and deprivation of 
a single amino acid results in both lower IGF-I levels and protection against renal 
and hepatic ischemic injury (Peng, Robertson et al. 2011).  
The therapeutic potential of fasting would be even greater if it also increased 
the death of cancer cells. We tested this possibility in collaboration with researchers 
at the NIA (Baltimore, USA) and the Giannina Gaslini Institute (Genova, Italy) by 
studying the effect of fasting on cancer cell survival in the presence or absence of 
chemotherapeutic agents (Lee, Raffaghello et al. 2012; Safdie, Brandhorst et al. 
2012). 
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Figure 3-1. Fasting provides a differential stress resistance to chemotherapy. 
The investment of the finite energy available in a cell or an organism is efficiently 
balanced between growth/ reproduction and maintenance/repair. However, 
challenging conditions, such as fasting and its consequent reduction of IGF-I, 
withdraws energy from growth/reproduction and reinvests it in maintenance/repair, 
thereby increasing cellular protection. This switch in cellular metabolic policy is 
mediated by negatively regulating mitotic pathways such as those major effectors 
downstream of IGF-I (PI3K/Akt and Ras/ERK). By contrast, oncogenic mutations, 
which often regulate cellular metabolism and growth, render tumor cells less 
responsive to fasting because of their independence from external cues. Therefore, 
cancer cells fail to, or only partially respond to fasting, and continue to promote 
growth, leaving them vulnerable to chemotherapy drugs. Modified from (Lee and 
Longo 2011) 
 
3.1  Starvation Sensitizes Yeast and Cancer Cells to Toxins 
We have previously shown that, unlike the wild-type DBY746 cells, yeast cells 
expressing an oncogene-like constitutive active form of Ras (RAS2val19) are not 
protected from oxidative and chemotherapeutic agents by prior starvation 
(Raffaghello, Lee et al. 2008; Lee, Safdie et al. 2010). We repeated some of the 
DSR based experiments in yeast (Fabrizio and Longo 2003; Fabrizio, Hoon et al. 
2010), by switching normal yeast cells from the standard glucose medium to water 
for 24 hours, followed by the exposure to various toxic agents and stressors. This 
starvation-mimicking incubation in water was used as a treatment to increase their 
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ability to survive in response to heat shock or oxidative stress, induced by hydrogen 
peroxide or menadione, both of which mimic the oxidation-dependent cytotoxicity of 
many chemotherapy drugs (Fig. 3-2) (Raffaghello, Lee et al. 2008; Lee, Safdie et al. 
2010). In contrast, the water-based starvation sensitized yeast cells carrying the 
RAS2val19 mutation and rendered them less able to withstand heat shock or oxidative 
stress (Fig. 3-2). This data suggests that, in contrast to the protection afforded to 
normal cells, starvation increases the susceptibility of yeast cells expressing an 
oncogene-like protein to stress. 
 
 
 
Figure 3-2. Effect of 24 hours of starvation prior to stress treatment in yeast. 
Effects of 24 hours of starvation prior to treatment on the survival of wild type 
(DBY746) and yeast cells expressing constitutively active Ras (RAS2Val19). 
Starvation was modeled by culturing non-dividing yeast cells in water for 24 hours. 
Ten-fold serial dilutions of cells (from left to right) were spotted on culture plates and 
incubated at 30°C for 2-3 days. For heat shock resistance, cells were incubated at 
55°C for 40 min. For oxidative stress resistance assays, cells were diluted to an 
OD600 in K-phosphate buffer (pH 6) and treated with 100-200 mM of hydrogen 
peroxide (H2O2) for 60 minutes, or cells were treated with 250 mM of menadione for 
30 min in K-phosphate buffer (pH 7.4). Collaborative data, modified from (Lee, 
Raffaghello et al. 2012). 
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To test whether this sensitization by short-term starvation may also occur in 
mammalian tumor cells, we incubated murine breast cancer cells (4T1) in cell culture 
medium containing serum collected from mice that were either fed ad lib or fasted for 
48 hours. 4T1 cells cultured in the medium supplemented with serum from fasted 
mice were more susceptible to the chemotherapeutic drugs doxorubicin (DXR) and 
cyclophosphamide (CP) compared to cells incubated in serum from mice fed ad lib 
(Fig. 3-3) and thus extended our fasting-based sensitization approach from yeast 
into mammalian cells. Based on our previous results that demonstrated that fasting 
greatly reduces the concentration of serum glucose and growth factors ((Lee, Safdie 
et al. 2010), see p.74 for reference), we incubated cells in concentrations of glucose 
mimicking those of normally fed and fasted mice, supplemented with either 10% or 
1% serum, respectively, to also model the reduction in IGF-I and other growth factors 
caused by fasting. Restricting the availability of glucose and growth factors in this 
way greatly retarded the proliferation of murine 4T1 breast cancer, B16 melanoma 
and GL26 glioblastoma cell lines by roughly 50%, 35% and 75%, respectively (Fig. 
3-4). 
 
 
Figure 3-3. Effect of serum from fasted and ad lib fed mice on survival of DXR- 
and CP-treated breast cancer cells. 
Murine breast cancer cells (4T1) were cultured in DMEM media supplemented with 
serum from mice that were either fed ad lib or fasted for 48 hours prior to serum 
collection and treated with 8 mM cyclophosphamide (CP) or doxorubicin (DXR). 
Survival presented as percentage of MTT reduction of treated cells to untreated 
control cells. All data presented as mean ± SEM; ** p <0.01, Student’s t-test, two-
tailed. Collaborative data, modified from (Lee, Raffaghello et al. 2012). 
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Figure 3-4. Effect of starvation on cellular proliferation in vitro. 
Murine breast cancer (4T1), melanoma (B16) and glioblastoma (GL26) cell lines 
were seeded 50,000 cells/well and cultured either in DMEM media supplemented 
with 2 g/L glucose and 10% FBS (control, mimicking ad lib conditions) or 0.5 g/L and 
1% FBS (starved, mimicking fasting-like conditions) immediately upon attachment. 
48 hours later, cell number was assessed by trypan blue exclusion. All data 
presented as mean ± SEM; *** p <0.001, Student’s t-test, two-tailed. Collaborative 
data, modified from (Lee, Raffaghello et al. 2012). 
 
 
Applying this combination of glucose and serum restriction for 24 hours before 
and during a 24 hour chemotherapy drug treatment in culture, sensitized 15 of 17 
cancer cell lines to DXR and/or CP (Fig. 3-5, and data not shown). We tested a wide 
variety of murine cancer (4T1 breast cancer, GL26 glioma, B16 melanoma, NXS2 
and Neuro-2a neuroblastoma) and human cancer (U87-MG glioblastoma, PC3 and 
22Rv1 prostate cancer, MCF-7 and C42B breast cancer, LOVO human colon 
cancer, HeLa cervical cancer, ACN and SH-SY5Y neuroblastoma, OVCAR3 ovarian 
carcinoma, MZ2-MEL melanoma, A431 epidermoid carcinoma and MDA-MB-231 
breast cancer) cell lines. Of note is that not all cancer cell lines were sensitized when 
treated with DXR (e.g. LOVO), although this adverse effect was abolished when CP 
was used to treat the cells.  
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Figure 3-5. Effect of starvation on DXR sensitivity of 17 different cancer cells in 
vitro. 
Cells were exposed to starvation-like conditions 24 hours before and 24 hours during 
DXR treatment. Control groups (red triangle) were cultured in 1.0 g/L and 2.0 g/L 
glucose, for human and murine cells respectively, supplemented with 10% FBS. 
Starved cells (grey dots) were cultured in 0.5 g/L glucose supplemented with 1% 
FBS. Survival was determined by MTT-reduction for murine (4T1 breast cancer, 
GL26 glioma, B16 melanoma, NXS2 and Neuro-2a neuroblastoma) and human 
(U87-MG glioblastoma, PC3 and 22Rv1 prostate cancer, MCF-7 and C42B breast 
cancer, LOVO human colon cancer, HeLa cervical cancer, ACN and SH-SY5Y 
neuroblastoma, OVCAR3 ovarian carcinoma, MZ2-MEL melanoma, A431 
epidermoid carcinoma and MDA-MB-231 breast cancer) cancer cell lines. Survival is 
presented as percentage of MTT reduction of treated cells to untreated control cells. 
All data presented as mean ± SEM; * p <0.05; ** p <0.01; *** p <0.001, Student’s t-
test, two-tailed. Collaborative data, modified from (Lee, Raffaghello et al. 2012). 
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Figure 3-6. Glucose restriction sensitizes glioma cells to Temozolomide 
treatment in vitro. 
Glioma cell lines (GL26, C6, LN229, A172 and U251) and murine primary mixed glial 
cells were tested for glucose-restriction induced sensitization to Temozolomide 
(TMZ). Cells were incubated in low glucose (0.5 g/L) or normal glucose (2.0 g/L) 
media, supplemented with 1% FBS for 24 hours. Low glucose modeling STS 
conditions sensitized murine GL26 glioma cells, rat C6 glioma cells and human 
A172, LN229, U251 glioma cells to TMZ in vitro. Murine primary glial cells were used 
to represent matching normal cells. Percent cell death was determined based on 
quantitative measurements of lactate dehydrogenase (LDH) release after 24 hour 
treatment with 0–8 mM TMZ. All data presented as mean ± SEM; * p <0.05; ** p 
<0.01; *** p <0.001, Student’s t-test, two-tailed. Collaborative data, modified from 
(Safdie, Brandhorst et al. 2012). 
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We also tested the effect of glucose restriction alone on cellular stress 
resistance to Temozolomide (TMZ), the standard chemotherapy drug for 
glioblastoma multiforme (GBM) treatment (Purow and Schiff 2009). Cells were 
incubated in either low glucose (0.5 g/L) or normal glucose (2.0 g/L) for 24 hours 
prior to and during drug treatment to model the serum glucose levels during short-
term starvation (STS) and ad libitum feeding, respectively (Fig. 3-6). Murine GL26 
cells, maintained in medium mimicking blood glucose levels of starved mice, 
displayed elevated cell death after TMZ treatment when compared to cells treated in 
normal conditions. A 3-fold higher TMZ dose (6 mM vs. 2 mM) was necessary to 
cause ~90% death in GL26 cells cultured in media containing 2.0 g/L glucose 
compared to 0.5 g/L glucose in the starvation-mimicking media. Similar effects were 
observed in the human glioblastoma cell lines LN229, A172, and to a lesser extent, 
U251 cells, suggesting that sensitization of cancer cells to the TMZ treatment by 
glucose restriction may apply to human glioma. In contrast to the malignant cells, 
TMZ toxicity to primary glial cells was not significantly affected by altering the 
glucose level. Our data suggest that glucose limitation sensitizes glioma cells, but 
not primary glial cells, to TMZ treatment in vitro (Fig. 3-6). These results indicate that 
short-term starvation can not only sensitize murine and human cancer cells, but 
further sensitize a broad range of different cancer types to chemotherapeutic agents.  
Our previous studies suggested that reduced serum levels of IGF-I are 
important for the protective effects of fasting for normal cells and showed that IGF-I 
infusion can reverse the fasting-induced protection of mice from the side effects 
caused by high-dose chemotherapy (Lee, Safdie et al. 2010). To test the role of IGF-
I in cancer cell sensitization, we incubated 4T1 cells with the antagonistic IGF-IR 
antibody (αIR3) for 24 hours prior to and during drug treatment in normal glucose 
conditions (Fig. 3-7). Normal glucose was used to eliminate the role of glucose 
deprivation on cancer cells as our previous experiment demonstrated that glucose-
deprivation plays a partial role during the fasting mediated sensitization. High levels 
of FBS (e.g. 10%) interfered with the αIR3 treatment, an effect most likely due to 
competitive binding of IGF-I and the antibody at the receptor, and we therefore 
tested the antibody in media supplemented with 1% FBS. The addition of αIR3 
sensitized murine breast cancer cells to treatment with 4 mM CP and the toxicity was 
significantly increased in a αIR3 dose dependent manner (Fig. 3-7).  
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Figure 3-7. Effect of inhibiting IGF-I signaling in the starvation-dependent 
sensitization of murine breast cancer cells to CP. 
4T1 breast cancer cells were incubated in DMEM (2.0 g/L glucose with 1% serum) 
and various doses of the neutralizing anti–IGF-IR monoclonal antibody α-IR3 for 24 
hours prior to and during drug treatment with 4 mM cyclophosphamide (CP). Survival 
presented as percentage of MTT reduction of treated cells to untreated control cells. 
All data presented as mean ± SEM; *** p <0.001, ANOVA, Tukey’s multiple 
comparison, compared to untreated control. 
 
Next, we tested whether re-substituting IGF-I, which is well known to inhibit 
apoptosis, can reverse the effects of starvation on the sensitization of 4T1 and B16 
cells. We found that adding 200 μM IGF-I to starvation-treated 4T1 and B16 cells 
(incubated in 0.5 g/L DMEM) reversed the sensitization (Fig. 3-8), suggesting that 
IGF-I can protect 4T1 breast cancer and B16 melanoma cells from chemotherapy. 
Thus, this data shows that both glucose and growth factor signaling, in particular the 
decrease in IGF-I levels caused by fasting, contribute to the sensitization of 
malignant cells to cytotoxic stress. In vitro, this fasting-mimicking model of glucose 
and growth factor deprivation causes the sensitization of tumor cells in strong 
similarity to the sensitization of oncogene expressing yeast cells. In contrast, we 
previously demonstrated that normal cells enter a protected mode when nutrients are 
scarce or absent. Fasting provides dual action by protecting normal cells and 
simultaneously sensitizing different cancer cell types of murine and human origin 
(Lee, Raffaghello et al. 2012). 
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Figure 3-8. Effect of IGF-I on starvation-dependent sensitization of cancer cells 
to DXR. 
4T1 breast cancer and B16 melanoma cell lines s were treated with rhIGF-I (200 μM) 
during glucose restriction (0.5 g/L vs. 2.0 g/L, under 1% FBS), followed by DXR (16 
μM) treatment. All data presented as mean ± SEM; *** p <0.001, Student’s t-test, 
two-tailed (N=3). Collaborative data, modified from (Lee, Raffaghello et al. 2012). 
 
3.2 Short-Term Starvation improved Efficacy of Chemo- and Radiotherapy in 
Subcutaneous Tumor Models  
To explore whether our in vitro results apply to mice, we studied 
subcutaneous allografts of murine glioma (GL26), breast cancer (4T1), melanoma 
(B16), metastatic neuroblastoma models (NXS2, Neuro-2a), and xenografts of 
human neuroblastoma (ACN), breast cancer (MDA-MB-231), and ovarian cancer 
(OVCAR3) cell lines. Fasting was achieved by complete food withdrawal for 48-60 
hours while allowing mice access to water. 
Malignant glioma, including anaplastic astrocytoma and glioblastoma 
multiforme (GBM), account for more than 50% of all primary brain tumors, with GBM 
being the most common malignant brain tumor in adults (Ohgaki and Kleihues 2005). 
This tumor is highly invasive and angiogenic (Purow and Schiff 2009), resulting in 
incurability and mortality rates higher than those for any other brain tumor, with the 
median survival for GBM being ~12 to 15 months (Stupp, Dietrich et al. 2002; Stupp, 
Mason et al. 2005). The multimodal treatment of GBM includes maximal surgical 
resection, followed by adjuvant radio- and chemotherapy (Zimmerman 1955; Gupta 
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and Sarin 2002; Fisher and Buffler 2005). Other than for the introduction of the 
chemotherapeutic drug Temozolomide (TMZ), the treatment protocol has generally 
not changed over the past decades. TMZ has a high tolerability and has been shown 
to prolong patient survival. In consequence, TMZ is currently the standard 
chemotherapy drug adopted for the treatment of high grade glioma of astroglial origin 
(Friedman, Kerby et al. 2000). We evaluated the effects of combining STS and TMZ 
treatments in a subcutaneous (s.c.) model of GL26 glioma (Fig. 3-9). GL26 tumors in 
the untreated control animals progressed rapidly, reaching the endpoint size of 2500 
mm3 within 22 days after tumor implantation. Two cycles of treatment with TMZ (30 
mg/kg each cycle) alone led to a deceleration of tumor progression; however the 
majority of the tumor-bearing animals in the TMZ treated group reached the endpoint 
volume at day 22 and there was considerable variability in this experimental group. 
Notably, two cycles of STS for 48 hours, in the absence of chemotherapy, retarded 
the progression of the glioma as effectively as the TMZ treatment during days 12 to 
20 and slowed tumor growth even further during and after the second STS cycle. 
The greatest effect in decreasing tumor progression was observed when starvation 
was combined with the TMZ treatment for two consecutive treatment cycles (Fig. 3-
9, A).  
Mice with tumor mass (s.c.) exceeding 2500 mm3 or showing signs of severe 
stress and deteriorating health (regardless of tumor load) were described as 
moribund. Starvation alone did not cause obvious signs of discomfort, but rather 
improved the animal condition as indicated by body weight and behavior (data not 
shown). In the STS+TMZ group, 85% of the mice appeared healthy with the tumor-
size below the tolerated endpoint volume by day 28. This indicates that the 
combination of both treatments was well tolerated and improved tumor-bearing 
survival (Fig. 3-9, B). In both the STS and TMZ groups, 40% of the animals survived 
until day 28 after tumor implantation. Notably, animals in the STS group had to be 
sacrificed solely based on tumor-size during days 23 to 28 while animals in the TMZ 
group showed an earlier onset of morbidity starting at day 17, in part caused by 
symptoms of chemo-toxicity, e.g. reduced food intake, loss of body weight and hypo-
activity. On the other hand, survival rates were dramatically lower in the control 
group (8.3%). 50% of the untreated glioma-bearing mice reached the maximum 
tumor load by day 20; by day 22 all but one mouse in this group had to be sacrificed. 
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Figure 3-9. Enhanced chemotherapy efficacy by fasting in a murine GL26 
glioma model extends onset of morbidity in tumor-bearing animals.  
(A) Subcutaneous tumor progression of murine GL26 glioma is shown as total tumor 
volume in mm3. Tumor measurement was started once the tumor became palpable 
under the skin at day 12. Control animals (N= 12) received no treatment and the 
tumor progressed rapidly. STS (N= 12) and STS+TMZ group (N= 6) were deprived of 
food for two 48 hour cycles (day 13-15; day 20-22, grey area). TMZ animals (N= 5) 
received 15 mg/kg/day of TMZ (red lines), totaling 30 mg/kg for each treatment 
cycle. STS+TMZ animals were injected at 24 hours and 48 hours of fasting with 15 
mg/kg TMZ per injection. Animals from STS and STS+TMZ groups showed reduced 
tumor progression and could therefore be monitored for a prolonged period 
compared to animals from the control and TMZ group. All data presented as mean ± 
SEM; ** p<0.01, ANOVA, Tukey’s multiple comparison, compared to control. (B) 
Morbidity of animals inoculated subcutaneous with GL26 glioma. Animals were 
euthanized once tumor volume exceeded 2500 mm3 or based on overall appearance 
and health status. Curve comparison with Log-Rank test (Mantel-Cox, * p<0.05). 
Collaborative data, modified from (Safdie, Brandhorst et al. 2012). 
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Surgical resection followed by radiotherapy is another standard care for 
glioma patients. As STS delayed tumor progression and improved survival when 
combined with chemotherapy, we wanted to determine whether fasting could also be 
beneficial in combination with radiotherapy. Radiotherapy (RTP) delivered in two 
cycles of 5 Gy and 2.5 Gy effectively retarded tumor growth when compared to the 
untreated control group (Fig. 3-10, A). Notably, up to day 22 the tumor progression 
for the RTP and STS groups was comparable. Once the second cycle of fasting was 
stopped, a more rapid growth in the STS group was observed compared to that in 
the RTP group. The most striking effect was noticed in mice receiving two cycles of 
fasting in combination with RTP, showing a significant reduction in tumor volume 
when compared to the control, STS and RTP groups (Fig. 3-10, A). 
 As for the TMZ experiments, animals were considered moribund and were 
sacrificed once the tumor volume reached 2500 mm3 or animals showed signs of a 
deteriorating health status (Fig. 3-10, B). Two cycles of radiotherapy alone were 
capable of significantly prolonging survival compared to the untreated control group 
and ~40% of the animals in this group survived until day 31, emphasizing the well-
established benefits of radiotherapy for the treatment of GBM. As discussed in the 
TMZ experiment, animals in the STS group displayed an enhanced survival when 
compared to the untreated control animals. Despite the fact that the tumor volume in 
the STS group progressed shortly after the 2nd fasting cycle, animals in this group 
benefited with delayed tumor progression and showed extended survival. These data 
suggest that STS augments the efficacy of TMZ and RTP in treating aggressive 
GBM (Fig. 3-10, B).  
To the best of our knowledge, we demonstrate for the first time that short-term 
starvation enhances the efficacy of radiotherapy for the treatment of gliomas (Safdie, 
Brandhorst et al. 2012). Considering the poor prognosis for patients diagnosed with 
GBM, the median survival being ~12 to 15 months (Stupp, Dietrich et al. 2002; 
Stupp, Mason et al. 2005), our results presented here may provide additional means 
to improve survival after diagnosis. 
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Figure 3-10. Enhanced radiotherapy (RTP) efficacy by fasting for GL26 glioma. 
(A) Subcutaneous tumor progression of murine GL26 glioma is shown by total tumor 
volume in mm3. Tumor measurement was started once the tumor became palpable 
under the skin at day 12. Control animals (N= 12) received no treatment and tumor 
progressed rapidly. STS (N = 12) and STS+RTP group were deprived of food for two 
48 hour cycles (day 13 to day 15 and day 20 to day 22, grey area). RTP (N= 9) and 
STS+RTP animals (N= 9) were treated with 5 Gy at day 15 and 2.5 Gy at day 22, 
totaling 7.5 Gy for the combined radiotherapy treatment; 2nd dose was lowered to 2.5 
Gy to reduce radiotoxicity. Animals from STS, RTP and STS+RTP groups showed 
reduced tumor progression and could therefore be monitored for a prolonged period 
compared to animals from the control group. All data presented as mean ± SEM; *** 
p<0.001, ANOVA, Tukey’s multiple comparison, compared to control at day 22. (B) 
Morbidity of animals inoculated subcutaneously with GL26 glioma and treated with 
radiotherapy, two 48 hour fasting cycles or combination of both (STS+RTP). Animals 
were considered moribund once tumor volume exceeded 2500 mm3 or based on 
overall appearance and health status. Curve comparison with Log-Rank test (Mantel-
Cox; ** p <0.01). Collaborative data, modified from (Safdie, Brandhorst et al. 2012). 
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In mice bearing subcutaneous breast cancer (4T1), two cycles of fasting alone 
(48 hours each) were as effective as two cycles of CP treatment (Fig. 3-11, A), yet 
the mice were able to regain normal weight within 5 days of re-feeding (Fig. 3-11, B). 
Similar effects were observed in mice bearing subcutaneous melanoma masses 
(B16 cells) treated with DXR (Fig. 3-11, C, D) and also in mice bearing 
subcutaneous glioma masses (GL26 cells) treated with DXR (Fig. 3-11, E, F), 
although the growth of melanoma cells was not affected by the second cycle of 
fasting, indicating that cancer cells may in some cases acquire resistance to fasting. 
The greatest therapeutic effect was observed when fasting was combined with 
chemotherapy drugs (DXR, 10 mg/kg or CP, 150 mg/kg) (Fig. 3-11, A, C, E). For 
4T1 breast cancer, two fasting cycles combined with CP maintained tumors size at 
less than half of that in the CP treatment alone group, even 20 days after the last 
treatment (Fig. 3-11, A). Similar effects were observed in subcutaneous melanoma 
and glioma models (Fig. 3-11, C, E). Pre-fasted mice receiving chemotherapy 
returned to their normal weight soon after the last fasting cycle (Fig. 3-11, B, D, F). 
The growth of subcutaneous human breast cancer (MDA-MB-231) and ovarian 
cancer (OVCAR3) xenografts was also retarded by fasting but returned to a size 
similar to that in animals on the control diet after refeeding (Fig. 3-11, G, H). This 
post-fasting cancer growth may be the result of binge-feeding and weight gain by 
pre-fasted mice given an ad lib diet. However, when fasting was combined with DXR, 
the progression of the human breast cancer tumors was dramatically retarded and 
the tumor did not progress (Fig. 3-11, G, H).  
To test the effect of fasting alone in a model of human cancer, we applied 
cycles of fasting in immune-compromised nude mice that were subcutaneously 
injected with human ACN neuroblastoma cells. After 34 days and 5 fasting cycles, 
the tumor size was less than half of that in normally fed mice (Fig. 3-12, A). In 
agreement with the other tumor mouse models, animals were able to return to the 
normal weight after each cycle (Fig. 3-12, B). These results suggest that cycles of 
fasting can delay the growth of some cancer cell types, in some cases as effectively 
as chemotherapy drugs, but that the combination of fasting and chemotherapy 
cycles provides a more effective, consistent and potent toxic effect on a wide range 
of tumors. 
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Figure 3-11. The sensitivity of allografted and xenografted tumors to STS and 
chemotherapeutic agents in mice. 
(A, C, E, G, H) Tumor progression as percent of initial size; (B, D, F) body weight. 
(A, B: 4T1; N=12), (C, D: B16; N=11) melanoma, and (E, F: GL26; N=8) glioma. 
Fasting in the glioma model was applied only once due to the rapid tumor growth in 
the control (ad lib, no chemotherapy) group. (G) Human breast cancer cells (MDA-
MB-231) were subcutaneously xenografted into nude mice. 4 cycles of fasting (48 
hours) and/or DXR were performed. Tumor measurements from mice that were fed 
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ad lib and treated with DXR were terminated at day 11 due to death of all mice from 
DXR toxicity (N=5). (H) Human ovarian cancer cells (OVCAR3) were subcutaneously 
xenografted into nude mice. 2 cycles of fasting (48 hours) and/or DXR were 
performed. Tumor measurements from mice that were fed ad lib and treated with 
DXR were terminated at day 9 due to death of all mice from DXR toxicity (N=5). In 
both xenograft models, fasted mice treated with DXR did not experience death from 
chemotherapy toxicity. All data presented as mean ± SEM; * p <0.05; ** p <0.01; *** 
p <0.001, Student’s t-test, two-tailed. Collaborative data, modified from (Lee, 
Raffaghello et al. 2012). 
 
 
 
 
Figure 3-12. Effect of STS on tumor progression of a human neuroblastoma 
xenograft. 
(A) Effect of fasting alone (48 hours for 5 cycles) in nude mice on tumor progression 
of a xenografted human neuroblastoma cell line (ACN; N=7) and on (B) body weight. 
All data presented as mean ± SEM; * p <0.05; ** p <0.01; *** p <0.001, Student’s t-
test, two-tailed. Collaborative data, modified from (Lee, Raffaghello et al. 2012). 
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3.3 Short-Term Starvation improves the Efficacy of Chemotherapy in an 
Intracranial GL26 Tumor Model 
In the United States, malignant glioma account for approximately 70% of the 
22,500 new cases of malignant primary brain tumors that are diagnosed in adults 
each year, with a 5 year survival rate that is less than 3% (Stupp, Mason et al. 2005; 
Wen and Kesari 2008). Due to the high mortality rates and low median survival in 
brain tumor patients, we were interested in determining if the effect of fasting on an 
intracranial GBM tumor model would be as effective as that seen in the s.c. model 
(see p. 103, Fig. 3-9, A). GL26 cells, engineered to express the firefly luciferase 
gene (GL26luc), were stereotactically implanted into C57BL/6 mice in the right frontal 
lobe. This allows us to monitor tumor progression by live bioluminescence imaging. 
Within six days of tumor implantation, the luciferase expression by tumor cells could 
be measured in all mice by bioluminescence imaging (BLI). Based on the 
bioluminescence intensity, mice were randomized into four experimental groups to 
achieve an even distribution (Fig. 3-13, Day 6).  
 
 
Figure 3-13. Bioluminescence expression in the intracranial GL26 tumor 
model. 
Bioluminescence expression at day 6 vs. day 12 after the tumor inoculation. Animals 
at day 6 were randomized into the four experimental groups (Control, N= 6; TMZ, N= 
5; STS, N= 11; or STS+TMZ, N= 12) and treatment was initiated. Tumor progression 
was monitored at day 12 to determine treatment benefits. Bioluminescence signaling 
measured as photons/sec. All data presented as mean ± SEM; * p<0.05, ANOVA, 
Tukey’s multiple comparison, compared to control at day 12. Collaborative data, 
modified from (Safdie, Brandhorst et al. 2012). 
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Temozolomide treatment in human patients is performed as 5 consecutive daily 
injections per treatment cycle (Villano, Seery et al. 2009). To accommodate the 48 
hour STS regimen, TMZ was delivered by two injections of 15 mg/kg into the lateral 
tail-vein after 24 hours and 48 hours of starvation. On day 12 after the tumor 
implantation, the tumor progression in all experimental groups was assessed by BLI 
(Fig. 3-14). Bioluminescence in the control group increased within six days from 
4500 to 850.000 photons/sec; an almost 200-fold increase (Fig. 3-13, Day 12). The 
STS and TMZ groups displayed a similar trend of increase in bioluminescence at day 
12 after the tumor implantation. However, one cycle of the combination of starvation 
and TMZ treatment reduced the bioluminescence signal of the implanted GL26luc 
cells significantly (p< 0.05, compared to control at day 12) (Fig. 3-14).  
 
 
 
 
Figure 3-14. Bioluminescence expression in the intracranial GL26luc tumor 
model at day 12.  
Bioluminescence imaging of GL26luc glioma bearing C57BL/6 mice at day 12 after 
intracranial tumor implantation. Animals are shown according to experimental group. 
Collaborative data, modified from (Safdie, Brandhorst et al. 2012). 
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The clinical condition and general health aspect of the mice declined rapidly, 
likely because of the increase in intracranial pressure caused by tumor proliferation. 
Amongst the most common manifestations of declining health was continuous weight 
loss in all groups, notable 6 to 8 days after the tumor implantation (Fig. 3-15). 
Despite the weight loss during the starvation cycle, mice in the STS group regained 
the bodyweight to that of control animals within one to two days after resuming 
feeding. Furthermore, we also observed improved activity, exploring of the cage and 
better grooming in STS+TMZ treated mice when compared to animals from all other 
groups. These results are consistent with our previous observation that animals 
treated with chemotherapy after fasting display a better health status compared to 
their ad lib fed counterparts in chemotherapy-treated groups (Raffaghello, Lee et al. 
2008). 
 
 
Figure 3-15. Body weight profile for mice inoculated with intracranial GL26luc 
glioma.  
Body weight profile for glioma-bearing animals receiving one cycle of either short-
term starvation (STS), TMZ treatment or both. STS and STS+TMZ animals initially 
reduce body weight during STS cycles (grey area) but regain the weight of untreated 
control and TMZ-treated animals within 1 to 2 days after re-feeding. TMZ and 
STS+TMZ animals received i.v. injections of 15 mg/kg Temozolomide on day 7 and 
day 8 (red lines), totaling 30 mg/kg for the treatment cycle. Tumor progression 
causes rapid weight loss following treatment in all experimental groups while saline 
injected sham animals (no tumor) recovered within one to three days from the 
inoculation procedure. Collaborative data, modified from (Safdie, Brandhorst et al. 
2012). 
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Mice that were starved prior to the administration of TMZ had a significant 
survival advantage (p< 0.05) over the TMZ, STS and control groups in the 
intracranial GL26 tumor model (Fig. 3-16). Animals in the control, STS and TMZ 
groups showed an onset of morbidity 13 days after tumor implantation. The onset of 
morbidity caused by tumor burden was delayed by one day in the STS+TMZ group 
and survival was slightly prolonged in this group; consistent with the reduced 
bioluminescence signal at day 12. Remarkably, when considering the fast 
progression of this tumor model, one mouse from the STS+TMZ group was alive for 
more than 80 days after tumor implantation. These results suggest that fasting in 
combination with TMZ treatment can decelerate tumor progression in the mouse 
model and may potentially lead to long-term survival in a small sub-population. 
 
Figure 3-16. Morbidity rate comparison of animals intracranially inoculated 
with GL26luc glioma cells.  
STS and STS+TMZ animals were fasted for 48 hours starting at day 6 (grey area). 
TMZ and STS+TMZ animals received i.v. injections of 15 mg/kg Temozolomide at 
day 7 and day 8 (red lines), totaling 30 mg/kg/cycle. Curve comparison with Log-
Rank test (Mantel-Cox; * p<0.05). Collaborative data, modified from (Safdie, 
Brandhorst et al. 2012). 
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To mimic oncologic treatment conditions in human patients, we attempted to 
extend survival by applying multiple cycles of chemotherapy treatment. As early as 4 
days after implantation of the tumor, mice received two injections of TMZ (total 30 
mg/kg, TMZ group) or were fasted for 48 hours (STS group). Mice in the STS+TMZ 
group received the combination of both treatments (Fig. 3-17, A). Before starting a 
second treatment cycle, we allowed animals from both STS treated groups to regain 
body weight to the values of non-starved groups (Fig. 3-17, B). By this time most 
animals had lost around 15% of bodyweight and appeared weak, making a shorter 
starvation period (24 hours) and a single dose of 15 mg/kg of TMZ at day 10 the only 
additional intervention possible. Two cycles of treatment (STS or TMZ) delayed the 
mortality of the tumor-bearing animals in comparison to the control group (Fig. 3-17, 
A), which showed a survival rate akin to that observed in our previous intracranial 
experiment (Fig. 3-16). Animals that received multiple doses of TMZ showed 
delayed onset of mortality compared to those in the control and STS groups (day 14 
vs. day 12 and day 8, respectively). Furthermore, the onset of morbidity was delayed 
in comparison to the animals that received a single dose of TMZ in the previous 
experiment (Fig. 3-16, day 13). The additional 2nd cycle of STS and TMZ further 
delayed morbidity in the experimental group receiving the combined treatments. Of 
note is however, that one mouse died relatively early (day 8) in the STS group which 
might be due to weight loss and tumor progression, resulting in a scenario that 
overwhelms the ability of the mouse to cope with these conditions. Nonetheless, the 
majority of the STS treated mice showed improvement over the untreated control 
group (Fig. 3-17, A). 
 
Despite our ability to delay the onset of mortality in tumor-bearing mice by 
intervening with treatments such as chemotherapeutic drugs and short-term 
starvation or the combination of both STS and TMZ, the extremely rapid progression 
of the intracranial GL26luc glioma model did not allow long-term survival. In a clinical 
scenario, where the tumor burden is reduced by resection, or where the glioma is 
less aggressive, STS in combination with adjunctive therapy may offer potentially 
greater benefits. 
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Figure 3-17. Two fasting cycles augment effects of TMZ-chemotherapy in the 
intracranial GL26 glioma model.  
(A) Morbidity rate comparison of animals inoculated intracranially with GL26luc 
glioma cells. Animals at day 4 were randomized into the four experimental groups 
(Control, N= 7; TMZ, N= 7; STS, N= 10; or STS+TMZ, N= 8). Treatment of all 
experimental groups was initiated earlier to allow increased response to short-term 
starvation and/or TMZ. STS and STS+TMZ animals were fasted for 48 hours starting 
at day 4 followed by a second 24 hour fasting regiment at day 10 (grey areas). TMZ 
and STS+TMZ animals received i.p. injections of 15 mg/kg Temozolomide at day 5 
and day 6 to match the first STS cycle and at day 11 to match the shorter second 
cycle (red lines), totaling 45 mg/kg. Curve comparison with Log-Rank test (Mantel-
Cox; *** p< 0.001). (B) Body weight profile for glioma-bearing animals receiving 
multiple rounds of either short-term starvation, TMZ-treatment or both. STS and 
STS+TMZ animals initially reduce body weight during STS cycles (grey area) but 
regain the weight of untreated control and TMZ-treated animals rapidly after 
refeeding. Collaborative data, modified from (Safdie, Brandhorst et al. 2012). 
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3.4 Fasting Enhances Cancer-free Survival of Mice with Metastatic Cancer 
receiving Chemotherapy 
Advanced metastatic tumors are extremely difficult to cure once tumor 
masses have spread to different organs. We therefore studied whether the 
combination of multiple fasting cycles and high-dose chemotherapy can increase 
survival in aggressive metastatic models before large tumor masses can be formed. 
To perform this experiment, we intravenously injected immune-competent mice with 
murine breast cancer cells (4T1), melanoma cells (B16), or two neuroblastoma cell 
lines (NXS2 and Neuro-2a). Fasting potentiated the effects of chemotherapy and 
extended the survival of mice injected with each type of cancer cell (Fig. 3-18 and 
Fig. 3-19).  
In the model of metastatic melanoma, one cycle of DXR treatment alone was 
not sufficient to extend survival, and only mice that were both fasted and treated with 
DXR showed extended maximum survival time (Fig. 3-18, A). DXR and fasting 
alone, but to a greater extent fasting combined with DXR, reduced the metastases of 
B16 melanoma cells to some organs when compared to mice fed the standard diet 
(Fig. 3-18, B). Lung metastases were detected in all mice, as expected from i.v. 
injections, and served as a control for tumor seeding. Melanoma spleen metastases 
were found in ~40% of mice treated with DXR, but only in 20% of mice that were 
fasted for a single cycle and 10% of mice that were fasted and also received DXR. In 
addition, unlike normally fed mice, metastases were not detected in the ovaries of 
fasted mice whether they received chemotherapy or not (Fig. 3-18, B). Overall, mice 
fasted and treated with DXR had a 40% reduction in metastases compared to 
controls (Fig. 3-18, C). In agreement with the results for melanoma cells, a single 
fasting cycle potentiated the effects of chemotherapy and extended survival in mice 
bearing metastatic breast tumor cells (4T1) (Fig. 3-18, D).  
To more closely mimic cancer treatment in humans and to determine whether 
the combination of fasting cycles and chemotherapy has the potential to cure 
subjects with aggressive metastatic malignancies, we tested the effect of multiple 
cycles of fasting cycles in combination with chemotherapy drugs on a schedule that 
more closely reflects the therapy regimen administered to children with 
neuroblastoma. We monitored the survival of two mouse models of metastatic 
neuroblastoma. Long-term survival (more than 180 days) was achieved in 42% of  
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Figure 3-18. Effect of fasting and chemotherapy treatment on survival and 
tumor load in metastatic melanoma and breast cancer mouse models.  
(A) Effect of 48 hours of fasting on survival of DXR-treated mice with metastatic 
murine melanoma (B16; N=9-10; P<0.05) (B) and metastasis in various organs. (C) 
The total number of organs with metastasis. All data presented as mean ± SEM; * p 
<0.05, Student’s t-test, two-tailed. (D) Effect of 48 hours of fasting on survival of CP-
treated mice with metastatic breast cancer (4T1). Collaborative data, modified from 
(Lee, Raffaghello et al. 2012). 
 
 
murine neuroblastoma (NXS2)–bearing mice, which underwent two cycles of fasting 
with high-dose DXR (16 mg/kg) treatment (Fasted/DXR) (Fig. 3-19, A), compared to 
the 100% mortality in the group receiving chemotherapy under a normal diet (DXR). 
To test the effect of fasting on another model of metastatic neuroblastoma, we 
combined fasting with a cocktail of two chemotherapy drugs administered only once 
[DXR (10 mg/kg) + cisplatin (8 mg/kg)]. We injected murine neuroblastoma cells 
(Neuro-2a) intravenously into mice and allowed the tumor cells to spread for 9 days 
before initiating chemotherapy (Fig. 3-19, B). Whereas all mice treated with the 
chemotherapy cocktail combined with an ad lib diet died by day 75, ~25% of the 
mice that were fasted, in addition to receiving the chemotherapy cocktail, achieved 
A B
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long-term survival (Fig. 3-19, B) while maintaining a normal weight (data not shown). 
At 300 days, these mice remained cancer-free. These results suggest that fasting 
cycles potentially sensitize a wide variety of tumor cell types to several of the most 
widely used chemotherapy drugs. This fasting-dependent potentiation of 
chemotherapeutic action significantly extended overall survival time and allowed 
long-term cancer-free survival, even in mice with a large number of dispersed cancer 
cells (Lee, Raffaghello et al. 2012). 
 
 
Figure 3-19. Effect of fasting and chemotherapy treatment on survival in 
metastatic neuroblastoma mouse models.  
(A) Effect of 48 hours of fasting on survival of mice with murine neuroblastoma NXS2 
that were treated twice with high dose DXR (16mg/kg). (B) Effect of 48 hours of 
fasting on survival of chemo-cocktail [DXR (10 mg/kg) + cisplatin (8 mg/kg)] treated 
mice with Neuro-2a neuroblastoma. Collaborative data, modified from (Lee, 
Raffaghello et al. 2012). 
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In summary, the data I presented so far, as well as previously established results 
(see introduction), all demonstrate that normal cells and cancer cells differ in their 
response to fasting. In the absence of nutrients, normal cells switch their metabolism 
towards maintenance pathways, whereas tumor cells are unable to activate this 
protective response. Our fasting approach is based on differences in metabolism 
between normal cells and cancer cells that can be used to enhance anticancer 
therapy by selectively increasing the resistance of normal cells to chemotherapy 
while simultaneously sensitizing malignant cells (Fig. 3-20). 
 
 
Figure 3-20. Modulating the effects of chemotherapy by means of fasting. 
Chemotherapy-induced oxidative stress reduces the rates of both the proliferation 
and the survival of cancer cells. It yields an objective response that can be quantified 
on the basis of shrinkage of the tumor volume (Panel A). However, chemotherapy 
also affects normal cells, leading to toxic side effects. Short-term fasting before or 
after chemotherapy, or at both times, induces differential stress resistance in normal 
and cancer cells. In normal cells, fasting activates protective metabolic pathways that 
confer resistance to oxidative stress (Panel B). In contrast, yeast cells transformed 
with an activated oncogene are unable to turn on the protective response and thus 
remain sensitive to oxidative stress. Additional experiments using mouse models of 
murine and human cancer showed that fasting specifically augments levels of 
oxidative stress and sensitivity to oxidative damage (e.g., that inflicted by 
chemotherapeutic agents) in cancer cells and that these effects are accompanied by 
DNA damage and apoptosis. Modified from (Laviano and Rossi Fanelli 2012) 
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3.5 Fasting Differentially Regulates Translation and Proliferation Genes  
To identify the gene expression changes that could differentially regulate 
chemotherapy resistance in normal and cancer cells in response to fasting, we 
collaborated with Rafael de Cabo and Alejandro Martin-Montalvo at the National 
Institute on Aging (NIA). Genome-wide microarray analyses were performed on liver, 
heart, skeletal muscle, and subcutaneous 4T1 breast tumor masses removed from 
mice that were either fasted for 48 hours or fed an ad lib diet. Fasting differentially 
regulated many genes involved in cellular proliferation such as the insulin signaling 
adaptor (Irs2) and the mitogenic hormone prolactin receptor (Prlr) in normal and 
cancer cells (Fig. 3-21, A). In many cases, proliferation-associated genes were 
down-regulated in normal tissues but up-regulated, or unaffected, in cancer cells. 
Surprisingly, the expression of translation and ribosome biogenesis/assembly genes 
such as elongation factor 1γ (Eef1g) and components of the 60S and 40S ribosomal 
proteins were significantly increased in response to fasting in breast cancer allografts 
(4T1), whereas in normal tissues they were either repressed or minimally affected 
(Fig. 3-21, B). A gene list of protein translation related clusters from the gene 
ontology analysis can be found in the supplementary material of our publication in 
Science Translational Medicine (Lee, Raffaghello et al. 2012). 
 In agreement with these results, 4T1 cells cultured under STS conditions for 
48 hours displayed a major increase in cellular protein concentration (Fig. 3-21, C) 
and in translation as estimated by incorporation of the methionine analog 
azidohomoalanine (AHA) (Fig. 3-21, D). In addition, the phosphorylation of the Akt 
and S6K proteins, which regulate translation and proliferation when phosphorylated, 
was elevated, and that of eIF2α, which impairs protein synthesis when 
phosphorylated, was reduced in tumors from fasted mice (Fig. 3-22, A). Similar 
results were observed in 4T1 cells undergoing STS in vitro, particularly in 
combination with CP treatment (Fig. 3-22, B). Despite this starvation-dependent 
activation of translation mechanisms, cancer cell numbers were greatly reduced in 
vitro (Fig. 3-4), a finding consistent with the retardation of tumor progression by 
fasting in vivo. In agreement with our previous studies (Raffaghello, Lee et al. 2008; 
Safdie, Dorff et al. 2009; Lee, Safdie et al. 2010; Safdie, Brandhorst et al. 2012) 
these results indicate that fasting promotes a differential regulation of pro-growth and 
pro-translation genes in normal and cancer cells. 
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Figure 3-21. Effect of fasting on genes involved in growth and proliferation.  
Microarray analysis on the liver, heart, skeletal muscle, and subcutaneous breast 
tumors (4T1) from normally fed or fasted (48 hours) mice of (A) cellular proliferation 
pathways and (B) translational machinery including ribosome assembly/biogenesis. 
(C) Effect of starvation on protein concentration in 4T1, B16, and GL26 cells (N=3). 
(D) Effect of starvation on the rate of AHA (methionine analog) incorporation in 4T1 
cells (N=3). All data presented as mean ± SEM; * p <0.05; *** p <0.001, Student’s t-
test, two-tailed. Collaborative data, modified from (Lee, Raffaghello et al. 2012). 
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Figure 3-22. Effect of fasting on pro-proliferative pathways in murine breast 
cancer cells.  
(A) Effect of fasting on Akt, S6K, and eIF2α phosphorylation in 4T1 murine breast 
cancer cells in vivo. (B) Effect of fasting, with our without cyclophosphamide (CP) 
treatment on Akt, S6K, and eIF2α phosphorylation in 4T1 murine breast cancer cells 
in vitro. Collaborative data, modified from (Lee, Raffaghello et al. 2012). 
 
3.6 Synergistic Effect of STS and Chemotherapy on DNA Damage  
To determine the mechanisms by which short-term starvation cycles reduce 
tumor progression, we tested the hypothesis that lower concentrations of 
extracellular glucose and growth factors may increase DNA damage in cancer cells. 
In both cultured 4T1 breast cancer cells (Fig. 3-23, A) and B16 melanoma cells (Fig. 
3-23, B), the reduction of glucose concentrations from those in ad lib fed mice (2.0 
g/L) to a concentration similar to that reached after fasting (0.5 g/L), in combination 
with low serum (1% FBS to mimic the fasting-dependent reduction in blood growth 
factors and proteins), increased DNA damage more than chemotherapy alone. 
Indeed, the combination of low glucose concentrations and treatment with a 
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Figure 3-23. Effect of fasting on chemotherapy-induced DNA damage.  
(A) Effect of starvation alone and when combined with CP in breast cancer (4T1) 
and (B) with DXR in melanoma (B16), and (C) with DXR in glioma (GL26) cells as 
determined by comet assay (N=6). The green signal represents intact and fractured 
DNA. Cells in both groups were cultured in normal glucose (2.0 g/L) or low glucose 
(0.5 g/L), respectively, supplemented with 1% FBS. Drugs were selected to match 
those in Fig. 3-11, A, C and E. Data from at least 3 independent experiments. All 
data presented as mean ± SEM; * p <0.05; ** p <0.01; *** p <0.001, Student’s t-test, 
two-tailed. Collaborative data, modified from (Lee, Raffaghello et al. 2012). 
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chemotherapeutic agent promoted a seemingly synergistic, 20-fold increase in DNA 
damage in both breast cancer and melanoma cells. In GL26 glioma cells, the effect 
of reduced glucose concentrations on DNA damage was additive with the drug 
doxorubicin (Fig. 3-23, C). These results indicate that starvation conditions and 
chemotherapy drugs can act in an additive or synergistic manner to promote DNA 
breaks in cancer cells. These effects may contribute to the chemotherapy-
potentiating effects that we observed in vivo. 
3.7 Fasting-induced Sensitization of 4T1 Cells is Associated with Oxidative 
Stress and Caspase-3 Activation 
Various chemotherapy drugs, including CP, damage DNA and trigger cell 
death in part by promoting oxidative damage (Berndtsson, Hagg et al. 2007). We 
therefore measured the level of reactive oxygen species, as indicated by 
dihydroethidium (DHE) oxidation, in 4T1 cells under standard and starvation 
conditions after treatment with CP. We detected more DHE oxidation in the cells 
after starvation, suggesting that starvation conditions promoted oxidative stress and 
possibly increased superoxide levels (Fig. 3-24, A and B). CP alone increased DHE 
oxidation (2-fold), and treatment of the cells with both starvation and CP resulted in 
even higher DHE oxidation levels (3.2-fold) (Fig. 3-24, B) compared to control. This 
increase in ROS may have contributed to the synergistic DNA damage caused by 
fasting and chemotherapy (Fig. 3-23).  
Because oxidative stress is a central promoter of apoptosis, we measured the 
effect of fasting on the activation of the pro-apoptotic enzyme caspase-3 both in vivo 
and in vitro. Cleaved caspase-3 was increased in allografted tumors, but not in 
normal organs, in response to fasting in mice (Fig. 3-25, A) and also in cancer cells 
undergoing starvation in vitro; an effect that was potentiated by treatment with CP 
(Fig. 3-25, B). Because caspase-3 was activated during fasting only in the 
transplanted tumors (Fig. 3-25, A and B), and because starvation conditions 
increased DNA damage, particularly in the presence of CP (Fig. 3-23), we conclude 
that the retarded tumor growth by fasting and the cell death caused by the 
combination of starvation and chemotherapy drugs may be at least partially 
attributed to increased apoptosis.  
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Figure 3-24. Effect of starvation on intracellular oxidative stress as estimated 
by a superoxide marker (DHE) in vitro. 
(A) Murine breast cancer cells (4T1) were fasted and treated with cyclophosphamide 
(CP) in vitro. Superoxide levels were estimated by dihydroethidium (DHE) staining. 
100X magnification. (B) Corrected total cell fluorescence was quantified using 
ImageJ (NIH) and corrected for background fluorescence. All data presented as 
mean ± SEM; * p <0.05; *** p <0.001, Student’s t-test, two-tailed. Collaborative data, 
modified from (Lee, Raffaghello et al. 2012). 
 
Figure 3-25. STS mediated activation of apoptosis in murine breast cancer 
cells.  
(A) Effect of fasting on caspase-3 cleavage in the liver, heart and allografted 4T1 
breast tumors in vivo and (B) in 4T1 breast cancer cells cultured under starvation 
conditions (restricted glucose (0.5 g/L) and growth factor (1% FBS) concentrations) 
in vitro. Cyclophosphamide (CP) treatment increases cleaved caspase-3 levels. 
Collaborative data, modified from (Lee, Raffaghello et al. 2012). 
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3.8 Reduced HO-1 Expression Mediates Part of the Cancer-sensitizing Effect 
of Fasting  
To understand the mechanisms of fasting-induced sensitization, we searched 
among the stress-responsive genes whose expression is regulated by fasting and 
CR. Based on our microarray (Fig. 3-26), we selected heme oxygenase-1 (HO-1), 
also known as heat-shock protein 32 (HSP32), as a promising candidate (Bakken, 
Thaler et al. 1972; Pearson, Lewis et al. 2008; Verweij, van Ginhoven et al. 2011). 
HO-1 protects against oxidative damage and apoptosis (Chen, Liu et al. 2004) and 
inhibits the cleavage of caspase-3 (see Fig. 3-25) (Inguaggiato, Gonzalez-Michaca 
et al. 2001; Liu, Chen et al. 2004). In addition, reduced HO-1 levels increase 
translation through the regulation of the heme-regulated eIF2α kinase, in agreement 
with our results on AKT, S6K and eIF2α phosphorylation (Fig. 3-22) (Chen 2007; Liu, 
Suragani et al. 2008). In our microarray, there was a trend for differential HO-1 
repression in the transplanted 4T1 tumors and we verified this observation by qRT-
PCR. Fasting caused a major increase in HO-1 expression in normal organs, but 
significantly repressed its expression in the transplanted tumors (Fig. 3-27, A). 
 
 
 
Figure 3-26. Heme oxygenase-1 (HO-1) and NFkB/RelA expression heatmap in 
normal organs and transplanted 4T1 tumor. 
Microarray analysis on the liver, heart, skeletal muscle, and subcutaneous breast 
tumors (4T1) from normally fed or fasted (48 hours) mice demonstrates a trend for 
the differential expression of HO-1, NFkB and RelA between normal tissue and 
transplanted 4T1 tumor. Data in collaboration with the NIA, not published. 
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In our microarray, transplanted 4T1 tumors showed a trend of differential 
down-regulation of NFkB (p50) and its partner RelA (p65) (Fig. 3-26). Because NFkB 
reduces oxidative stress via HO-1 and/or MnSOD (Mercurio and Manning 1999; Luo, 
Kamata et al. 2005; Alam and Cook 2007) and since functional binding sites for 
NFkB are present in the promoter of HO-1 (Paine, Eiz-Vesper et al. 2010), we tested 
whether NFkB expression was also reduced in 4T1 cells in response to fasting. qRT-
PCR confirmed that fasting reduces the expression of NFkB (p50) in 4T1 tumors 
(Fig. 3-27, B), suggesting that the HO-1 response to fasting may, at least, be 
partially regulated by NFkB.  
The increase in HO-1 expression in normal organs by fasting is consistent 
with the fact that fasting protects mice against DXR induced toxicity (Lee, Safdie et 
al. 2010), which can also be achieved by increasing HO-1 in vivo and in vitro 
(Suliman, Carraway et al. 2007). In contrast, inhibiting HO-1 expression has been 
well documented to inhibit tumor progression and increase cancer cell death, as well 
as sensitize them to toxins; thus positioning HO-1 as a promising target for cancer 
treatment (Sahoo, Sawa et al. 2002; Fang, Sawa et al. 2004; Marinissen, Tanos et 
al. 2006; Nowis, Legat et al. 2006; Hirai, Sasahira et al. 2007; Kim, Kim et al. 2008; 
Mayerhofer, Gleixner et al. 2008; Liu, Liang et al. 2011). 
 
Figure 3-27. Fasting differentially regulates the expression of heme 
oxygenase-1 (HO-1) and NFkB.  
Expression of (A) HO-1 and (B) NFkB was significantly induced in the heart, liver, 
and skeletal muscle of mice fasted for 48 hours but significantly repressed in the 
grafted breast tumor cells. All data presented as mean ± SEM; * p <0.05; Student’s t-
test, two-tailed. Collaborative data, not published. 
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To test the role of heme oxygenase-1 in the fasting-dependent sensitization to 
chemotherapy in vitro, we induced HO-1 expression in 4T1 cells using hemin and 
found that we could partially reverse the sensitization to CP under fasting conditions 
(Fig. 3-28, A). Conversely, the HO-1 inhibitor zinc protoporphyrin (ZnPP) sensitized 
4T1 cells to CP under normal, ad lib mimicking conditions (Fig. 3-28, B) but did not 
cause additional sensitization under fasting mimicking conditions. To confirm these 
findings, we over-expressed HO-1 in 4T1 cells by stably transfecting a rHO-1 
construct (Fig. 3-28, C). Similar to the induction of HO-1 by hemin, the over-
expression of HO-1 causes the partial reversion of the fasting induced sensitization 
in murine breast cancer cells. Cells that were transfected with the empty pcDNA 
vector do not show these effects and remained sensitized when treated with CP in 
fasting mimicking media (Fig. 3-28, D).  
 
 
Figure 3-28. Heme oxygenase-1 (HO-1) mediated sensitization of murine breast 
cancer cells.  
Murine breast cancer cells (4T1) were treated with either (A) hemin, a commonly 
used inducer of HO-1 (10 µM), or (B) ZnPP (20 µM), a commonly used HO-1 
inhibitor, in normal (2.0 g/L glucose, 10% FBS) or fasting mimicking (0.5 g/L glucose, 
1% FBS) cell culture conditions for 24 hours, followed by an additional 24 hours with 
cyclophosphamide (CP). (C) Stably transfected 4T1 cells expressing HO-1 were 
cultured in normal or STS conditions for 24 hours, followed by an additional 24 hours 
with CP. (D) Stably transfected 4T1 cells expressing the empty pcDNA vector were 
cultured in normal or STS conditions for 24 hours and an additional 24 hours with 
CP. All data presented as mean ± SEM; * p <0.05; *** p <0.001, Student’s t-test, two-
tailed. Collaborative data, not published. 
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Changes in metabolic pathways of malignant cells cause a high dependence 
on glucose as the main carbon source to maintain high cellular proliferation rates; 
fasting however deprives malignant cells of this energy/carbon source. We evaluated 
mitochondrial function of tumor cells grown in either ad lib- or fasting-mimicking 
media conditions because in order to maintain proliferation, malignant cells need 
cellular energy such as ATP. ATP deficiencies force cells to undergo cell cycle arrest 
or even apoptosis (Izyumov, Avetisyan et al. 2004; Lum, Bauer et al. 2005). In order 
to test whether the depletion of nutrients causes functional changes, we measured 
basal and stimulated mitochondrial functions utilizing the Seahorse Bioscience XF24 
analyzer. The Seahorse Bioscience XF24 instrument measures the rate of change of 
analytes, in particular the amount of dissolved oxygen and pH, in the media 
immediately surrounding living cells cultured in a 24-well microplate in real-time. 
Changes in the extracellular media are caused by the consumption or production of 
analytes by the cells. Therefore, a sensitive measurement of the media flux can be 
used to determine rates of cellular metabolism with great precision and in a non-
invasive, label-free manner.  
Our data reveals that cells grown under ad lib conditions show a significantly 
higher basal oxygen consumption rate (OCR) than cells grown under glucose- and 
serum-restricted conditions, suggesting reduced mitochondrial respiration under 
fasting-like conditions (Fig. 3-29, A). Next, we characterized mitochondrial function 
by sequential addition of pharmacological inhibitors of the mitochondrial respiratory 
chain (Fig. 3-29, B). To estimate the proportion of the basal OCR linked to ATP 
synthesis through ATP-synthase, we injected the complex V inhibitor oligomycin. 
Oligomycin decreases the OCR to the extent to which cells use mitochondria for ATP 
production (Fig. 3-29, C, ATP), while the remaining OCR is attributed to processes 
other than cytochrome c oxidase (Fig. 3-29, C, Non-mito) or proton leak (Fig. 3-29, 
C, Proton) (Brand 1990; Brown, Lakin-Thomas et al. 1990; Brown 1992). To 
measure the maximal OCR potential that 4T1 tumor cells can undergo in ad lib or 
fasting-mimicking media conditions, the uncoupler FCCP was added (Fig. 3-29, C, 
Max). FCCP, a proton ionophore, renders the inner mitochondrial membrane 
permeable for protons which cause the electron transfer chain to be uncoupled from 
the proton gradient (Dranka, Hill et al. 2010). Taken together, the data shown in Fig. 
3-29 indicates that 4T1 tumor cells, grown under fasting-mimicking media conditions 
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have a sub-maximal capacity when compared to cells that were maintained in a 
glucose- and serum-rich environment. Reduced mitochondrial integrity has been 
linked to the intracellular production of reactive oxygen species (Lee and Wei 2007). 
Future work will have to establish if the reduction in maximal respiratory capacity 
provides a link to the increased ROS levels we measured in fasted cells.  
To determine whether HO-1 plays a role in maintaining mitochondrial 
respiration under fasting conditions, we exposed 4T1 cells over-expressing heme 
oxygenase-1 to the same assay conditions. Over-expressing HO-1 had no rescue 
effects under fasting conditions on baseline oxygen consumption rate (Fig. 3-29, A) 
and the oxygen consumption attributed with mitochondrial ATP production, proton 
leak and the maximal respiratory capacity (Fig. 3-29, C). 
Fasting causes an increase in ketone bodies that are produced from acetyl-
CoA in the mitochondrial matrix by breaking down fatty acids. The ability to oxidize 
fatty acids supplies normal cells with energy when other nutrients are scarce or 
absent. We therefore tested if injections of palmitate, the most common fatty acid in 
mammals, provide efficient means for malignant cells to produce energy. Murine 
breast cancer cells grown in media conditions mimicking glucose and growth factor 
levels of ad lib fed mice were able to utilize palmitate for fatty acid oxidation, as 
indicated by an increased OCR after palmitate injection (Fig. 3-30). Surprisingly, in 
culture-media conditions mimicking glucose and serum levels of fasted mice, 4T1 
cells did not respond to the palmitate injection. We detected no increase in oxygen 
consumption, suggesting that these cells were unable to utilize fatty acids for 
mitochondrial energy production when glucose is scarce. In stark contrast to normal 
cells, which can utilize fatty acids, this proves to be a striking disadvantage for fasted 
malignant cells. As mentioned above, a sufficient supply of nutrients is essential for 
cellular growth. Fasting and the acute deprivation of glucose, as well as the inability 
to utilize fatty acids, might provide effective means to intervene with the rapid 
proliferation of malignant cells. The over-expression of HO-1 reversed this deficiency 
of murine breast cancer cells, indicating that cellular redox homeostasis and fatty 
acid utilization in cancer cells are interconnected and plays a crucial role in the 
fasting-mediated sensitization. 
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Figure 3-29. Mitochondrial function is altered by cellular starvation in murine 
breast cancer cells. 
(A) Baseline oxygen consumption rates (OCR) of normal (4T1) and heme 
oxygenase-1 over-expressing (4T1-HO1, striped bar) murine breast cancer cells 
grown for 48 hours in either ad lib (grey bar) or STS (red bar) mimicking media. (B) 
Mitochondrial respiration assay for 4T1 cells grown for 48 hours in either ad lib (grey 
bar)- or fasting (red bar)- mimicking media conditions as assayed by mitochondrial 
oxygen consumption rate. O= Oligomycin, a complex V inhibitor; F= FCCP, a proton-
uncoupler; R= Rotenone, a complex I inhibitor. Normalized to basal levels. (C) The 
contribution of the mitochondria, non-respiratory chain, ATP production, proton 
leakage and maximal capacity to the total oxygen consumption. Normalized to basal 
levels. All data presented as mean ± SEM; ** p<0.01, *** p<0.01, ANOVA, Tukey’s 
multiple comparison. Unpublished results. 
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Figure 3-30. Cellular starvation alters fatty acid oxidation in murine breast 
cancer cells.  
Fatty acid oxidation (FAO) of 4T1 cells grown for 48 hours in either ad lib (grey 
circle)- or fasting (red square)-mimicking media. Mitochondrial respiration was 
assayed through the mitochondrial oxygen consumption rate (OCR). **P< 0.01; 
***P< 0.001, Student’s t test. Unpublished results. 
 
 
Because we detected higher levels of DHE oxidation, indicative for higher 
amounts of reactive oxygen species in 4T1 cells under starvation conditions after 
treatment with CP in vitro (Fig. 3-24), we measured superoxide levels in the 
mitochondria of 4T1-HO1 cells using the MitoSox Red flourogenic dye. Imaging of 
stained 4T1 cells revealed that fasting mimicking cell culture conditions increased 
the fluorescence, which could be partially reversed by over-expressing HO-1 (Fig. 3-
31, A). We analyzed the relative fluorescence of 4T1 and HO-1 over-expressing cells 
in a 96-well plate after exposure to fasting mimicking media conditions and in 
combination with cyclophosphamide (Fig. 3-31, B). 4T1 cells treated with 16 mM CP 
had a measurable increase in their relative super oxide levels (Fig. 3-31, B; *, P< 
0.05) and fasting had a similar effect (**, P< 0.01). Fasting in combination with 
chemotherapy resulted in a roughly 30% increase in the measurable superoxide 
levels and thus confirms prior results (***, P< 0.001). 4T1 cells over-expressing HO-1 
showed a trend towards lower superoxide levels in ad lib  
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Figure 3-31. Relative superoxide levels are reduced in HO-1 over-expressing 
murine breast cancer cells.  
(A) Normal murine breast cancer cells (4T1) and HO-1 over expressing cells (4T1-
HO1) were grown in either ad lib or fasting mimicking cell culture conditions for 48 
hours and incubated with 2.5 µM MitoSOX reagent for 10 min at 37°C. Fluorescent 
microscopy at 20X (top row) and 100X (bottom row) magnification. (B) Relative 
superoxide levels were measured in either untreated or chemotherapy treated 4T1 
and 4T1-HO1 cells grown in ad lib (AL) or fasting-mimicking (STS) cell culture 
conditions for 48 hours. All data presented as mean ± SEM; * p<0.05, ** p<0.01, *** 
p<0.001, ANOVA, Tukey’s multiple comparison. See text for details. Collaborative 
data, not published. 
A
B
Relative Superoxide Levels
4T
1 
A
L
4T
1 
S
TS
4T
1-
H
O
1 
A
L
4T
1-
H
O
1 
ST
S
0.9
1.0
1.1
1.2
1.3
1.4 untreated
CP (16mM)
F
o
ld
 c
h
a
n
g
e
133 
 
 
Figure 3-32. Effect of HO-1 modulation on tumor size in fasted mice.  
(A) Mice bearing subcutaneous 4T1 breast tumors were treated intra-peritoneally 
with hemin, an inducer of HO-1 (30 mg/kg/day), during each 48 hour fast (N=6-8), or 
(B) ZnPP, an inhibitor of HO-1 (40 mg/kg/day) for 48 hours (D; N=6-8). The tumor 
size was measured as percent increase compared to the first tumor measurement at 
day 12 post tumor implantation. The panels on the right side demonstrate the final 
tumor volume for each treatment group at day 31 post tumor implantation. All data 
presented as mean ± SEM; * p<0.05; Student’s t-test, Fasted or Control vs. Fasted/ 
Hemin or ZnPP. Collaborative data, not published.  
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conditions with or without CP treatment but demonstrated significantly less relative 
superoxide levels when treated with CP in fasting mimicking media conditions (**, P< 
0.01). This data thus demonstrates that fasting and cyclophosphamide both, 
individually or in combination, increase mitochondrial superoxide production and that 
over-expressing HO-1 in ad lib mimicking conditions provides no additive beneficial 
effects but becomes increasingly important when cellular conditions are causing cell 
stress. The over-expression of HO-1 thus confers higher stress resistance when 
cells are exposed to fasting and or chemotherapeutic drugs and makes heme 
oxygenase-1 central to our hypothesis. 
To test whether the stimulation HO-1 expression could reverse the anti-
proliferative effects of fasting in vivo, we injected mice bearing subcutaneous 4T1 
tumors with hemin (30 mg/kg/day; i.p.) during the fasting regimen. Two cycles of 60h 
fasting caused a significant reduction in tumor size, which was reversed by the 
concurrent hemin treatment (Fig. 3-32, A). Notably, normally fed mice treated with 
the HO-1 inhibitor ZnPP (40 mg/kg/day; i.p.), displayed a tumor size that was 
comparable to the tumor volume observed in fasted mice (Fig. 3-32, B).  
However, these studies only tested the fasting depending reduction of tumor 
growth and did not consider chemotherapeutic agents. To test the role of HO-1 in the 
fasting-mediated sensitization of malignant cells to chemotherapeutic drugs, we next 
used the previously established HO-1 over-expressing 4T1 cell line, as well as cells 
expressing the empty pcDNA vector, to evaluate the tumor growth without the HO-1 
modulation by hemin or ZnPP (Fig. 3-33). As expected, fasting significantly reduced 
the growth of the tumor derived from cells expressing the empty control vector. 
However, fasting did not retard the growth of grafted 4T1 tumors that over-express 
HO-1, but instead reversed growth in these tumors to a level that was not 
significantly different from the untreated tumor. Short-term fasting for two cycles, 
when combined with CP treatment, significantly reduced the tumor progression 
compared to the untreated and fasting-alone treated groups and was the most 
effective treatment option in the normal 4T1 cells. Over-expressing HO-1 on the 
other hand partially protected 4T1 cells from this fasting depending sensitization 
(Fig. 3-33). The tumor size, at day 32 post tumor implantation, for the 4T1 cells 
expressing high levels of HO-1 treated with STS and CP was not significantly 
different from normal 4T1 cells treated with fasting alone.  
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Figure 3-33. Effect of heme oxygenase-1 (HO-1) over-expression on the 
fasting-dependent sensitization in 4T1 cells.  
Effect of fasting on tumor size in mice bearing subcutaneous 4T1 tumors over-
expressing HO-1 (pHO-1) and control (empty vector) 4T1 tumors for 48 hours and 
treated with CP (150 mg/kg; i.p.; N= 8-10). Tumor values on day 32 are shown in the 
right panel. All data presented as mean ± SEM. Student’s t-test, ** P<0.01, *** 
P<0.001, compared to the control group. Collaborative data, not published. 
 
Together, these studies indicate that reduced HO-1 expression is important 
for the fasting-dependent sensitization of 4T1 breast cancer cells. Of note is however 
that “rescuing” HO-1 level, either through the induction with hemin or by over-
expressing HO-1, does not fully reverse the fasting-mediated sensitization to 
chemotherapeutic agents (Fig. 3-33). Based on the fact that fasting causes a wide 
array of intracellular changes, including changes in genes associated with stress 
protection, as shown here with HO-1 and NFkB, as well as changes in the 
extracellular surroundings of the tumor (e.g. a lower blood pressure, hormonal 
changes, reduced availability of glucose and other metabolites necessary to maintain 
cellular proliferation), it is unlikely that fasting mediates its effect solely through heme 
oxygenase-1. Therefore, future experiments will need to address additional changes 
that cause tumor cells to become sensitized to chemotherapeutic agents by short 
cycles of starvation.  
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3.9 Dietary Interventions: The Effects of Short-Term Calorie Restriction on 
Glucose and IGF-I Levels  
The studies I described above, including cell culture- and animal-models, 
indicate that fasting may actually reduce chemotherapy side effects by selectively 
protecting normal cells, while simultaneously sensitizing tumor cells to 
chemotherapeutic agents. However, we are aware of the fact that most oncologists 
will not actively recommend a fasting–based approach to their patients if alternative 
diet-based strategies are available. Dietary recommendations during cancer 
treatment are based on the prevention, or reversal, of nutrient deficiencies to 
preserve lean body mass and minimize nutrition-related side effects such as 
decreased appetite, nausea and taste- or bowel-changes (Doyle, Kushi et al. 2006). 
Consequently, for cancer patients who have been weakened by prior chemotherapy 
cycles or are emaciated, many oncologists could consider a fasting-based strategy 
to be potentially harmful. We thus aimed to establish if CR and/or diets defined in 
macronutrient composition (including dietary protein, carbohydrate and fat) can be 
used as an alternative to our short-term starvation based models of differential stress 
resistance (DSR) and differential stress sensitization (DSS). 
 
Short-term starvation increases cellular protection against high-dose 
chemotherapy (Raffaghello, Lee et al. 2008; Lee, Safdie et al. 2010), and sensitizes 
malignant cells to chemotherapeutic drugs (Lee, Raffaghello et al. 2012; Safdie, 
Brandhorst et al. 2012). All these effects were linked to reduced serum levels of 
glucose and IGF-I. STS has the most pronounced effects once animals lose 
approximately 20% bodyweight, which occurs usually relatively fast after 60 hours of 
a water-only fasting regimen. Once at the 20% weight loss point, serum IGF-I is 
reduced by approximately 75%, and glucose by 70%. These are usually the lowest 
levels we can measure while still maintaining the capacity in mice to recover from the 
fasting cycle. Thus, we used the 20% weight-loss as a criterion to compare glucose 
and IGF-I levels of calorie restricted diets to those obtained from a 60 hour STS 
regimen.  
We tested different calorie-restricted diets, ranging from a relatively mild 40% 
reduction to the very severe 90% reduction, in 12 to 15 week old female CD-1 mice. 
The 20% weight-loss threshold was reached at 4 days for 90% CR, 6 days for 80% 
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CR, 9 days for 60% CR, or 13 days for 40% CR (Fig. 3-34, A). As expected, the time 
to achieve 20% weight-loss is strongly dependent on the severity of the calorie 
restriction (linear fit with r2= 0.9976; Fig. 3-34, B). At 48 hours, the reduction in blood 
glucose levels showed a trend to correlate with the severity of the calorie restriction 
(linear fit with r2= 0.7931; data not shown). The 60 hour fasting regimen (STS) 
reduced blood glucose levels by 70% compared to that in ad lib fed mice (Fig. 3-34, 
C; P< 0.001). The 4 day 90% CR regime reduced blood glucose by approximately 
40%, significantly less than STS (P< 0.05). In addition, we observed a trend for the 
effect of CR in lowering blood glucose depending on the length of CR-feeding: the 
glucose levels in the 13-day 40% CR feeding was significantly (P< 0.05) lower than 
in the 4 day long 90% CR group. However, no calorie restricted group resulted in 
blood glucose levels that were lower than in the 60 hour fasting group; and 9 or more 
days of CR were required to obtain glucose lowering effects in the range of those in 
the fasted group (Fig. 3-34, C). Mice of all experimental CR groups, independent of 
the severity of the restriction, reached similar serum IGF-I levels once the 20% 
weight-loss margin was reached and had significantly (P< 0.001) lower IGF-I levels 
than mice in the ad lib control group (Fig. 3-34, D).  
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Figure 3-34. Calorie restriction reduces bodyweight, glucose and IGF-I.  
(A) Female CD-1 mice, age 12-15 weeks were either fed ad lib (grey square) with 
AIN93G rodent standard chow, exposed to 40%, 60%, 80% and 90% calorie 
restricted (CR) AIN93G diets (triangles) or fasted (STS, green rectangle) until mice 
lost 20% of their initial bodyweight (dotted line). N= 5 per experimental group. All 
data presented as mean ± SEM. (B) Linear fit for the severity of the CR regimen vs. 
the duration (days) until 80% bodyweight was reached. (C) Blood glucose levels for 
mice once 80% bodyweight was reached. Red line represents mean (D) Serum IGF-I 
levels for mice once 80% bodyweight was reached. Red line represents mean; *** 
p<0.001, ANOVA, Tukey’s multiple comparison. Modified from Brandhorst et al.; 
under review. 
Body Weight
0 2 4 6 8 10 12 14
70
80
90
100
110
Day
B
o
d
y
 W
e
ig
h
t 
(%
)
Glucose (at 80% BW)
AI
N9
3G
CR
40
% 
CR
60
%
CR
80
%
CR
90
%
ST
S
0
50
100
150
200
*
***
(m
g
/d
l)
IGF-1 (at 80%  BW)
AI
N9
3G
CR
40
%
CR
60
%
CR
80
%
CR
90
%
ST
S
0
100
200
300
400 ***
(n
g
/m
l)
A
C
B 80% BW to CR
0 2 4 6 8 10 12 14
0
20
40
60
80
100
0.9976
Day
%
C
R
D
AIN93G
CR40%
CR60%
CR80%
CR90%
STS
139 
 
3.10 The Effect of Macronutrient Defined Diets on Glucose and IGF-I levels 
We designed a set of macronutrient-defined diets (Fig. 3-35) based on the 
AIN93G rodent chow to determine whether the restriction of specific dietary 
constituents could mimic the effects of STS or short-term CR, on blood glucose 
and/or serum IGF-I. The low protein diets 20% P-1 (soybean oil as fat source) and 
20% P-2 (coconut oil as fat source) have calories from protein sources reduced to 
20% compared to the original AIN93G formulation while carbohydrates and fat are 
increased to maintain the diets isocaloric to AIN93G. The 0% P diet contains no 
protein; carbohydrates as well as fat are increased proportionally to keep the diet 
isocaloric to the standard chow. The LCHP diet has the calories from carbohydrate 
sources reduced to 20% compared to the original AIN93G formulation (13% vs. 
63.9%) but supplies more protein and fat. The high fat ketogenic diet 60% HF was 
designed to supply 60% of the consumed calories from fat sources, the calories 
coming from protein and carbohydrates were reduced proportionally. The 90% HF 
diet is a ketogenic diet that contains 90% of the calories from fat while supplying only 
minimal (less than 1%) carbohydrates and has 9% of the calories from protein. Due 
to the higher fat proportions, the LCHP (4.4 kcal/g), 60% HF (5.3 kcal/g) and 90% HF 
(7.1 kcal/g) diets have a high caloric-density compared to the AIN93G standard chow 
(3.8 kcal/g) (Fig. 3-35).  
Female CD-1 mice were fed ad lib with the experimental diets for nine 
consecutive days to establish bodyweight profiles (Fig. 3-36, A and C) and to 
monitor the caloric intake (Fig. 3-36, B and D). We did not observe any significant 
food aversion but noticed that mice fed with the diet lacking proteins completely (0% 
P) reduced food consumption after 6 days (Fig. 3-36, B). The reduced calorie intake 
caused weight-loss for animals in this experimental group (Fig. 3-36, A). Mice in the 
ketogenic high-fat groups (60% HF and 90% HF) consumed more calories during the 
9 days of feeding than mice fed with the AIN93G standard chow (Fig. 3-36, D) and 
mice fed ad lib with the ketogenic 90% HF diet rapidly gained weight after 4-5 days 
(Fig. 3-36, D). CD-1 mice in the experimental groups fed with diets 20% P and LCHP 
showed no difference in calorie intake or bodyweight compared to the mice fed with 
the AIN93G control diet (Fig. 3-36, A and B).  
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Figure 3-35. Calories supplied by macronutrients of experimental diets in %.  
AIN93G standard chow was the reference diet and supplied to all mice. The 
experimental diets modified in the macronutrient composition (fat, protein and 
carbohydrates) were all based on this diet. The low carbohydrate LCHP diet had 
calories from carbohydrates reduced to 20% compared to the AIN93G formulation 
(13% vs. 63.9%) but contained more protein (45.2%) and fat (41.8%). Diets 20% P-1 
(soybean oil as fat source) and 20% P-2 (coconut oil as fat source) had calories from 
protein sources reduced to 20% compared to the AIN93G formulation; the 0% P diet 
contained no protein; all these diets were isocaloric to the AIN93G standard chow. 
The ketogenic high fat diet 60% HF was designed to supply 60% of the consumed 
calories from fat sources. The calories coming from protein and carbohydrates were 
reduced proportionally. The 90% HF diet was a ketogenic diet which contains 90% of 
fat while supplying only minimal carbohydrates (less than 1%) and half of the protein 
content (9%). Modified from Brandhorst et al.; under review. 
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Figure 3-36. Effects of macronutrient defined diets on bodyweight and food 
intake.  
Five female CD-1 mice, age 12-15 weeks were either fed ad lib with AIN93G rodent 
standard chow (black circle) or with (A) two different low protein diets (20% P-1 and 
20% P-2), a diet low in carbohydrates but high in protein (LCHP), a protein deficient 
diet (0% P) or (C) a high fat diet (60% HF) and ketogenic diet (90% HF). (B) Daily ad 
lib calorie intake for diets AIN93G, 20% P-1, 20% P-2, LCHP and 0% P. (D) Daily ad 
lib calorie intake for diets 60% HF and 90% HF; AIN93G shown as reference. All 
data presented as mean ± SEM. Modified from Brandhorst et al.; under review. 
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At days 2, 5 and 9, blood glucose levels from mice on the macronutrient 
modified diets were not different from those on the standard chow diet (Fig. 3-37, A 
and data not shown). By contrast, serum IGF-I levels were significantly elevated (P< 
0.05) in mice on the ketogenic 60% HF diet for 9 days but not for mice fed with the 
ketogenic 90% HF diet (Fig. 3-37, B). Interestingly, not only the macronutrient 
composition (e.g. the protein content) but also the fatty acid source differentially 
modulated circulating IGF-I levels: the low protein diet 20% P-1 (containing soybean 
oil as the only fat source) did not reduce IGF-I levels but the low protein diet 20% P-2 
(coconut oil as the only fat source) significantly (P< 0.05) reduced IGF-I levels and 
there were no differences in these diets other than the fat source. The most 
noticeable effect on serum IGF-I was in mice fed the protein deficient diet 0% P for 9 
days. Circulating IGF-I was reduced to approximately 30% of that in mice on the 
standard chow (Fig. 3-37, B). The protein deficient diet 0% P was the only diet that 
reduced serum IGF-I levels comparable to the 60 hour short-term starvation.  
 
 
 
Figure 3-37. Effects of macronutrient defined diets on glucose and serum IGF-
I.  
Five female CD-1 mice, age 12-15 weeks were either fed ad lib with AIN93G rodent 
standard chow or fed with macronutrient defined diets as described in detail in the 
text. (A) Blood glucose levels after 9 days of ad lib feeding. STS (60 hours) as a 
reference. (B) Serum IGF-I levels after 9 days of ad lib feeding. STS (60 hours) as a 
reference. Lines represent mean; *p<0.05,*** p<0.001, ANOVA, Tukey’s multiple 
comparison compared to AIN93G control. Modified from Brandhorst et al.; under 
review. 
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3.11 Short-term Caloric Restriction and Fasting improve Stress Resistance 
In mice, reduced serum IGF-I and blood glucose levels promote the capability 
to cope with toxicity induced by high-dose chemotherapeutic agents (Lee et al., 
2010; Raffaghello et al., 2008). Since short-term calorie restriction, but not the 
macronutrient defined diets (except for complete protein removal), reduced IGF-I and 
glucose levels, we used a combined approach to test whether diets with defined 
macronutrient deficiency fed at 50% of the regular daily calorie intake could result in 
enhanced chemo toxicity protection. 20% P diets were not included in the stress 
resistance experiments due to the fact that the 0% P diet showed much more 
pronounced effects on serum IGF-I. 
 
Stress resistance was tested in CD-1 mice fed either ad lib with AIN93G 
standard chow or with macronutrient defined diets reduced to 50% of the normal 
calorie intake for three days prior to doxorubicin (DXR, 24 mg/kg, i.v.) treatment (Fig. 
3-38). In the 50% calorie restricted groups mice lost 12-15% of their initial 
bodyweight after 3 days, whereas in the STS group mice lost 20% of their weight 
after 60 hours. Following DXR treatment, AIN93G chow was provided ad lib for all 
animals and the mice regained weight until chemotoxicity-induced weight-loss set in 
(Fig. 3-39, A and B). The weight-loss continued in all experimental groups until day 
8 post injections, after which many animals slowly recovered. Mice fed the calorie 
restricted 0% P and LCHP diets never fully recovered their initial weight loss (Fig. 3-
39, A). Animals started to succumb to chemotoxicity 9-18 days post injection (Fig. 3-
38), in agreement with the reported onset and nadir days of myelo-suppression after 
DXR treatment (http://dailymed.nlm.nih.gov). Mice were considered survivors if they 
remained alive 25 days post DXR injection. Mice fed ad lib with the AIN93G diet ,3 
days prior to DXR injection, showed the worst outcome with only 16% surviving by 
day 25 (Fig. 3-38). In contrast to the ad lib fed mice, the great majority (89%) of 
fasted (60 hours) mice survived the high-dose chemotherapy. Control mice treated 
with DXR showed signs of toxicity including reduced mobility, ruffled hair and 
hunched back posture whereas mice in the STS group showed no visible signs of 
stress or pain after the treatment (data not shown). Three-day feeding of the 
combination of 50% CR with macronutrient modification prior to DXR injection 
improved the stress resistance in mice and resulted in 45-55% survival (Fig. 3-38). 
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There was no indication that fat or carbohydrate content affected the results because 
all diets achieved a similar protection. The data indicates that short-term CR, not the 
fat or carbohydrate composition of the diet, confers partial chemo-protection which 
are not as potent as to those caused by fasting. Mice fed the 50% CR LCHP diet 
performed worse than all other CR fed groups, presumably because of the effect of 
the high protein content of this diet on IGF-I (Fig. 3-35). 
 
 
 
Figure 3-38. Stress resistance test for calorie restricted macronutrient defined 
diets.  
Female CD-1 mice were fed ad lib (AIN93G), were fasted for 60 hours (STS) or fed 
with 50% calorie restricted diets (CR) with defined macronutrient compositions 
(AIN93G, LCHP, 0% P, 60% HF, 90% HF) for 3 days (green box) prior to an intra-
venous injection of doxorubicin (24 mg/kg, red dashed line). Survival was followed 
for 25 days post injection, after which the remaining animals were considered 
survivors. Survival data plotted from pair-matched pooled experiments with the 
statistical software Prism (GraphPad Software). Modified from Brandhorst et al.; 
under review. 
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Figure 3-39. Bodyweight profile during the stress resistance test for calorie 
restricted macronutrient defined diets.  
(A) Bodyweight profile for mice that were fed ad lib (AIN93G) or fed with 50% calorie 
restricted (CR) diets with defined macronutrient compositions (60% HF, LCHP, 0% 
P) for 3 days (green box) prior to an intra-venous injection of doxorubicin (24 mg/kg, 
red dashed line). (B) Bodyweight profile for mice that were fed ad lib (AIN93G), fed 
with 50% calorie restricted diets with defined macronutrient compositions (AIN93G, 
90% HF) for 3 days or were fasted for 60 hours (red box) prior to an intra-venous 
injection of doxorubicin (24 mg/kg, red dashed line). Modified from Brandhorst et al.; 
under review. 
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Blood glucose measurements showed that three-day feeding of the calorie 
restricted and macronutrient modified diets was not sufficient to significantly reduce 
glucose levels, with the exception of the 50% CR ketogenic 90% HF diet (Fig. 3-40). 
The reduction in glucose levels in the ketogenic group however was not associated 
with enhanced stress resistance (Fig. 3-38). Mice in the STS group had significantly 
lower blood glucose levels than all other experimental groups (Fig. 3-40). 
 
Figure 3-40. Blood glucose for calorie restricted macronutrient defined diets 
after 72 hours.  
Blood glucose levels were measured after 3 days of feeding ad lib and CR diets, as 
well as after 60 hours of STS. Lines represent mean.* p<0.05, *** p<0.001, ANOVA, 
Tukey’s multiple comparison. Modified from Brandhorst et al.; under review. 
 
3.12 A Low Protein Diet does not Delay GL26 Glioma Progression 
Diets low in protein have been shown to lower cancer risks (Youngman 1993) 
while high-calorie and high-protein diets are linked to obesity and promote hormonal, 
metabolic, and inflammatory alterations that modulate carcinogenesis (Kaaks and 
Lukanova 2002; Calle and Kaaks 2004). To test the effects of a low protein diet in a 
subcutaneous glioma model we switched mice from the standard chow (18.8% 
protein-derived calories, Fig. 3-35) to a diet low in protein (20% P-1, 3.9% protein-
derived calories) 10 days after the implantation of GL26 cells when the tumor 
became palpable (Fig. 3-41). Low protein diet fed mice displayed tumor progression 
that was not distinguishable from that in mice fed ad lib with the AIN93G diet (Fig. 3-
41). These results indicate that the tumor progression could not be retarded by 
protein-restriction once the tumor was established.  
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Figure 3-41. The Effect of protein restriction on GL26 tumor progression in 
vivo.  
Subcutaneous tumor progression of murine GL26 glioma is shown by total tumor 
volume in mm3. Tumor measurements were started once the tumors became 
palpable under the skin at day 10. Animals were fed ad lib with either AIN93G (N= 5) 
as a control, or with the low protein diet 20% P-1 (N= 6). All data presented as mean 
± SEM. Modified from Brandhorst et al.; under review. 
 
3.13 Short-term Intermittent Calorie Restriction does not Enhance Efficacy of 
Chemotherapy against Breast Cancer  
The efficacy of STS in augmenting the treatment of various cancers is two-
fold: it protects normal cells/tissues against chemotherapy-induced toxicity and 
sensitizes malignant cells to chemotherapeutic agents (Lee, Safdie et al. 2010; Lee, 
Raffaghello et al. 2012; Safdie, Brandhorst et al. 2012). Nonetheless, even short 
cycles of fasting (e.g. 4 days) can be a challenge for the majority of people and thus 
the “milder” calorie restricted approach could be a more feasible solution. To test 
whether a short-term intermittent 50% CR (ICR) diet could result in similar beneficial 
effects as the established fasting protocols, we implanted murine 4T1 breast cancer 
cells subcutaneously into female BalB/C mice and monitored the tumor progression. 
Twelve days after tumor implantation, the tumor volume was measured and mice 
were assigned to either the untreated control group (AIN93G), a group treated with 
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cisplatin (CDDP) or a group intermittingly fed with 50% CR (ICR) for three days prior 
to cisplatin treatment. The tumor in the untreated control group progressed rapidly 
and reached the experimental endpoint 54 days after tumor implantation (Fig. 3-42). 
Three cycles of cisplatin treatment delayed the tumor progression; the tumor volume 
of these mice was approximately half the size of that in untreated mice (Fig. 3-42). In 
contrast to STS (Lee, Raffaghello et al. 2012), an intermittent 50% calorie restricted 
AIN93G feeding regimen fed to mice for three days prior to the cisplatin injections did 
not result in the sensitization of the tumor and did not augment the chemotherapy 
(Fig. 3-42). Tumor volumes in this experimental group did not significantly differ from 
tumor volumes in mice that were treated with cisplatin alone.  
 
 
 
Figure 3-42. The effect of caloric restriction on 4T1 tumor progression in vivo.  
Subcutaneous tumor progression of murine 4T1 breast cancer is shown by total 
tumor volume in mm3. Tumor measurements were started once the tumors became 
palpable under skin at day 12. Control animals (N= 10) received no treatment, 
cisplatin (CDDP) animals (N= 9) were injected at days 15, 33 and 44. The first CDDP 
dose was delivered at 12 mg/kg by intra-venous injection, the two subsquent 
injection were delivered at 8 mg/kg to avoid chemotoxicity. Mice in the 50% ICR+ 
CDDP group (N= 9) were fed in intermittent regimens with the AIN93G diet reduced 
to 50% of the daily calorie intake of the control group for three days (ICR, green box) 
prior to cisplatin injection. Injection schedule inditical as for the CDDP group. All data 
presented as mean ± SEM; *** p<0.001, ANOVA, Tukey’s multiple comparison, 
compared to control of the respective day. Modified from Brandhorst et al.; under 
review.  
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4 Discussion 
Most cancer drugs are being developed for specific tumor types, and in many 
cases, they are effective for only a subset of patients with a specific tumor. 
Furthermore, the development of each of these targeted cancer drugs is extremely 
costly, and assembling sufficient data for Food and Drug Administration approval 
requires years of clinical testing (Crown 2001; Garattini and Bertele 2002). Although 
there are undoubtedly targeted drugs that will be effective in the treatment of specific 
cancers, there would be advantages to therapies that could be available sooner, at a 
lower cost, and that could be effective for a wide range of cancers. Here, we have 
taken advantage of the relative independence of cancer cells from growth signals 
and their unresponsiveness to anti-growth signals (Hanahan and Weinberg 2011) to 
show that this inability of cancer cells renders them unable to cope effectively with 
the markedly altered cellular environments during short cycles of complete starvation 
(Lee, Raffaghello et al. 2012; Safdie, Brandhorst et al. 2012). 
4.1 Fasting vs. Calorie Restriction 
Fasting is a simple, cost-effective, and feasible dietary intervention to increase 
cellular protection. We have previously reported its ability to selectively protect the 
host, but not malignant cells, to chemotherapy agents (Raffaghello, Lee et al. 2008; 
Lee, Safdie et al. 2010). Here, I provide evidence for a fasting-dependent 
sensitization of a wide variety of murine and human cancer cells. Nutrient and growth 
factor deprivation causes the sensitization to various chemotherapy drugs and 
thereby increases the chemotherapeutic index for in vivo and in vitro treatment 
modalities. However, the beneficial effects of fasting do not reside in the field of 
cancer treatment alone, but extend even further to renal (Mitchell, Verweij et al. 
2010), hepatic (Domenicali, Caraceni et al. 2001; Verweij, van Ginhoven et al. 2011), 
cerebral (Go, Prenen et al. 1988), and cardiac ischemic injury (Varela, Marina 
Prendes et al. 2002), which cause considerable cellular damage by glucose 
restriction, hypoxia, and oxidative stress (Loor and Schumacker 2008). Furthermore, 
fasting also imparts a potent anti-inflammatory effect in vivo (Mitchell, Verweij et al. 
2010), whose role in enhancing cancer-therapy and reducing the side effects of the 
chemo-treatment warrants further investigation (Zitvogel, Kepp et al. 2011). 
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Adaptation to fasting involves a multiplicity of physiological responses 
including metabolic changes, e.g. the switch to alternative nutrient sources due to 
reduced glucose availability and the reduction of growth factors such as IGF-I 
(Greenspan 2001; Strohman 2002; Lee, Safdie et al. 2010). In this thesis, and in 
previously published results, we have shown that a major reduction in blood glucose 
and IGF-I levels is partly responsible for the beneficial effects of DSR and DSS. In 
mice, a 60 hour short-term fasting regime reduces bodyweight by 20% or more, 
serum IGF-I by up to 75%, and glucose by up to 70%, increases IGFBP-1 11-fold 
and allows animals to regain their normal weight rapidly after re-feeding (Lee, Safdie 
et al. 2010). Under these conditions, animals become highly stress resistant 
(Raffaghello, Lee et al. 2008; Lee, Safdie et al. 2010), in agreement with results 
obtained from S. cerevisiae (Longo 1999). When we applied 20% weight-loss as an 
experimental endpoint, various degrees of CR regimens resulted in progressively 
quicker weight loss and also reduced IGF-I and glucose. However, we also observed 
that the much shorter (60 hours) STS regimen had more pronounced effects on 
blood glucose level than most of the CR diets, even when the CR diets were 
maintained for 9-13 days and caused an equivalent 20% weight loss.  
For established murine breast cancer allografts, the combined treatment with 
short-term intermittent 50% CR and cisplatin did not result in the augmentation of 
chemotherapy efficacy (in contrast to the combination of STS and chemotherapy). 
The results I describe suggest that short cycles, up to 72 hours, of a 50% CR did not 
significantly reduce blood glucose levels and may not cause a sufficient reduction in 
the carbon sources metabolized by murine breast cancer cells within this regime. 
Thus, short periods of an intermittent CR regiment, although “milder”, are not 
feasible to reduce tumor progression and to induce tumor sensitization. Still, this 
does not exclude that long-term CR regiments might have beneficial effects. Seyfried 
et al. demonstrated that calorie restriction reduced biomarkers of tumor progression 
and angiogenesis (Kari, Dunn et al. 1999; Yu and Rohan 2000) and led to a 
reduction in tumor growth in a CT-2A malignant mouse astrocytoma model. However 
a 13 day 40% CR resulted only in a 45% reduction in IGF-I levels when compared to 
ad lib fed control animals, and also caused a major and chronic weight loss 
(Seyfried, Sanderson et al. 2003).  
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The less pronounced effects of calorie restricted diets, when compared to 
short-term starvation, might be explained by a distinct physiological response that is 
unique to conditions under which nutrients are completely absent (Lee and Longo 
2011). For example, the decrease in blood glucose caused by short-term fasting in 
this study was 70% and occurred within 60 hours vs. the 40% glucose reduction 
caused by a 90% CR diet after 96 hours. When deprived of food, mammals generally 
undergo distinct metabolic stages (Wang, Hung et al. 2006) and these changes 
trigger the down-regulation of pathways involved in proliferation, cell growth and the 
reduced production of reactive oxygen species, while simultaneously increasing 
genomic stability and cellular stress resistance (Sohal and Weindruch 1996; 
Hursting, Slaga et al. 1999; Holzenberger, Dupont et al. 2003; Longo and Fontana 
2010; Lee and Longo 2011).  
 
The effects of prolonged CR have been known for over a century now 
(Moreschi 1909; McCay CM 1935) and one could argue why calorie restriction as a 
treatment modality is generally not considered. The problems associated with 
translating CR into any clinical application is that long-term CR delays, but does not 
stop, the progression of many malignant diseases (Mukherjee, Abate et al. 2004; 
Bonorden, Rogozina et al. 2009). CR is also associated with a chronic reduced 
weight state that might be detrimental for cachectic cancer patients, or patients at 
risk to become cachectic. In addition, CR might chronically reduce fat and other 
reserves that may increase frailty, particularly in elderly patients (Seyfried, 
Sanderson et al. 2003). In fact, prolonged CR can delay wound healing and immune 
function, which might present an additional hurdle for the great majority of patients 
receiving chemotherapy or undergoing surgery (Kim and Demetri 1996; Reed, Penn 
et al. 1996; Kristan 2008; Fontana, Partridge et al. 2010). Furthermore, the 75% 
reduction in serum IGF-I caused by a 2 to 5 day fast in mice and humans cannot be 
achieved by a more moderate CR which does not reduce IGF-I levels in humans 
unless the protein intake is also restricted (Clemmons and Underwood 1991; 
Fontana, Weiss et al. 2008; Lee, Safdie et al. 2010). Even when combined with 
protein restriction, chronic CR only causes a 30% reduction of IGF-I in humans 
(Fontana, Weiss et al. 2008).  
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By contrast, based on the DSR studies and on clinical data, fasting for a 
limited period can have a potent protective effect on the host. In a recent report 
published by our lab, 10 patients with a variety of malignancies, including tumor 
stages IA to IV/DI, voluntarily fasted for up to 180 hours in combination with 
chemotherapy, and reported reductions in common chemotherapy-associated side-
effects such as vomiting, diarrhea, fatigue and weakness (Safdie, Dorff et al. 2009). 
Notably, in the cases where cancer progression could be followed, there was no 
evidence that fasting protected tumors or interfered with chemotherapy efficacy. At 
the University of Southern California Norris Comprehensive Cancer Center (Los 
Angeles, CA, USA), the Mayo Clinic Cancer Center (Rochester, MN, USA) and the 
Leiden University Medical Center (Leiden, Netherlands), there are currently ongoing 
clinical trials to study the effects of shorter fasting cycles (two to three days) in 
combination with chemotherapy in cancer patients (ClinicalTrials.gov Identifier: 
NCT00936364, NCT01175837, NCT01304251), which should begin to reveal the 
potential of STS in the enhancement of cancer treatment for humans within the next 
few years. Notably, both in the ongoing clinical trials and in the case studies, patients 
fasted (water only) for 48-72 hours before and also for 24 hours after chemotherapy. 
A period of fasting after chemotherapy administration may be of particular 
importance because chemotherapy drugs can act as carcinogens by causing DNA 
damage, potentially leading to secondary tumors and other toxicities (Carter 1984; 
Margison, Santibanez Koref et al. 2002). In fact, the combination of re-feeding after 
fasting and treatment with potent carcinogens can enhance the growth of aberrant 
crypt foci in liver, colon and rectum (Laconi, Tessitore et al. 1995; Premoselli, Sesca 
et al. 1998; Sesca, Premoselli et al. 1998), probably because prolonged fasting can 
cause cell death and atrophy in organs such as the liver. Re-feeding, which causes 
the cell proliferation needed to re-establish normal organ size, may lead to DNA 
damage if high concentrations of toxins are still present. Chemotherapy drugs are 
generally not potent carcinogens and we showed that toxicity to multiple organs is 
reduced, not increased, even when re-feeding is initiated immediately after 
chemotherapy (Raffaghello, Lee et al. 2008; Safdie, Dorff et al. 2009; Lee, Safdie et 
al. 2010). Still, our recommendation is that the period of fasting after chemotherapy 
should be based on the half-life of the chemotherapy drug to minimize toxicity to 
153 
 
normal cells when re-feeding begins. In the near future, animal and clinical studies 
should focus on the investigation of the effect of post-chemotherapy fasting.  
4.2 The Induction of Differential Stress Sensitization by STS 
Mutations that increase cellular protection and extend longevity (e.g. growth 
hormone deficiencies) often cause reduced growth and fertility (Kirkwood, Kapahi et 
al. 2000). Changes in the extracellular environment, such as caused by fasting, can 
have similar effects: In simple organisms such as S. cerevisiae, stress resistance to 
oxidants and chemotherapeutic drugs can be increased by up to 10-fold in response to 
fasting and up to 1,000-fold in those cells lacking homologs of Ras, AKT and S6 kinase 
(Raffaghello, Lee et al. 2008). Nevertheless, this improved resistance to oxidative 
stress can be completely reversed, and even further decreased below wild type 
levels, in yeast cells expressing oncogene-like genes such as sch9 (Longo and 
Finch 2003; Raffaghello, Lee et al. 2008), thereby linking stress resistance to the 
GH/IGF-1 axis. 
The IGF-I pathway has been shown to affect both animal life span and 
sensitivity to oxidative stress, consistent with the greater resistance to oxidative 
stress in IGF-I receptor deficient mice (Holzenberger, Dupont et al. 2003). The 
forkhead box protein O1 (FOXO1), a down-stream target of IGF-I/AKT signaling, can 
enter the nucleus, in the absence/reduction of IGF-I/AKT signaling, where it can 
modulate a wide array of genes involved in oxidative stress resistance, longevity, 
and metabolism (Kim, Kim et al. 2008; Partridge and Bruning 2008; Guevara-
Aguirre, Balasubramanian et al. 2011). In consequence, it is a key mechanism 
involved in protection against age associated stress and disease development. IGF-I 
exerts a potent tumorigenic effect on a variety of cancer cells by increasing their 
proliferative rate and inhibiting apoptosis (Prisco, Romano et al. 1999; Ramsey, 
Ingram et al. 2002). Studies in mice with deficiencies in the downstream effectors of 
IGF-R signaling, including mTOR inhibition by rapamycin (Harrison, Strong et al. 
2009) and S6K1 (Selman, Tullet et al. 2009), demonstrate the central role of 
intracellular mitogenic pathways downstream of IGF-I in regulating lifespan and 
stress resistance while simultaneously reducing tumor growth (Pinkston, Garigan et 
al. 2006; Garcia, Busuttil et al. 2008; Ikeno, Hubbard et al. 2009). In addition, 
humans with growth hormone receptor deficiency have significantly lower circulating 
IGF-I levels, and also exhibit drastically reduced incidence of cancer and diabetes, 
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which are more common among age matched relatives with intact growth hormone 
receptor (Guevara-Aguirre, Balasubramanian et al. 2011).  
Cancer cells are self sufficient in growth signals, with little to no 
responsiveness to physiological anti-growth signals, and in many cases do not 
undergo cell cycle arrest due to check point deregulation (Longo, Lieber et al. 2008; 
Hanahan and Weinberg 2011). In fact, it has been shown that pre-treatment with 
non-toxic doses of cell cycle arresting drugs (e.g. DXR) or growth factor inhibitors 
(inhibitors of MEK or EGF receptor) protect normal cells but not cancer cells against 
chemotherapy (Blagosklonny, Bishop et al. 2000; Blagosklonny, Robey et al. 2000; 
Demidenko, Halicka et al. 2005). In cancer cells, the acquisition of mutations and 
epigenetic modifications seems to impose a trade off: the loss of sophisticated 
responses acquired during evolution to rapidly adapt to a variety of environments, 
including starvation. Whereas cancer cells are often able to overcome the obstacles 
generated by anti-cancer therapies, including chemotherapy drugs as well as 
inhibitors of angiogenesis, signal transduction, and growth factors, they may not be 
sufficiently heterogeneous or adaptable to overcome wide-acting conditions such as 
starvation, particularly if combined with cancer therapeutics. One such example is 
the dependency on glucose to maintain high levels of cellular proliferation (Vander 
Heiden, Cantley et al. 2009). 
 In vitro, 19 out of the 21 murine and human cancer cell lines we tested were 
sensitized under fasting-mimicking conditions. We also noticed that glucose or 
serum restriction both individually sensitize cancer cells, yet the combination of both 
of these restrictions has, as can be expected, more potent effects. Glucose 
restriction alone was sufficient to sensitize various glioma cell lines. Glucose is the 
major energy source for proliferating cells, such as malignant cells, with elevated 
blood glucose being associated with increased cancer risk (Rapp, Schroeder et al. 
2006; Stocks, Rapp et al. 2009). Many cancer cells have elevated glucose uptake 
rates and rely on glycolysis followed by lactic acid fermentation even in the presence 
of oxygen, a phenomenon known as the Warburg effect (Warburg 1956; Oudard, 
Boitier et al. 1997). In normal cells, the reduction of blood glucose, as well as IGF-I, 
likely contribute to a differential regulation of the activation of stress resistance 
transcription factors that are negatively regulated by nutrient sensing pathways 
(Longo, Lieber et al. 2008; Fontana, Partridge et al. 2010) and cell cycle progression 
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(Blagosklonny and Pardee 2001). In contrast, for cancer cells low glucose presents a 
specific and major challenge, particularly in the presence of chemotherapy drugs. 
Serum starvation alone had similar effects in a multitude of human and murine cell 
lines. I have also demonstrated that the effects of serum starvation can be imitated 
by the dose dependent and specific blocking of the IGF-I receptor with the αIR3 
antibody in murine breast cancer cells. Even more so, the substitution of IGF-I under 
low serum conditions reversed the sensitization of 4T1 breast cancer and B16 
melanoma cell lines in vitro. 
 
Not every cell line responded to each drug we tested (e.g. the human colon 
cancer cell line LOVO showed no response to DXR but was sensitized when treated 
with CP) and thus indicates that our fasting-based approach can individually be 
optimized to the chemotherapeutic agent. We have yet to establish why two of the 
cancer cell lines did not respond to the starvation-mimicking conditions in vitro. One 
possibility could be that these cancer cell lines acquired mutations that make them 
irresponsive even to the reduction in glucose and/or IGF-I. Sabatini and colleagues 
showed that certain human cancer cell lines, when grown as tumor xenografts in 
mice, are highly sensitive to the anti-growth effects of caloric restriction, whereas 
others are resistant (Kalaany and Sabatini 2009). Cancer cells that form CR-resistant 
tumors carry mutations that cause constitutive activation of the phosphatidylinositol-
3-kinase (PI3K) pathway and, in culture, proliferate in the absence of insulin or IGF-I. 
The substitution of an activated mutant allele of PI3K with wild-type PI3K in 
otherwise isogenic cancer cells, or the restoration of PTEN expression in a PTEN-
null cancer cell line, was sufficient to convert a CR-resistant tumor into one that is 
sensitive to CR (Kalaany and Sabatini 2009). However another, more simplified, 
explanation for why we did not see sensitizing effects in a couple of cell lines could 
simply be the usage of chemotherapeutic agents that are not effective for this 
particular malignancy. For example, one of the cell lines that did not respond to DXR 
or CP treatment screen was the human astrocytoma cell line U87-MG. The treatment 
of this malignancy would usually involve Temozolomide (TMZ), the standard 
chemotherapy drug adopted for the treatment of high grade glioma of astroglial origin 
(Friedman, Kerby et al. 2000; Villano, Seery et al. 2009). When we tested mouse, rat 
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and human glioma cell lines under fasting-like conditions, we sensitized these glioma 
cell lines to TMZ treatment.  
To test the efficacy of a fasting-mediated sensitization in vivo, we utilized a 
variety of different tumor models, including subcutaneous, intra-cranial and 
metastasizing models of tumor allografts and xenografts. We studied the progression 
of subcutaneous allografts of murine glioma (GL26), breast cancer (4T1) and 
melanoma (B16) and all of these models showed the most potent effects when short 
cycles of fasting were combined with chemotherapy. Interestingly, for some allograft 
models such as breast cancer, two repeated cycles of fasting for only 60 hours were 
as effective as two cycles of chemotherapy. STS alone may have the potential to be 
utilized in cases where patients cannot continue, or opt out of, the treatment with 
chemotherapeutic agents. However, it should be noted that the growth of B16 
melanoma cells was not affected by the second cycle of fasting, which might 
potentially indicate that some cancer cells may have acquired resistance to fasting 
alone. Future studies should evaluate if repeated cycles of fasting may cause cancer 
cells to adapt to the challenges induced by starvation conditions. We also tested the 
growth of subcutaneous human breast cancer (MDA-MB-231) and ovarian cancer 
(OVCAR3) xenografts. Both cancer cell lines were also retarded by short-term 
starvation but returned to a size similar to that in animals on the control diet after re-
feeding. Of note is that, when mice are re-fed after starvation and chow is provided 
ad lib, mice respond with severe binge eating (personal observation). The food 
intake in the first 2 to 3 days post fasting can be increased by up to 100-150%. 
During this period the mice consume significantly more calories and macronutrients, 
which can essentially “fuel” tumor growth. The effects of starvation alone in the two 
models might be more potentiated if animals are allowed to consume only control-
matched amounts of food. However, this binge eating seems to be a rodent specific 
effect and human cancer patients are not encouraged to consume high calorie meals 
after ending their fast, but rather slowly re-adopt the body to normal food. 
Nonetheless, in the murine xenografts model the progression of the human breast 
cancer tumors was dramatically retarded and the tumor did not progress when 
fasting was combined with DXR. We have encountered no situation in which fasting 
was protective for cancer cells. 
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We aimed to evaluate the potential benefits of STS for glioma treatment in 
greater detail due to the severity of this disease. The multimodal treatment of GBM, 
based on surgical removal of the tumor followed by chemotherapy and radiotherapy, 
has improved the survival of GBM patients. However, the frequency of recurrence 
and rapid progression in adults emphasizes the need for a major enhancement of 
the therapy to achieve long-term survival without relying exclusively on the uncertain 
and very long and expensive drug development process. In addition, chemotherapy 
often causes severe toxic side effects and might even fail due to the development of 
drug resistance as glioma, and GBM in particular, are among the most inherent 
chemotherapy-resistant tumors (Pyrko, Schonthal et al. 2007; Kreisl 2009). The aim 
of our study was to investigate whether fasting, which could be rapidly, inexpensively 
and widely integrated into existing cancer treatments by clinicians, can improve the 
efficacy of chemo-and radiotherapies in treating mouse models of aggressive GBM. 
The intracranial inoculation of C57BL/6 mice with GL26luc cells showed a fast tumor 
progression that led to severe signs of illness such as back-hunching, reduced 
grooming (ruffled coat) and hypo-activity, possibly due to increasing intracranial 
pressure. One cycle of TMZ treatment at day 7 and 8 after tumor inoculation, or a 48 
hour STS alone, extended the median survival from 14 to 15 days, although this 
effect was not statistically significant. By contrast, the combination of STS and TMZ 
delayed the onset of mortality and significantly extended median survival to 16 days. 
Remarkably, one animal in the STS+TMZ group achieved long-term survival. These 
results indicate that the combination of starvation with TMZ, the standard 
chemotherapy drug for the treatment of malignant glioma, has the potential to extend 
survival, at least in a portion of the subjects treated. When we expanded the 
treatment to two cycles, we limited the 2nd treatment to 24 hours of starvation 
because of a loss of body weight prior to STS, presumably due to tumor burden. 
Despite the shortened starvation regimen and the reduced TMZ dose, the STS+TMZ 
group showed an extended survival compared to that of the single cycle treated 
group. Although this may be seen as a limited improvement for the treatment of 
advanced stage glioma, the fasting-based sensitization has the potential to achieve a 
better health outcome in the treatment of a residual disease after the tumor 
resection. 
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The longer survival in the subcutaneous glioma model compared to the 
intracranial one allowed us to analyze the beneficial effects of STS in combination 
with TMZ- or radiotherapy. Both treatments, which are standard care in glioma 
treatment, significantly delayed tumor progression when combined with fasting. 
Notably, STS alone was capable of retarding tumor progression in the subcutaneous 
model to a degree comparable to that caused by radiotherapy during the earlier 
stages of tumor development. Consistent with our STS-based approach, which 
results in blood glucose reduction, others have shown that the reduction in blood 
glucose availability, e.g. by 2-deoxy-D-glucose (a glucose analog and glycolytic 
inhibitor), can selectively enhance radiation-induced damage in tumor cells while 
protecting normal cells (Singh, Singh et al. 1990; Mohanti, Rath et al. 1996). 
However, fasting, which affects the levels of many growth factors and metabolites, is 
likely to be much more effective against a wider range of tumors than interventions 
that affect the levels of specific metabolites, such as glucose, alone. Thus, this 
dietary intervention may represent an alternative to GBM patients who are unable to 
receive or opt out of the conventional treatments. 
 
Advanced metastatic tumors are extremely difficult to cure once tumor 
masses have spread to different organs. We therefore we aimed to investigate 
whether the combination of multiple fasting cycles and high-dose chemotherapy can 
increase survival in aggressive metastatic cancer models. In models of intravenously 
injection of murine breast cancer cells, melanoma cells and two neuroblastoma cell 
lines (NXS2 and Neuro-2a) in immune-competent mice, the combination of STS and 
chemotherapy significantly extended survival and reduced the spreading of tumor 
cells into distant organs. As outlined in the introduction, cancer metastasis is a 
multistep process driven by the complex molecular interactions that occur between 
the disseminating cancer cell and its changing microenvironment. The rate limiting 
steps regulating this process are tumor-induced angiogenesis, extracellular matrix 
(ECM) degradation, cell movement through tissue barriers, including entry into and 
exit from blood vessels, and survival/proliferation. Previous studies demonstrate that 
manipulation of IGF-I levels, e.g. by dietary intervention such as CR, influences 
tumor growth and metastasis. Up-regulation of the IGF-I pathway stimulates tumor 
proliferation, progression and metastasis and conversely, the down-regulation of this 
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pathway results in anti-tumorigenic activity in vivo (Baserga, Peruzzi et al. 2003). 
The functional disruption of the IGF-I receptor decreases breast cancer metastasis in 
immune deficient nude mice by suppressing cellular adhesion, invasion, and 
metastasis of breast cancer cells to the lung, lymph nodes, and lymph vessels (Kari, 
Dunn et al. 1999). Of particular interest for the reduced metastasis are molecules 
that enable motile and invasive properties, thus allowing malignant cell to invade the 
underlying stroma. Such molecules include the matrix metalloproteinases (MMPs). 
These zinc-dependent collagenases have been implicated in ECM degradation and 
are associated with tumor-dependent angiogenesis and invasion (Samani, Yakar et 
al. 2007). The IGF system plays a role in the regulation of several of the MMPs and 
can thereby promote tumor invasion. Several labs identified the IGF-I receptor as a 
promoter of MMP(-2) synthesis and tumor invasion, as measured in vitro (Yoon and 
Hurta 2001; Grzmil, Hemmerlein et al. 2004; Zhang, Bar-Eli et al. 2004). Further, the 
down- or up-regulation of IGF-IR expression altered MMP-2 expression levels, 
invasion, and metastasis in a Lewis lung carcinoma model of liver metastasis (Long, 
Navab et al. 1998). We have not yet established if STS indeed modulates MMP 
expression. I propose that the pronounced effects of STS on IGF-I might result in 
decreased MMP expression and thus might be involved in the reduced metastasis in 
our models.  
 
Gene expression profiling by genome-wide microarray analyses on the liver, 
heart, skeletal muscle, and subcutaneous 4T1 breast tumor mass from mice, fasted 
for either 48 hours or fed an ad lib diet, was performed to investigate genes that are 
differentially regulated in normal and cancer cells in response to fasting. The 
microarray analysis clearly indicates that fasting differentially regulates genes 
involved in cellular proliferation and found that the expression of translation and 
ribosome biogenesis/assembly genes was significantly increased in response to 
fasting in the autografted breast cancer (4T1). In normal tissues these genes were 
either repressed or minimally affected. In agreement with this increase in the 
expression of translation genes, tumor cells cultured under STS for 48 hours showed 
increased cellular protein concentration, had increased levels of phosphorylation of 
Akt and S6K proteins, and reduced phosphorylation of eIF2 in autografted tumors 
of fasted mice. It thus appears as if 4T1 tumor cells, when exposed to starvation, 
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attempt to compensate for the lack of nutrients and growth factors by increasing 
translation, although counter-intuitive. As a result, cancer cells appear to consume 
even more energy, eventually promoting oxidative stress and cell death. In fact, 
translation is closely coupled with cell cycle progression and cell growth (Meric and 
Hunt 2002), and is a costly process that can consume 50 to 75% of the cellular 
energy in rapidly dividing cells (Rolfe and Brown 1997; Princiotta, Finzi et al. 2003). 
The regulation of translation in mammalian cells is tightly coupled to nutrient status 
through the mTOR pathway and the modulation of translation initiation by altering the 
phosphorylation status of the eIF4E-binding protein (4E-BP1) and S6K. S6K and 4E-
BP1 are also partly regulated by PI3K and its downstream protein kinase Akt and 
thus the phosphorylation of S6K is stimulated by several growth factors, such as 
platelet-derived growth factor and IGF-I (Graves, Bornfeldt et al. 1995). PTEN is a 
phosphatase that negatively regulates PI3K signaling. PTEN-/- cells have 
constitutively active Akt, causing increased S6K activity and S6 phosphorylation 
(Neshat, Mellinghoff et al. 2001). Consequently, S6K activity is inhibited both by the 
PI3K inhibitors wortmannin and LY294002 or by the mTOR inhibitor rapamycin 
(Thomas and Hall 1997). 
In accordance with the hypothesis that the promotion of cellular proliferation is 
accompanied by a decrease in cellular maintenance (Kirkwood, Kapahi et al. 2000), 
we observed increased DNA damage and the induction of apoptosis in cancer cells. 
The reduction in cellular maintenance might be responsible for the effect of fasting 
on the sensitization of 4T1 cells. We noted a considerable increase in the ROS-
dependent staining in malignant cells with DHE and MitoSox Red under fasting-
mimicking cell culture conditions. Under these conditions, cancer cells responded 
with the effort to increase pro-proliferative signaling. The hyper-activation of the Akt 
and Tor-S6K pathways may be the underlying cause for the increase in reactive 
oxygen species (Nogueira, Park et al. 2008). In fact, in both yeast and higher 
eukaryotes, the activation of Akt and Tor-S6K pathways sensitizes cells to oxidative 
damage, in part by inactivating stress resistance transcription factors (Fabrizio, 
Pozza et al. 2001; Wei, Fabrizio et al. 2008). In addition, data suggest that high 
levels of intracellular ROS contribute to PTEN inactivation by oxidation with a 
subsequent PI3K/Akt pathway hyper-activation (Silva, Yunes et al. 2008). These pro-
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oxidizing conditions caused by starvation may in turn promote the observed increase 
in DNA damage and apoptosis. 
4.3 HO-1 is a Mediator of Differential Stress Sensitization in Malignant Cells. 
The ability to communicate with the environment to respond to changes, in 
particular to adverse events, is a critical component to maintain cellular function and 
enables survival even in stressful conditions. Therefore, most cells have developed a 
cellular stress response that allows adjusting gene expression profiles in response to 
these stimuli, particularly through the establishment of proteins involved in cellular 
defense mechanisms. On the other hand, the continuous, or rather, exaggerated 
translational activity in fasted tumor cells may consume the limited cellular energy at 
the cost of inducible stress-resistance factors such as NFkB and HO-1, when 
nutrients are scarce or absent. This fasting-induced decrease in NFkB and HO-1 
expression in transplanted 4T1 tumors may explain at least parts of the sensitization 
effects observed in these cells. 
Heme oxygenase-1 is a microsomal membrane protein that catalyzes the 
oxidative cleavage of heme molecules to generate biliverdin, free heme iron and 
carbon monoxide (CO). HO-1 is critical in at least two physiological pathways: a) the 
recycling of iron molecules from senescent erythrocytes (Kovtunovych, Eckhaus et 
al. 2010) and b) the maintenance of cellular homeostasis under stressful conditions 
(Otterbein, Soares et al. 2003; Gozzelino, Jeney et al. 2010). Previous research 
demonstrated that the maintenance of cellular homeostasis by HO-1 is promoted by 
potent anti-inflammatory, anti-proliferative and anti-oxidant activities of CO and bile 
pigments. In turn, this may be of particular importance in human pathologies 
including inflammation (e.g. sepsis and asthma), cardiovascular diseases (e.g. 
myocardial infarct), atherosclerosis, hypertension, transplant graft rejection and 
cancer (Liu, Chen et al. 2004; Ryter and Choi 2009).  
In normal cells, the expression of HO-1 is triggered by heme, as well as a 
diversity of stressors including ultraviolet radiation, hypoxia, inflammation, heavy 
metals, hydrogen peroxide and nitric oxide (Prawan, Kundu et al. 2005). In addition, 
we show here that STS induces HO-1 expression in the liver, heart and muscle. 
Owing to this vast variety of stressors, HO-1 is regulated by a multitude of 
transcription factors to fine-tune the response to specific conditions. Among these 
factors are members of the heat shock factor (HSF), nuclear factor-κB (NFkB), 
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nuclear factor-erythroid 2 (NF-E2 and more particular Nrf2) and activator protein-1 
(AP-1) families as well as the hypoxia inducible factor-1 (HIF-1) and cAMP response 
element-binding protein (CREB) (Alam, Stewart et al. 1999; Prawan, Kundu et al. 
2005; Alam and Cook 2007). Although heme itself is proposed to enhance hmox-1 
gene transcription by binding BACH1 (Igarashi and Sun 2006), most of the HO-1 
induction is regulated by transcription factors that are themselves regulated by 
signaling cascades that integrate protein phosphorylation status and redox reactions. 
As such, a substantial amount of data emphasizes the role of mitogen activated 
protein kinases (MAPK), the Janus kinase (JAK)-signal transducer and activator of 
transcription (STAT) signaling cascade and the PI3K/AKT in the regulation of HO-1 
(Kyriakis and Avruch 2001; Yang, Sharrocks et al. 2003).  
HO-1 levels are usually elevated in cancer cells, including lymphosarcomas, 
prostate cancer, brain tumors, adenocarcinomas, hepatomas and melanomas (Was, 
Dulak et al. 2010), compared to the surrounding tissue. However, during the fasting-
induced sensitization, HO-1 was significantly reduced. Due to the protective role of 
HO-1 in protecting cancer cells from oxidative damage and reduction of apoptosis 
(Baranano, Rao et al. 2002; Gozzelino, Jeney et al. 2010), we hypothesized that 
restoring HO-1 levels, via induction with hemin or over-expression with a rHO-1 
construct, could partially reverse the STS induced sensitization to chemotoxic 
agents. Vice versa, the reduction of HO-1 by ZnPP treatment caused sensitizing 
effects under ad lib conditions. To test whether the depletion of nutrients by STS 
causes functional changes, we measured basal and stimulated mitochondrial 
functions. When we aimed to analyze the changes of mitochondrial respiration 
caused by STS, we noticed that cells grown under ad lib conditions show a 
significantly higher basal oxygen consumption rate (OCR) than cells grown under 
glucose- and serum-restricted conditions. These findings suggest reduced 
mitochondrial respiration under fasting-like conditions. The over-expression of HO-1 
had no effects on baseline oxygen consumption rate and the oxygen consumption 
attributed with mitochondrial ATP production, proton leak and the maximal 
respiratory capacity; indicating that HO-1 does not alter the mitochondrial respiration.  
Under normal conditions, differentiated cells rely primarily on mitochondrial 
respiration to produce ATP and utilize glucose to maintain energy production. 
Fasting conditions result in the fast depletion of glucose while increasing 
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ketonebodies in the blood. Fatty acids become the main source of cellular energy 
and reducing equivalents such as NADPH. We therefore tested if palmitate provides 
sufficient energy for malignant cells when glucose is depleted. Murine breast cancer 
cells, grown in media conditions mimicking glucose and growth factor levels of ad lib 
fed mice, were able to oxidize fatty acids while 4T1 cells, grown in culture-media 
conditions mimicking glucose and serum levels of fasted mice, suggested that these 
cells cannot utilize fatty acids. The over-expression of HO-1 reversed this deficiency 
of murine breast cancer cells, indicating that cellular redox homeostasis and fatty 
acid utilization in cancer cells are interconnected and plays a crucial role in the 
fasting-mediated sensitization. This hypothesis is supported by a recent report 
showing that the inhibition of fatty acid oxidation by etomoxir (a fatty acid transport 
inhibitor), reduced cell viability and elevated intracellular ROS levels (Pike, Smift et 
al. 2011). In our study, under STS conditions, we measured increased DHE and 
MitoSox Red staining, both indicative for increased levels of reactive oxygen species 
production. Elevated ROS levels may significantly contribute to the STS-mediated 
sensitization of cancer cells. Pike et al. noted that the inhibition of fatty acid oxidation 
resulted in decreased levels of reduced glutathione and NADPH (Pike, Smift et al. 
2011). The induction of HO-1, via hemin or the over-expression of a rHO-1 construct 
might reverse this sensitization and restore fatty acid oxidation by maintaining 
cellular redox homeostasis. We will aim future studies to address in greater detail if 
STS indeed depletes the intracellular pool of ATP, as well as NADPH and other 
reducing systems, and how HO-1 mediates its essential role in reversing the 
observed effects on fatty acid oxidation. In addition, experiments to block fatty acid 
oxidation, such as the utilization of etomoxir, might provide means to improve the 
sensitization of cancer cells.  
The experiments on HO-1, mitochondrial respiration and fatty acid oxidation 
were all performed in one murine cell line. Yet, matching the above reported 
observation on the central role of HO-1 in 4T1 cells is that the proliferative action of 
HO-1 can be down-regulated by siRNA, resulting in the inhibition of pancreatic tumor 
growth (Berberat, Dambrauskas et al. 2005), while in murine and human melanomas 
the over-expression of HO-1 increased cellular proliferation (Was, Cichon et al. 
2006). Still, the observed reduction in HO-1 levels may only be of minor significance 
for other cell lines, since different oncogenes and tumor-specific combinations of 
164 
 
mutations may affect the response to fasting. We will therefore test more human and 
murine cancer cells to establish the role of HO-1 and to determine additional 
mediators (e.g. FOXO) of the STS-induced cancer sensitization.  
 
The data I present in this dissertation revealed that the beneficial effect of 
STS in cancer treatment can be twofold. On the one hand, STS dampens the levels 
of nutrients and growth factor signaling, resulting in the cellular protection of normal 
cells, but not cancer cells because oncogenic mutations negate this adaptive stress 
resistance response. On the other hand, STS causes changes in the blood that 
promote cancer cell death and further sensitize cancer cells to cytotoxic stimuli, such 
as chemotherapy drugs and radiation (Fig. 4-1). However, the twofold contribution of 
the STS-induced DSR may be unique to the cancer cell types. 
4.4 Macronutrient Deficient Diets do not Mimic STS Effects 
Above, I outlined that fasting can differentially protect mice but not the tumor 
allograft to chemotherapeutic agents while protecting the host from chemotherapy 
induced toxicities. Fasting itself acts growth-static, i.e., inhibited tumor progression, 
which was particularly noticeable during the fasting cycles where we could usually 
observe only very limited tumor growth. Despite the fact that fasting is safe, 
economical, feasible, and effective in reducing chemotherapy-related side-effects in 
cancer patients at advanced stages (Safdie, Dorff et al. 2009), prolonged and/or 
repeated fasting cycles still impose a challenge to even the healthiest individuals. 
Therefore, understanding the major dietary components that mediate the beneficial 
effects of fasting may introduce the use of substitution diets to selectively protect the 
host against chemotherapy toxicity. 
Dietary protein, and the resulting amino acid-content, seems to affect 
longevity and healthy aging (Ross and Bras 1973; Pamplona and Barja 2006). 
Restricting protein intake shares some of the physiological effects of CR, including a 
decreased metabolic rate, reduced oxidative damage, enhanced hepatic resistance 
to toxins and oncogenic insults, decreased preneoplastic lesions and tumors 
(Maeda, Gleiser et al. 1985; Rodrigues, Sanchez-Negrette et al. 1991; Youngman, 
Park et al. 1992; Ayala, Naudi et al. 2007). Furthermore, both CR and protein 
restriction reduce serum IGF-I levels (Spindler 2010), which might be one of the 
contributors to longevity extension as the IGF-I-like signaling pathways regulate 
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Figure 4-1. A model for fasting-dependent sensitization of tumor cells to 
chemotherapy.  
In response to fasting, glucose and IGF-I, as well as other pro-growth 
proteins/factors (oncogenes) are reduced. Malignant cells respond to this reduction 
by activating AKT/S6K and eIF2α in an attempt to increase translation. This comes 
at the price of reducing the expression of stress resistance proteins NFkB and HO-1. 
Consequently, in contrast to normal cells, the finite amount of cellular energy would 
have to be allocated favorably to growth over maintenance in malignant cells. These 
changes lead to the increase in oxidative stress, DNA damage, activation of 
caspase-3, and eventually cell death. 
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lifespan in various model organisms such as C. elegans, D. melanogaster and mice 
(Guarente and Kenyon 2000; Kenyon 2005; Russell and Kahn 2007; Bartke 2008; 
Fontana, Partridge et al. 2010). Despite the well-established effects of protein 
deficient diets in reducing IGF-I and inducing cellular stress resistance, we did not 
detect any benefits in short-term protein restricted mice (0% P and 20% P, 72 hours 
to allow a comparison to STS) with regard to stress resistance and tumor 
progression. In a subcutaneous glioma model, ad lib feeding of a diet low in protein 
did not significantly reduce tumor progression once the tumor was palpable. This 
may be partially due to this diet not reducing glucose and/or IGF-I levels during the 
feeding regimen. However, glioma is a particularly aggressive tumor, so many 
additional cancer models should be tested in combination with protein restricted or a 
combination of CR and protein restricted diets to establish whether these 
interventions can be effective in delaying cancer progression. Mice in the group fed 
with a calorie restricted low carbohydrate diet (LCHP) had the worst survival of all 
CR groups, comparable to that of mice in the control group. The fact that mice in this 
group consumed similar, or higher amounts of fat-derived calories (20.9% in 50% CR 
LCHP vs. 17.2% ad lib AIN93G) and more importantly protein-derived calories 
(22.6% in 50% CR LCHP vs. 18.8% ad lib AIN93G) during three days of feeding, 
might explain this lack of protection. Of note is that the results presented on the 
induction of stress resistance are based on relatively short (72 hour) feeding periods, 
thus we cannot exclude that longer CR regimen with either altered calorie and/or 
macronutrient restrictions could result in an improved stress resistance.  
 
Ketogenic diets are used extensively in the treatment of refractory epilepsy in 
children, but have also been studied in cancer treatment (Seyfried, Sanderson et al. 
2003). To determine how this approach would compare with our stress resistance 
and potentially tumor sensitization experiments, we designed two ketogenic diets: 
our 90% HF diet (% calorie ratio of fat: carbohydrates: protein of 90%: 1%: 9%; Fig. 
1) is nearly identical (± 0.5% variation) to the classic ketogenic diet with a ratio of fat: 
carbohydrates: protein of 90%: 1.4%: 8.6% respectively. The high-fat diet 60% HF 
(% calorie ratio of fat: carbohydrates: protein of 60%: 31%: 9%) contains fat ratios 
similar to the fat ratio used in the modified Atkins diet (% calorie ratio of fat: 
carbohydrates: protein of 60%: 5%: 35%)(Kossoff and Dorward 2008), but we 
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reduced the protein content because previous work has established that protein, and 
not carbohydrates, regulate IGF-I levels in human (Cahill 1970; Fontana, Weiss et al. 
2008). The results we describe here, demonstrate that neither glucose nor IGF-I 
levels were significantly reduced after feeding both ketogenic diets for 9 consecutive 
days.  
To evaluate the effects of saturated vs. unsatured fatty acids, as well as 
medium- vs. long-chain fatty acids in cancer treatment, we designed two diets that 
were isocaloric to the control diet with soybean oil or coconut oil as a fat source but 
had low protein content. Long-chain unsaturated fatty acids are found in most 
commonly used dietary fats and vegetable oils such as soybean oil, while short- and 
medium-chain saturated fatty acids (e.g. lauric acid and myristic acid) are found in 
relatively high abundance in palm kernel oil and coconut oil. The medium-chain 
triglycerides (MCT) can easily by hydrolyzed in the gastro-intestinal tract and can be 
transported through the portal venous system towards the hepatocytes, while most 
of the long-chain fatty acids are transported as chylomicrons in the lymphatic system 
and packaged into triglycerides in the liver. MCTs can easily be fed into the 
mitochondrial β-oxidation (Aoyama, Nosaka et al. 2007), while long-chain 
triglycerides (LCT) rely on transporters, such as carnitine, to enter the mitochondrial 
matrix in hepatocytes (Calabrese, Myer et al. 1999). Data from human studies has 
indicated that consumption of MCTs or diets with higher unsaturated to saturated 
fatty acid ratio are associated with decreasing blood glucose, improving lipid profile, 
and reducing obesity (Ghosh 2007; Xue, Liu et al. 2009). In a study of biochemical 
and anthropometric profiles in women with abdominal obesity, dietary 
supplementation with coconut oil promoted a reduction in abdominal obesity 
(Assuncao, Ferreira et al. 2009). 
In agreement with the partial effects on blood glucose and IGF-I, the results I 
presented above indicate that 72 hours of 50% CR, but also of diets restricted in 
carbohydrates or proteins, have only partial effects on stress resistance. None of the 
50% dietary restricted and macronutrient defined diets fed for 3 days, except for the 
ketogenic 90% HF diet, lowered blood glucose levels, which has been shown to 
promote host-protection and tumor sensitization. Interestingly, a 50% reduction in the 
calories consumed on a ketogenic diet leads to a 30% reduction in blood glucose 
levels after 3 days of feeding, an effect presumably due to the very low carbohydrate 
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content (less than 1%) of this diet. However, our stress resistance experiment 
indicates that this reduction did not improve survival. It is noteworthy, that no mice 
from any of the CR diets, neither the control diet nor the macronutrient defined diets, 
achieved protection equivalent to that caused by 60 hours of fasting. Thus it appears 
that the limited changes in blood glucose and IGF-I, caused by specific 
carbohydrates or protein-restricted diets, will most likely not improve, or have limited 
effects on, stress-resistance and/or reduce tumor progression. However, additional 
studies with extended feeding regimes and larger experimental group size will be 
necessary to understand whether specific diets may be sufficient to achieve DSR 
and DSS effects that are close to those caused by fasting cycles. Future studies 
could also evaluate the effects of various macronutrient-defined and CR diets on 
ROS production, tumor progression and stress resistance. 
In summary, the previously described fasting-dependent differential protection 
of normal and cancer cells (DSR) (Raffaghello, Lee et al. 2008; Safdie, Dorff et al. 
2009; Lee, Safdie et al. 2010) and the tumor cell-specific sensitization presented 
here (Differential Stress Sensitization, DSS) indicate that short-term starvation 
conditions, or modified diets that promote similar changes, have the potential to 
enhance a wide variety of standard cancer therapies. Owing to the consistent effects 
on glucose and IGF-I, and consequent effects on protection of normal and 
sensitization of cancer cells without the chronic under-weight, periodic fasting cycles 
appear to have the highest potential to protect patients treated with a variety of 
chemotherapy drugs, while simultaneously augmenting treatment-efficacy. If 
confirmed in the currently still ongoing clinical trials, repeated fasting cycles could 
also provide an alternative to chemotherapeutic treatment for early stage patients 
that may not be considered sufficiently at risk to receive chemotherapy, or for 
patients with more advanced malignancies who receive chemotherapy and are at 
high risk for recurrence. In addition, fasting cycles in combination with 
chemotherapy, could extend the survival of advanced stage cancer patients by 
retarding the tumor progression and reducing the side effects. 
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5 Perspectives 
According to the American Cancer Society, the general dietary 
recommendation for cancer patients that receive chemotherapeutic agents is to 
maintain or even to increase their caloric intake (Doyle, Kushi et al. 2006). This 
seems to be common wisdom and generally well accepted and practiced, 
presumably because it appears as if feeding the body during times of sickness 
implies a better health status. Notably, circulating IGF-I is regulated by protein intake 
and total energy (Clemmons and Underwood 1991; Underwood, Thissen et al. 
1994). Low-protein and low-calorie diets have a strong effect on circulating 
concentrations of several pro-growth factors, including IGF-I, and clinical biomarkers 
(Fontana 2006; Fontana, Weiss et al. 2008). Considering the fact that the average 
American consumes more protein than needed (Fulgoni 2008), which has been 
shown to be a major risk factor for tumor progression (Metges and Barth 2000), there 
is an urgent need to re-evaluate the current dietary recommendation for cancer 
patients. The studies I presented in this dissertation suggest that a shift in the dietary 
recommendations for cancer patients might allow for an improvement of the 
treatment efficacy. 
Our data demonstrates that short cycles of fasting are able to selectively 
protect mice but not tumor cells from chemotherapy. In addition, the effect of short-
term starvation is extended beyond selectively protecting normal cells to sensitizing 
murine and human cancer cells to chemo- and radio-therapy. Furthermore, 
mimicking starvation-like conditions reveals that IGF-I signaling and glucose 
deprivation, without the use of chemotherapeutic agents, reduces tumor progression. 
This is important since it provides a basis to study mechanisms of stress resistance 
through metabolic manipulations, with the potential of discovering drug targets that 
can weaken the cellular defense of malignant cells. Our studies showed that fasting 
causes a differential expression of stress regulating transcription factors and indicate 
that reduced heme oxygenase-1 level, under STS conditions, plays a central role in 
mediating cancer cell sensitization. This understanding of DSR also reveals another 
approach to mimic fasting: targeting specific signal transduction pathways by 
pharmacological interventions. The data I presented in this dissertation suggests 
multiple candidate targets including IGF-I (extracellular) and its receptor, 
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downstream effectors such as the PI3K/Akt and Ras/ERK pathways (intracellular) 
and transcription factors that mediate the fasting induced cancer sensitization, e.g. 
NFkB and HO-1. Nonetheless, metabolic reprogramming during fasting is proposed 
to impact various pathways within the cell and it appears unlikely that the targeted 
disruption of one of these pathways in cancer cells will have as a broad impact as 
starvation.  
  
Despite its beneficial effects, even short cycles of fasting remain a challenge 
to most patients, especially for those patients prone to weight loss. Ongoing 
research from Dr. Longo’s lab at the University of Southern California focuses on 
developing substitution diets that mimic the beneficial effects of fasting, while 
providing sufficient supply of minerals, vitamins, etc. In various communications with 
patients enrolled in the clinical trials at the Keck School of Medicine that focus on 
fasting, the majority of patients (~70%) indicated they would rather participate in a 
dietary substitution study. A product designed in our lab, described here only as 
“fasting mimicking diet” (FMD) due to pending patents, was distributed to patients 
that volunteered in helping us to adopt the taste and to test the effects on blood 
parameters. One volunteer, a male patient diagnosed with multiple myeloma in April 
2006, started a fasting-related dietary regimen in June 2011 after he became 
unresponsive to his treatment regiment (Revlimid, Velcade and Dexamethasone). 
After the patient tested multiple rounds of fasting or fasting mimicking diets, his 
marker protein stabilized. The patient donated serum to us that was collected at the 
end of one FMD-regime; as well as during a period of normal food intake. I used this 
serum for preliminary measures to determine if changes occurred that have 
sensitizing effects on a human cancer cell line (Fig. 5-1). In strong similarity to the 
STS in vitro results I presented before, serum collected at the end of an FMD regime 
significantly reduced cell survival of a human prostate cancer cell line (PC3) by 40% 
when compared to cells grown in ad lib serum.  
 
I propose that in the near future, fasting and fasting-mimicking diets will be 
applied to the clinical scenario where they will improve the treatment efficacy for a 
wide range of diseases, not limited to cancer alone.  
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Figure 5-1. A fasting-mimicking diet reduces survival of a human prostate 
cancer cell line in vitro.  
Human prostate cancer cells (PC3) were incubated for 48 hours in human serum 
that was collected after normal food intake (ad lib) or at the end of a fasting 
mimicking diet (FMD) regime. All cells were grown in 10% of each serum; glucose 
was matched to the patients glucose levels at the time of collection (1.25 g/L ad lib, 
0.9 g/L FMD). Survival presented as percentage of MTT reduction of ad lib to FMD. 
All data presented as mean ± SEM; *** p <0.001, Student’s t-test, two-tailed. 
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